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There is a growing body of literature using multi-criteria decision analysis (MCDA) methods 
for prioritising health interventions. However, there has been very little application of MCDA 
to prioritise funding for research across health conditions, including non-communicable 
diseases (NCDs). NCDs are non-transmissible diseases that are not spread from person to 
person – e.g. diabetes mellitus, coronary heart disease, back pain, dementia and depression. 
Given limited resources, funding needs to be systematically allocated for research into the most 
pressing NCDs by explicitly identifying priorities for health research. Methods based on 
MCDA have attracted increasing attention by policy-makers and researchers by systematically 
forming and solving the multi-dimensional aspects of the decision problem, particularly in the 
health system. This thesis aims to investigate the use of MCDA to support health research 
funding across NCDs. 
Following chapters of introduction and a review of commonly used methods, the thesis 
includes three main chapters (i.e. Chapters 3, 4 and 5), as well as the concluding chapter that 
provides policy implications and research contributions of the thesis. In Chapter 3, a widely-
used MCDA method – i.e. the Potentially All Pairwise RanKings of all possible Alternatives 
(PAPRIKA) method administered through 1000minds software – is applied to create a priority 
list of NCDs to support health research funding. Informed by the literature, a set of 
prioritisation criteria – e.g. deaths, loss of quality-of-life and cost of the disease – is specified 
to evaluate NCDs in terms of their priority for health research funding decision-making. Their 
weights, representing their relative importance, are calculated based on a survey of 
stakeholders from various sectors of the New Zealand (NZ) health system.  
The most important criterion for prioritising NCDs in terms of their overall burden to society 
(and hence their importance for health research funding) is ‘deaths across the population’ 
(mean weight = 27.7%), followed by ‘loss of quality-of-life across the population’ (23.0%), 
then ‘cost of the disease to patients and families’ (18.6%), ‘cost of the disease to the health 
system’ (17.2%) and the least-important criterion, ‘disproportionately affects vulnerable 
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groups’ (13.4%). The criteria are used to rate NCDs based on evidence concerning their 
performance on the criteria. The rated NCDs are then ranked using the criteria mean weights 
from the survey. Each NCD’s total score is presented based on a 0-100% scale, where 100% 
indicated an NCD with the highest levels on all criteria, and 0%, an NCD with the lowest levels 
on all criteria. The NCDs ranking is categorised into four tiers: Priority 1 (very critical): 
coronary heart disease, back and neck pain, diabetes mellitus; Priority 2 (critical): dementia 
and Alzheimer’s disease, stroke; Priority 3 (high): colon and rectum cancer, depressive 
disorders, chronic obstructive pulmonary disease, chronic kidney disease, breast cancer, 
prostate cancer, arthritis, lung cancer; Priority 4 (medium): asthma, hearing loss, melanoma 
skin cancer, addictive disorders, non-melanoma skin cancer, headaches. The MCDA-based 
framework developed in Chapter 3 enables incorporating multiple criteria for evaluating a 
range of NCDs in terms of their priority for research funding and the involvement of a diverse 
range of stakeholders. This framework is hence more likely to generate a priority list that is 
more acceptable to the key stakeholders. This priority list shows that it is essential to 
incorporate the multi-dimensional nature – e.g. mortality, morbidity and health care costs – of 
NCDs when evaluating their priority and eligibility for health research funding. 
In Chapter 4, PAPRIKA is compared with the most well known and thus, the most widely-used 
MCDA method – i.e. the Analytic Hierarchy Process (AHP) administered using Expert Choice 
software. AHP is considered as a benchmark among the MCDA methods by many MCDA 
practitioners. Both AHP and PAPRIKA are two prominent MCDA methods that have been 
used in many different fields and appeared in many publications. It is worthwhile to compare 
the two methods based on their theoretical foundations. Along with AHP and PAPRIKA, their 
associated decision-making software – i.e. Expert Choice and 1000minds – are considered in 
the evaluation framework. The findings indicate that AHP (and Expert Choice) and PAPRIKA 
(and 1000minds) use different theoretical foundations at different stages of the decision-
making process from eliciting participants’ preferences to calculating the criteria weights and 
alternatives scores. As such, PAPRIKA uses choice-based pairwise comparison questions, 
whereas AHP uses ratio scale-based paired comparison questions to elicit participants’ 
preferences. AHP, unlike PAPRIKA, does not enforce the transitivity property. 
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In Chapter 5, an empirical framework is established to evaluate the performance of AHP (and 
Expert Choice) and PAPRIKA (and 1000minds) based on the NCD survey (the main subject 
of this thesis), as well as a second survey about smartphones. In the framework, a holdout 
choice task is employed for investigating the performance of AHP (and Expert Choice) and 
PAPRIKA (and 1000minds) to predict participants’ actual choices. The findings reveal that 
PAPRIKA (and 1000minds) is more likely to outperform AHP (and Expert Choice) based on 
both decision case studies about NCDs and smartphones. PAPRIKA could produce repeatable 
results over time and show higher validity to predict participants’ actual choices. 
Given the diversity of MCDA methods and in the absence of a gold standard, evaluating the 
chosen MCDA method(s) based on their theoretical foundations may not be sufficient. An 
appropriate MCDA method is also required to produce robust results. Ideally, the theoretical 
and empirical frameworks developed in Chapters 4 and 5 could help MCDA practitioners 
consider a holistic approach to justify the choice of MCDA – which is the primary purpose of 
‘step 7’ in the MCDA process – and choose a method that is developed on sound theoretical 
foundations and that generates robust results.
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1.1 Problem statement 
Research into health problems afflicting society, including health inequities borne by 
vulnerable population groups, is very important (Khan et al. 2019; Smith et al. 2009). Although 
billions of dollars are invested in health research annually, only a small proportion of this 
spending targets health problems imposing the greatest burden on society (Viergever 2013), 
and often without much attention to achieving a more equitable distribution of health outcomes 
(Allen 2017; Viergever 2013). Given limited resources available for health research, it is 
necessary to systematically prioritise health conditions for eligibility for research funding, and 
thereby improve health equity and support vulnerable population groups (Besar Sa’aid et al. 
2020; Hoedemaekers & Dekkers 2003; Tromp & Baltussen 2012). Despite the importance of 
such priority-setting being generally well accepted, the development of priority lists of the most 
important research ‘investment opportunities’ remains challenging in practice (Rottingen et al. 
2013; Smith et al. 2009).  
Notwithstanding a large number of studies into prioritising health interventions per se, very 
few studies have focused on prioritising health conditions, including non-communicable 
diseases (NCDs) (Adeyi et al. 2008; Allen 2016; Marsh et al. 2017) – the subject of this thesis. 
Examples of NCDs are diabetes mellitus, coronary heart disease, back and neck pain, dementia 
and depression, as explained in more detail in Section 1.3. Like many other countries, New 
Zealand (NZ) is grappling with the problem of allocating limited health research resources 
across NCDs. This problem has become more critical as health burdens associated with NCDs 
continue to grow rapidly (Bullen et al. 2015; WHO 2014). 
In essence, methods based on Multi-Criteria Decision Analysis (MCDA)1 are increasingly used 
for priority-setting in the health system, contributing towards more efficient allocation of health 
resources (Allen 2016; Marsh et al. 2017; Viergever et al. 2010). MCDA has attracted 
increasing attention by policy-makers and researchers by explicitly forming and solving the 
                                                 
1 Main MCDA methods such as PAPRIKA and Analytic Hierarchy Process (AHP) are explained in more depth 




multi-dimensional aspects of the problem, particularly in the health system. Marsh et al. (2014) 
and (2017) indicate that MCDA has been widely used to support studies on prioritising health 
interventions, but very few studies have used MCDA to prioritise health conditions, including 
NCDs, to support health research funding decision-making. The term ‘support research funding 
decision-making’ is used in this thesis because additional considerations such as the cost of the 
research and its likelihood of success are also important (and not included in this framework) 
when research projects are being assessed and funds are allocated in pursuit of value for money. 
This thesis contains three main chapters. Chapter 3 begins by applying a widely-used MCDA 
method – i.e. Potentially All Pairwise RanKings of all possible Alternatives (PAPRIKA) 
administered using 1000minds software2 – to develop and pilot an MCDA-based framework 
in NZ to support priority-setting for health research funding across NCDs. PAPRIKA is a 
choice-based decision-making method that is increasingly used and appeared in many 
publications. The World Health Organization (WHO) has recently used PAPRIKA to create a 
priority list of antibiotic-resistant bacteria to support the “discovery, research, and development 
of new antibiotics” (Tacconelli et al. 2018). The framework developed in Chapter 3 is used to 
elicit the preferences of key stakeholders – e.g. patients, members of the general public, health 
workforce, health (and medical) researchers and policy-makers – in terms of NCDs’ priority 
for health research funding. Participants’ preferences are then integrated with the scientific 
evidence on NCDs to support health research funding in NZ.  
Chapter 4 introduces a theoretical framework for evaluating and choosing the best MCDA 
methods based on their theoretical foundations. Often supported by specialised decision-
making software, a large number of MCDA methods have been developed over the past few 
decades. The great diversity of MCDA methods (and software) has posed difficulty choosing 
the best MCDA method (and software). PAPRIKA is compared with the most well known and 
                                                 
2 It is noteworthy to mention that one of the supervisors (Professor Paul Hansen) co-invented the PAPRIKA 
method and co-owns 1000minds software used in the thesis. Commercial users of this software pay license fees; 
however, academic users (i.e. researchers and students) mostly use the software for free. The author found it 
convenient to use 1000minds due to supervisory expertise and no-cost access. This is the primary reason for using 
PAPRIKA (and 1000minds) in the thesis. In addition, as indicated shortly, PAPRIKA is widely used for priority-
setting and appeared in numerous publications (Golan et al. 2012; Hansen & Ombler 2008; Tacconelli et al. 2018; 




thus the most widely-used MCDA method – i.e. the Analytic Hierarchy Process (AHP) 
administered using Expert Choice software – to implement the theoretical framework 
developed in Chapter 4. PAPRIKA and AHP are grounded on varying theoretical foundations 
and use various mathematical algorithms to calculate the criteria weights and alternatives 
scores. As such, AHP is a ratio scale-based MCDA method and PAPRIKA is a choice-based 
decision-making method. Unlike AHP, PAPRIKA enforces transitivity to reduce the number 
of questions, and thereby the decision-making burden for participants. 
Chapter 5 addresses an empirical framework for evaluating the performance of PAPRIKA and 
AHP based on real-world decision case studies. The problem of choosing the best MCDA 
method(s) becomes more challenging, particularly when different methods may potentially 
generate conflicting results for the same decision problem. According to the literature, the 
inconsistencies in the results yielded by different MCDA methods are somehow inevitable and 
should be accepted as an expression of different methodologies used by different MCDA 
methods. In the absence of a gold standard, it is important that the chosen MCDA method can 
produce robust results. In pursuit of finding the robust method, an empirical framework is 
developed in Chapter 5 to evaluate the robustness of results given by the selected MCDA. This 
framework is used to examine the successful applications and performance of PAPRIKA (and 
1000minds) and AHP (and Expert Choice) based on two real-world decision case studies about 
NCDs (the primary focus of the thesis) as well as a second survey designed about smartphones. 
As the online surveys are distributed among the university students and the students may not 
have enough information or interest in the NCD subject, a second survey is designed about 
smartphones that seem to be more appealing to students. 
The following section represents the main research questions. The rest of this chapter deals 
with explaining the overall burden of NCDs and the importance of using methods based on 
MCDA to set priorities and guide health research funding more effectively across NCDs. The 
chapter then gives a summary of the burden of NCDs as well as the health research priority-




1.2 Research questions 
This thesis aims to address the following guiding research questions: 
1) What are the commonly used methods, applying a multi-criteria based approach, to support 
health research funding across health conditions, including across NCDs? 
2) Which method systematically solves the decision problem by calculating the criteria weights 
and alternatives scores?  
3) Which method has been used by the leading international organisations such as the WHO to 
support research funding into health conditions? Which method to use in Chapter 3 to prioritise 
NCDs eligibility for health research funding?  
The questions encompassed in research questions 1, 2 and 3 are addressed in Chapter 2. 
4) What are the potential prioritisation criteria to assess and rank NCDs in terms of their priority 
for research funding in NZ? Which NCDs are eligible for receiving research funding in the NZ 
health care setting?  
5) Whose preferences should be included in the priority-setting framework to support health 
research funding across NCDs? 
6) Does the method used in Chapter 3 (for establishing a priority-setting framework to support 
health research funding across NCDs) produce repeatable results? Are participants’ stated 
preferences associated with their background characteristics? 
The questions encompassed in research questions 4, 5 and 6 are addressed in Chapter 3. 
7) What are other alternative methods (and their associated software package) that could be 
used for prioritising NCDs to support health research funding? How well the chosen methods 




8) What facilities/features are offered by the associated software packages to improve the 
decision-making process and support the results?  
The questions encompassed in research questions 7 and 8 are addressed in Chapter 4. 
9) How to evaluate the performance of selected methods in practice? How well the chosen 
methods can predict participants’ actual choices? 
10) Which selected method (and software) can perform better – i.e. produce legitimate and 
robust results – based on real-world decision case studies?  
The questions encompassed in research questions 9 and 10 are addressed in Chapter 5. 
1.3 Non-communicable diseases (NCDs) 
The world’s morbidity profile is undergoing an epidemiological transition from communicable 
diseases to NCDs (Nikolic et al. 2011). NCDs are non-transmissible diseases that are not spread 
from person to person. They mainly arise from genetic or behavioural causes, and they are 
often characterised by slow deterioration and long duration (Adeyi et al. 2008; Strong et al. 
2006). Examples of NCDs are coronary heart disease, diabetes mellitus, back and neck pain, 
dementia and depression. The global burden of NCDs is growing quickly due to population 
ageing and unhealthy lifestyles, particularly among children and younger adults (Benziger et 
al. 2016; Nikolic et al. 2011; WHO 2018a). 
NCDs are the leading cause of mortality and morbidity worldwide. They constitute almost 70% 
of all Years of Life Lost (YLLs) due to premature death, as well as 66.5% of all Years Lived 
with Disability (YLDs) (Alwan 2011; Richards et al. 2016; WHO 2017).3 NCDs contribute to 
substantial economic burden incurred by households and Governments due to productivity loss 
and inability to work (Chaker et al. 2015; Mendis 2015; WHO 2014). Some NCDs 
disproportionately affect people in lower socio-economic families (Sharma 2017). NCDs have 
                                                 




a significant impact on households’ impoverishment and push them toward unhealthy 
lifestyles, which increases the risk of developing NCDs (Nikolic et al. 2011).  
There are several knowledge gaps and issues about NCDs (and evaluating them) that need to 
be addressed to overcome the overall burden of NCDs. First of all, generating accurate and 
consistent data is essential for reversing health losses caused by NCDs (Alwan 2011). Lack of 
data – as well as inconsistency in presenting data – distorts the real picture of NCDs, negatively 
affects health system performance and tracking changes over time becomes difficult (AIHW 
2014). Practical strategies for reversing the NCDs epidemic require standardised and reliable 
data by which health systems can set better health research priorities across NCDs (Nikolic et 
al. 2011; Richards et al. 2016). 
Second, the burden of NCDs can be chronic and complicated, and it can not be reflected only 
in terms of death outcomes. However, most systems only measure and judge health 
improvement based on rates of mortality (Duttine 2016; Vos et al. 2016). According to the 
global burden of disease (GBD) Study 2015 (Vos et al. 2016), YLDs attributable to NCDs are 
increasing faster than YLLs. In spite of worldwide efforts to reduce NCD deaths, the nonfatal 
– i.e. disability – and financial burden of NCDs remains neglected (Lisy et al. 2016; Richards 
et al. 2016). According to the WHO, the four main groups of NCDs are cardiovascular diseases, 
cancers, chronic respiratory diseases and diabetes (Alwan 2011). However, there are three other 
major NCD groups – mental, neurological and musculoskeletal disorders – that are recognised 
as the significant causes of disability and rising health care funding in many countries (Blakely 
et al. 2019; Bloom et al. 2011; Dieppe 2013). Therefore, it is essential to examine the multi-
faceted burden of NCDs when evaluating and prioritising them for health research funding.  
Third, Disability Adjusted Life Years (DALYs)4 are commonly used as a summary metric of 
population health loss and designed to quantify the overall disease burden of NCDs. DALYs 
are widely used as a numerical value, which can be compared within and across countries 
(Parks 2014; Vos et al. 2016). There are several arguments against using DALYs as a sole 
                                                 




metric.5 As such, DALYs show the overall burden of disease, and it is not obvious which 
component – i.e. YLLs or YLDs, and their extents – contribute mainly to overall health loss 
(Gibney et al. 2013). In addition, DALYs only reflect productivity loss (Chaker et al. 2015) 
and do not take into account the health care expenditure attributed to NCDs (Arnesen & 
Kapiriri 2004). Therefore, the two components – i.e. YLLs and YLDs – of DALYs should 
preferably be used in conjunction with costs when evaluating NCDs priority for health research 
funding. 
Finally, despite being responsible for high rates of mortality and morbidity worldwide (60% of 
DALYs), NCDs receive a relatively small proportion of global health funding compared to 
other leading causes of health loss (Allen 2017b; IHME 2016). Strong arguments have been 
made that the burden of NCDs cannot be reversed without increasing funding sources for NCDs 
(Frumkin & Haines 2019; Heller et al. 2019). In addition, health research systems need to be 
in tune with the needs of patients and that research funding should be allocated in proportion 
to need (Allen 2017a). The WHO Global Forum for Health Research (GFHR) also emphasises 
the importance of using structured priority-setting frameworks to direct investment into areas 
of greatest need to improve health equity and support vulnerable population groups (Viergever 
2010).  
1.4 Allocating health research funding to NCDs 
Allocating scarce resources across competing alternatives is taking place every day in many 
different fields. However, it is usually more challenging for health policy-makers to explicitly 
set priorities for research funding (Regier & Peacock 2017). Scarce health research funding 
needs to be prioritised and distributed in an explicit and structured way across disease areas, 
populations and interventions. However, in many health systems, the resource allocation 
decisions often rely on historical or political decision-making processes (Mitton & Donaldson 
2004), which has led to suboptimal use of health resources (Knottnerus & Tugwell 2017). 
                                                 




Adopting a structured framework is more likely to help policy-makers set better health research 
priorities and more effectively allocate health research funding across NCDs. 
Decision-making in the real world is multi-dimensional and complex (De Montis et al. 2000). 
MCDA is well recognised as being a useful tool for amalgamating the multi-dimensional 
aspects of the decision problems (Doumpos & Zopounidis 2014). There exists ample evidence 
on MCDA’s practicality for supporting real-world decision-making (Drake et al. 2017; El 
Amine et al. 2014; Regier & Peacock 2017). Studies have shown that MCDA methods help 
“overcome humans’ tendency to be selective and biased” [p. 257] (Mysiak 2006) by capturing 
the views of multiple stakeholders for evaluating and prioritising multiple alternatives each 
based on multiple and explicit prioritisation criteria. MCDA is also concerned with 
systematically solving the real-world decision problems, weighting criteria and scoring 
alternatives (Angelis & Kanavas 2017). Therefore, using MCDA-based methods enables 
MCDA practitioners to explicitly set priorities (Marsh et al. 2016; Thokala et al. 2016). In this 
thesis, MCDA6 is used to develop a priority-setting framework to integrate the preferences of 
main stakeholders with current evidence to support health research funding decision-making 
across NCDs. As explained earlier, The term “support research funding decision-making” is 
used in this thesis because additional considerations such as the cost of the research and its 
likelihood of success are also important (and not included in the framework) when research 
projects are being assessed and funds are allocated in pursuit of ‘value for money’. 
As the priority-setting framework is piloted and tested in NZ, the following section provides 
an overview of the country profile regarding the burden of NCDs, the health care financing 
system and priority-setting within the NZ health system with a particular focus on the NZ 
priority-setting system for health research. 
                                                 
6 Chapter 2 briefly describes MCDA. Main MCDA methods (including the methods used in this thesis – i.e. 




1.5 New Zealand overview 
In 2018, the population of NZ was approximately 4.9 million people with a life expectancy of 
79.1 years for males and 83.5 for females in 2017. Table 1.1 presents further information about 
NZ’s demographic profile. NZ, like other developed countries, is struggling with several 
challenges such as population ageing, health inequity gaps – e.g. barriers to access and utilise 
health services – and the increasing burden of NCDs. “Addressing these challenges is 
considered crucial for keeping an affordable and sustainable health system in New Zealand” 
[p. 1] (NZ MOH 2016b; OECD 2017). 
Table 1.1: New Zealand country profile 
Indicator (year)  
Population (2018) 4,926,000 
Life expectancy at birth m/f years (2017) 80/84 
Population proportion between ages 30 and 70 years (%, 2014) 49.3 
The probability of dying between ages 30 and 70 years from 
the four main NCDs (%, 2014) 
11 
People over 60 (% of the total population, 2016) 23 
Income group  High  
GDP per capita (US$, 2017) 42,940.58 
Total expenditure on health per capita (US$, 2018) 3,923 
Total expenditure on health as % of GDP (2018) 9.3 
Ethnic groups (% of the total population, 2014) European (74), Māori (15), Asian (12), 
Pacific ocean (7), others (1) 
GDP: Gross Domestic Product; Note: Percentages of ethnicities add up to more than 100% as people may belong to more than 
one ethnic group. (Source: Latest data from Statistics New Zealand available at https://stats.govt.nz, WHO, World Bank and 
OECD data available at https://data.oecd.org/new-zealand.htm). 
 
1.5.1 NCDs and population ageing in NZ 
Elderly New Zealanders (aged 65 and over) constitute more than a quarter of the NZ 
population. This group is projected to increase rapidly in the near future, eventually surpassing 
the number of children alive (Aldrich 2010; Khawaja & Thomson 2000; Statistics New Zealand 




responsible for approximately 88% of total health loss (represented in terms of DALYs) in NZ, 
followed by 8% due to injuries and less than 4% from pretransitional causes – i.e. common 
infectious diseases, nutritional deficiency disorders and neonatal disorders. NCDs constituted 
the largest share of health losses and have increased from 82% in 1990 to 88% in 2013 to 89% 
in 2016 (NZ MOH 2016b; WHO 2018b).  
In 2016, ischemic heart disease (IHD),7 lung cancer, cerebrovascular disease,8 colon and 
rectum cancer and chronic obstructive pulmonary disease (COPD), dementia and Alzheimer’s 
disease and chronic kidney disease were the major NCDs attribute to high rates of mortality. 
Other NCDs such as back and neck pain remained the leading causes of disability, followed by 
depressive disorders and headaches (Bullen et al. 2015; IHME 2019). The rate of mortality in 
some NCDs – e.g. breast and colorectal cancer – is higher in NZ relative to other counties in 
the Organisation for Economic Co-operation and Development (OECD). NZ has one of the 
highest rates of hospital admissions for chronic obstructive pulmonary disease (COPD) and 
asthma (OECD 2017). 
NZ, like other countries, is facing a disability transition as a result of increased rates of YLD 
caused by NCDs. Disability – i.e. living longer in poor health – now accounts for more than 
half of total health loss in NZ (52% of total DALY in 2013) (NZ MOH 2016b). The NZ health 
system has been more successful at decreasing the rates of mortality in many fatal NCDs than 
disability (i.e. nonfatal aspects) attributed to many NCDs such as musculoskeletal, neurological 
and mental disorders (NZ MOH 2016b). 
1.5.2 Financing and priority-setting within the New Zealand health care system 
NZ has a publicly-funded national health system. The health and disability system provides all 
citizens with free or subsidised specialist and hospital services. Almost 82% of all health 
expenditures are publicly-funded by the Government (Blakely et al. 2015; NZ Treasury 2016). 
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The primary sources of funding come from Vote Health,9 around $19.871 billion in 2019-2020. 
Other funding sources include Accident Compensation Corporation (ACC)10 and private 
sources such as insurance and out-of-pocket payments.  
Over 60% of Vote Health is administered to District Health Boards (DHBs)11 for providing 
health services within their regions. Almost 19% of Vote Health is allocated to national services 
such as public health services, disability support services, specific screening programmes, 
mental health services, elective services and Māori health services. NZ household funding on 
health care is one of the lowest among OECD countries (OECD 2017). However, a significant 
proportion of the NZ population has unmet health needs due to financial barriers. Individuals 
with lower socio-economic status – e.g. from Māori (indigenous people of NZ) and Pacific 
Island backgrounds – are particularly at risk of forgoing health care when they need it, which 
endangers their health (OECD 2017). 
Although the primary health system in NZ is heavily subsidised, patients need to contribute 
based on their income level, in terms of co-payment, which may be slightly different across 
health care services, medicines and patients. Patients may need to pay the surcharges in 
addition to co-payment, where the price of medicines is higher than the subsidy (PHARMAC 
2018). Alongside publicly-funded health care, the private sector provides mostly non-urgent 
procedures, which are mostly funded through private health insurance and out-of-pocket 
funding. There are other non-governmental organisations – such as Cancer Society of NZ – 
that cover some of the patients’ expenses (Foster & Preval 2011; NZ MOH 2014d).  
NZ’s first health research strategy was published in 2017 by the Health Research Council 
(HRC) of NZ and the Healthier Lives National Science Challenge (NZ HRC 2018). The 
Healthier Lives National Science Challenge programme has focussed on the four areas of 
                                                 
9 The NZ health system is mainly paid through general taxes. The NZ Government decides how much of the 
received public funds is spent on health care services each year. This amount is called ‘Vote Health’. 
10 ACC is a NZ entity that provides compulsory insurance for accidental injuries to support everyone in NZ. 
11 District Health Boards (DHBs) are responsible for the provision of health and disability services to a population 
within defined geographical areas. They are established by the Public Health and Disability Act 2000 in 2001. 
There are currently 20 DHBs in NZ. Each DHB receives public funding from MOH on a population-based formula 
that considers the total number, age, socio-economic situations and the ethnicity groups. Each DHB is governed 




cancer, cardiovascular disease, diabetes and obesity to guide health research priorities for the 
period from 2017 to 2027 (NZ Healthier Lives 2017). How these NCDs have been prioritised 
for research funding is unknown, and there is no explicit information about why these NCDs 
were prioritised over others.  
Holmes et al. (2014) [p. 11] point out that “despite the preference for explicit and evidence-
based approaches to prioritisation, it appears New Zealand continues to struggle to apply and 
implement explicit approaches, particularly in horizontal priority-setting – that is prioritising 
across diseases or services, not just within them. There remains tension between ‘due process’ 
and ‘technical analysis’ at all levels of the New Zealand health system”.12 Given these issues 
for NZ and other countries, setting explicit and rigorous research priorities to guide research 
needs and funding across NCDs is becoming increasingly important (Smith et al. 2009). 
1.6 Structure of the thesis 
The thesis is structured as follows. 
Chapter 2 provides an overview of the most commonly used methods that apply a multi-criteria 
approach to set health research priorities and guide research funding across various health 
conditions, including NCDs.  
Chapter 3 starts by establishing a set of prioritisation criteria, which is an important step in the 
decision-making process. An online priority-setting framework is developed through 
1000minds software that administers the PAPRIKA method. The framework is applied to 
calculate the criteria weights based on the preferences of a wide range of key stakeholders from 
different sectors of the NZ health system. The criteria are used to rate NCDs based on evidence 
concerning their performance on the criteria. The rated NCDs are then ranked using the criteria 
mean weights from the survey. The study results are supported by using further analysis such 
as test-retest reliability (to examine the repeatability of the results over time) and cluster 
                                                 
12 A report prepared by the Disease Epidemiology, Equity & Cost-Effectiveness Programme (BODE³), 




analysis (to find possible associations between participants’ preferences and their background 
characteristics). 
Chapter 4 explains how PAPRIKA (and 1000minds) and AHP (and Expert Choice) work with 
a real-life example. The chapter then takes a theoretical approach to evaluate and compare 
PAPRIKA with the most widely-used MCDA method – i.e. AHP – including their associated 
decision-making software – i.e. Expert Choice and 1000minds – in terms of three groups of 
criteria related to method, software and user experience.  
Chapter 5 undertakes an empirical approach to develop a set of checks – e.g. consistency, 
reliability and validity – to examine the performance of AHP and PAPRIKA. A holdout choice 
task is employed in this chapter to evaluate the validity of the results given by AHP and 
PAPRIKA, in the absence of real-world data about participants’ actual choices. The successful 
applications of AHP (and Expert Choice) and PAPRIKA (and 1000minds) are evaluated based 
on two real-world decision examples about NCDs (the primary focus of the thesis) and a second 
survey designed about smartphones as the online surveys are distributed among the students, 
and the NCD subject might not be an appealing subject to them. In addition, participants’ 
perceived ease-of-use of the surveys implemented through Expert Choice and 1000minds are 
examined in practice based on the two decision examples in this chapter. 
Chapter 6 presents a summary of the key findings and research contributions, together with 





Disability Adjusted Life Years (DALYs) 
DALY is measured through a combination of mortality – i.e. reduced life expectancy – and 
morbidity – i.e. loss of health-related quality-of-life – estimates. One DALY accounts for one 
lost year of a perfectly healthy life. The DALY formula (Arnesen & Kapiriri 2004) is: 
DALY = YLL + YLD, 
Where YLL measures Years of Life Lost due to premature mortality and YLD is Years Lived 
with Disabilities. YLL and YLD are measured as shown below. 
YLL = N × L, 
Where ‘N’ is the number of total death, and ‘L’ is the standard life expectancy at the time of 
death. 
YLD = I × D × DW, 
Where ‘I’ indicates the rate of incidence or number of newly emerged cases of the disease, ‘D’ 
is the average duration of the health condition until remission or death. ‘DW’ shows the 
disability weight, which reflects the severity of the health condition on a scale from 0 (perfect 
health) to 1 (equivalent to death). YLD is adjusted by age-weighting and time-discounting. 
More detailed information about DALY and its components is available from Mooney and 
















Health research funding decision-making is a key element that helps strengthen health research 
systems. A variety of methods are used to set research priorities and support health research 
funding decision-making for different purposes. The various methods and approaches that are 
available to guide priority-setting for health research funding differ on essential aspects of the 
priority-setting process. The choice of the method is important as it affects the priority-setting 
process and the results. This chapter provides information about commonly used methods that 
applied multi-criteria based approaches to set health research priorities for various purposes.  
Five methods are discussed in the following sections: (1) the Essential National Health 
Research (ENHR) Strategy, (2) Child Health and National Research Initiatives (CHNRI), (3) 
Combined Approach Matrix (CAM), (4) James Lind Alliance (JLA) and (5) MCDA (Viergever 
et al. 2017; Yoshida 2016). As real-world decision problems are often multi-dimensional in 
nature (Mühlbacher & Kaczynski 2016), only methods that consider a multi-criteria based 
approach to examine the multiple aspects of alternatives and set health research priorities are 
considered and reviewed.13 The five methods are summarised in Table 2.1 and then explained 
more fully in turn. 
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Table 2.1: Five examples of commonly used methods, applying a multi-criteria based approach, to set health research priorities  
Method Brief description 
The Essential National Health 
Research (ENHR) Strategy 
ENHR has been developed by the Commission on Health Research for Development (COHRED) and uses a step by step guide 
for setting research priorities. It is focussed on health equity, involving various participants (broad-based consultation), 
considering both quantitative and qualitative information (criteria) (COHRED 1997). 
The Child Health and Nutrition 
Research Initiative (CHNRI) 
The Global Forum for Health Research (GFHR) has been developed the CHNRI. CHNRI aims to improve child health and 
nutrition of all children in low and middle-income countries through research to inform health policy. This method considers a 
set of criteria to more carefully assess many competing research options. The criteria are answerability, effectiveness, 
deliverability, the potential for a substantial reduction of disease burden and the impact on equity (Black 2016). 
Combined Approach Matrix (CAM) CAM has been developed by GFHR. It considers all ‘economic’ and ‘institutional’ dimensions and factors affecting the population 
health status. The method also includes all information necessary for setting the priorities and making rational choices to reverse 
the burden of disease (Yoshida 2016). Economic dimensions include disease burden (and its determinants), the current level of 
knowledge, cost and effectiveness and resource flows. Institutional dimensions include the individual, household, community, 
health ministry, other health institutions, sectors other than health and macro-economic policies (Tomlinson et al. 2011). 
James Lind Alliance (JLA) method JLA is a non-profit organisation established in 2004. It focuses on involving patients and health professionals on an equal basis. 
JLA uses a nominal group technique to ensure all voices are considered in the priority-setting process. It aims to identify and 
consider uncertainty in the priority-setting framework by using the available information from reports and systematic reviews 
(Nygaard et al. 2019). 
Multi-Criteria Decision Analysis 
(MCDA) 
MCDA involves evaluating more than just two alternatives based on considering multiple criteria. MCDA supports the decision-
making process by incorporating a wide range of stakeholder views and enables the decision results to be made based on 
integrating social and ethical values with scientific evidence. MCDA methods use various theoretical foundations and 
mathematical algorithms to calculate the criteria weights and alternatives scores (Belton & Stewart 2002; Hansen & Devlin 2019; 




2.2 The Essential National Health Research strategy 
The Essential National Health Research (ENHR) strategy was first proposed by the Council on 
Health Research for Development (COHRED)14 in 1990 to improve national health research 
systems. The ENHR strategy has been developed and formed as a step-by-step manual for 
setting health research priorities based on the analyses and experiences of different countries 
that conducted the strategy. This strategy aims to make research more effective based on these 
three principles: putting national priorities first, working for improving health equity and 
linking theory to action for development (COHRED 1997; Okello & Chongtrakul 2000). 
ENHR focusses on equity in health and aims to guide national health research in funding, 
priority-setting and capacity building to improve health status with a particular focus on the 
poor and vulnerable groups who are often worst affected and whose health problems are often 
neglected. In the process of priority-setting, the ENHR strategy uses a multi-criteria approach 
and has an emphasis on recruiting a wide range of stakeholders, including researchers, policy-
makers, health providers and the public to ensure legitimate and acceptable results (Yoshida 
2016). 
The strategy, however, has some methodological limitations (Montorzi et al. 2010; Yoshida 
2016). First, there are no clear guidelines proposed on how to develop and apply the 
prioritisation criteria. Second, interventions and research options are not identified 
systematically and they are based mainly on participants’ subjective views and knowledge. 
Third, the strategy itself does not provide clear guidance or a systematic method for 
determining criteria weights and rating health research options.  
2.3 The Child Health and Nutrition Research Initiative 
The Child Health and Nutrition Research Initiatives (CHNRI) was developed by the WHO 
Global Forum for Health Research (GFHR) in 2007. CHNRI was first developed for 
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prioritising health and nutrition research investments and is commonly used to set health 
research priorities in other areas. The method is used to identify research gaps and priorities in 
national or global health research systems (Rudan et al. 2008; Yoshida et al. 2016).  
The process of priority-setting in CHNRI involves a collaborative consensus of participating 
parties. CHNRI incorporates the principles of three main dimensions: medical (e.g. public 
health concerns), social (e.g. health inequity) and key stakeholders’ views (i.e. preferences) 
that could be useful to set health research priorities at all levels. CHNRI usually considers five 
criteria for evaluating health research options. They include answerability, equity, impact on 
the burden, deliverability and effectiveness (Kapiriri et al. 2007). 
The advantages of this method include considering different criteria in the priority-setting 
process, involving both technical and non-technical stakeholders and the flexibility of the 
process according to various contexts and needs. This method, however, takes into account the 
participation of a limited group of people in the various steps of the priority-setting process. 
Although CHNRI applies a multi-criteria approach, there is a lack of detailed information about 
scoring methods used to determine criteria weights and rank health research needs (Bryant et 
al. 2014; Yoshida 2016). 
2.4 Combined Approach Matrix 
Combined Approach Matrix (CAM) was also developed by GFHR in 1999. CAM proposes a 
five-step process to compile a large body of information to establish a multi-criteria approach 
for setting health research priorities. The five components of this process are disease burden, 
determinants, the current level of knowledge, cost and effectiveness and resource flows to 
identify knowledge gaps and research needs at national and global levels. CAM helps gather 
all available information about health problems, risk factors and groups and compares the cost-
effectiveness of interventions at different levels (GFHR 2004). 
CAM brings together economic and institutional dimensions into a single tool for priority-




health sector. Similar to ENHR, this strategy encourages practitioners to use a broad range of 
main stakeholders such as individuals and main institutions and parties in both public and 
private sectors (Ghaffar 2009; Okello & Chongtrakul 2000).  
Although compiling and summarising a large amount of information is considered an 
advantage for CAM, several studies indicate that it is sometimes difficult to access the 
appropriate information. Likewise, it is difficult to verify the validity of the existing data. This 
method mainly provides the information and evidence base for setting health research 
priorities. The method itself does not generate the priorities, as it does not provide a clear 
methodology to score the criteria and the research priorities. Therefore, it may not be 
systematically repeatable over time (GFHR 2004; Yoshida 2016). 
2.5 James Lind Alliance (JLA) method 
James Lind Alliance (JLA) is a non-profit organisation based in the United Kingdom. It was 
established in 2004. JLA uses a priority-setting partnership approach to involve main 
stakeholders such as patients and health professionals (on an equal basis) to set health research 
priorities. It uses a nominal group technique to ensure that all voices are considered in the 
decision-making process. JLA aims to increase awareness amongst both parties, and identify 
what matters to both patients and health professionals, to ensure that research priorities are 
beneficial and relevant to end-users. Uncertainty is a key element considered by JLA to find 
the solution to the unanswered questions in the priority-setting process. The method uses the 
available reports and systematic reviews to collect both qualitative and quantitative data to deal 
with the decision problem, and answer the unanswered questions – i.e. uncertainties – about 
the benefits and effects of treatment (Nygaard et al. 2019).  
Dealing with uncertainty in the priority-setting process is not always an easy task as there might 
be a lack of reliable and up-to-date data (Yoshida 2016). In addition, the method does not 
involve other key stakeholders, such as health policy-makers and researchers, in the decision-
making process. The method collects both qualitative and quantitative information and data for 




priorities as it does not provide a transparent methodology to weight the criteria and score 
health research priorities. Therefore, the method may not provide systematically reliable results 
over time (GFHR 2004; Yoshida 2016). 
2.6 Multi-Criteria Decision Analysis (MCDA) 
MCDA15 is a branch of operations research with a fundamental grounding in economics, 
mathematics and psychology. MCDA helps stakeholders consider several conflicting factors – 
i.e. criteria – in a rational and consistent way (Belton & Stewart 2002; Ryan 2004). MCDA is 
based on the premise that the alternatives (in this case, health conditions, including NCDs) can 
be described by their characteristics – i.e. criteria – and the extent to which individuals value 
the alternatives depends on their preferences for those characteristics (Baltussen et al. 2010). 
Unlike other methods commonly used for priority-setting, MCDA is concerned with forming 
and explicitly solving the real-world decision problems, weighting criteria and scoring 
alternatives (Angelis & Kanavas 2017).  
MCDA involves evaluating multiple alternatives based on considering multiple criteria. 
MCDA supports the decision-making process by incorporating a wide range of stakeholder 
views and enables the decision results to be made based on integrating social and ethical values 
with scientific evidence (Angelis & Kanavas 2017; Belton & Stewart 2002). It provides a 
systematic framework to break down a complicated decision problem into more manageable 
components. MCDA has been increasingly used in many different fields over the past few 
decades, and it is gaining more attention due to its potential to deal with complex real-world 
problems (Briggs et al. 2012; IJzerman et al. 2014). 
A large number of MCDA methods have been developed over the past few decades. MCDA 
methods – e.g. PAPRIKA and AHP – use various theoretical foundations and mathematical 
algorithms to calculate the criteria weights and alternatives scores (Viergever et al. 2017). 
Many MCDA methods are supported by specialised decision-making software packages 
                                                 
15 MCDA is also known as Multi-Criteria Decision-Making (MCDM). Main MCDA methods such as PAPRIKA 




(Oleson 2016; Weistroffer & Li 2016). Weistroffer and Li (2016) [p. 1302] indicate that these 
software packages help MCDA practitioners “at various stages of the decision-making process, 
including problem exploration and formulation, identification of decision alternatives and 
solution constraints, structuring of preferences and trade-off judgments”. 
A review of MCDA methods undertaken by Marsh et al. (2014) show MCDA has been 
extensively used to support priority-setting of health interventions, but very few studies used 
MCDA to prioritise health conditions to support health research funding decision-making. 
Viergever et al. (2017) [p. 233] argue that “the lack of explicit use of MCDA in health research 
priority-setting exercises may reflect a lack of awareness by health research priority-setting 
experts on the body of literature around MCDA”.  
Some studies criticised the use of MCDA as follows. Most of these criticisms are not 
fundamental as they are typically related to the implementation of MCDA (Baltussen et al. 
2019). First, MCDA, similar to other economic evaluation methods, failed to incorporate 
opportunity costs in the priority-setting process (Oliveria et al. 2019; Sculpher et al. 2017). 
Second, other studies argue that with a large number of MCDA methods available, it is difficult 
for MCDA practitioners to choose the best method (Baltussen et al. 2010) (this issue was 
discussed and addressed in Chapters 4 and 5). Three, some other studies made an argument 
that different MCDA methods may produce different results and it may not be obvious which 
MCDA method provides the right solution to the decision problem (this issue was addressed 
in Chapter 5). Nevertheless, as explained in Chapter 4, several studies point out that the 
inconsistencies in the results yielded by different MCDA methods are somehow inevitable and 
should be accepted as an expression of different methodologies and preference elucidation 
modes used by different MCDA methods (Hobbs & Horn 1997; Hyde 2006; Lienert et al. 
2016).  
2.7 Why MCDA? 
Several methodologies have been developed – such as ENHR, CHNR, CAM and JLAs, as 




helpful for exploring and compiling all available information and considering the perspectives 
of main stakeholders. Although these methods use a multi-criteria based approach to evaluate 
the alternatives, the methods themselves do not generate the priorities since they do not propose 
a structured and explicit methodology to score the research priorities based on the criteria 
(Rudan et al. 2010; Yoshida 2016). “By contrast, MCDA is concerned with more formally 
structuring and solving decision problems, usually involving the explicit weighting of criteria 
and trade-offs between them” [p. 2] (Hansen & Devlin 2019). 
MCDA provides an explicit framework to break down a complicated decision problem into 
more manageable components. Using MCDA methods for setting health research priorities 
improves the various steps of the priority-setting process – e.g. stakeholder recruitment, 
identifying criteria, eliciting criteria weights, scoring alternatives, aggregating individuals’ 
preferences – as well as the legitimacy of the decisions made (IJzerman et al. 2014; Oleson 
2016; Viergever et al. 2017; Weistroffer & Li 2016). Using explicit methods, such as MCDA, 
helps “identify health research priorities in a repeatable and transparent manner” [p. 7] 
(McGregor et al. 2014). 
As mentioned earlier, MCDA helps improve the quality of the decision-making process by 
involving multiple decision criteria since one single criterion is not considered sufficient for 
solving real-life decision problems. In addition, when using explicit approaches like MCDA, 
it is possible to systematically identify and resolve errors and support the robustness of results 
at various stages of the MCDA process. Informed by the literature and given its advantages 
relative to other alternative methods to set health research priorities (IJzerman et al. 2014; 
Marsh et al. 2017; Thokala et al. 2016; Viergever et al. 2017), MCDA is used in this thesis to 
guide health research funding across NCDs. This thesis begins with using a widely-used 
MCDA method – i.e. PAPRIKA – to support health research funding decision-making into 
NCDs in Chapter 3. The WHO has recently used PAPRIKA to create a priority list of antibiotic-




PAPRIKA is then compared with the most widely-used MCDA method – i.e. AHP.16 Main 
MCDA methods, including AHP and PAPRIKA – and their associated software – i.e. Expert 
Choice and 1000minds – as well as the justified reasons for adopting these two prominent 
examples of MCDA methods in this thesis are described in Chapter 4. 
Chapter 3 describes how a priority-setting framework is developed using the PAPRIKA 
method – that is administered using 1000minds software – to create a priority list of NCDs to 
guide health research funding decision-making in NZ. 
                                                 
16 AHP and PAPRIKA are two prominent examples of widely-used MCDA methods compared to other methods 
in the MCDA literature. AHP is the most widely-used and thus the most well known MCDA method. AHP and 
PAPRIKA can produce individual-level data from participants’ stated preferences. Simple Multi-Attribute Rating 
Technique (SMART) is another example of very few MCDA methods that generate individual weights for each 
participant. Interested readers are referred to (Nemeth et al. 2019; Mustajoki et al. 2005) to read about this method 








3 Developing an MCDA-based framework to 






This chapter reports on the results of an MCDA-based framework developed to elicit key 
stakeholders’ preferences relating to NCDs in terms of their priority for health research funding 
in NZ. The preferences of stakeholders were incorporated with evidence on NCDs to create a 
priority list of NCDs. In pursuit of supporting the survey results, additional analyses were 
performed to check the test-retest reliability of the survey and explore whether participants’ 
background characteristics could predict their preferences. Ideally, the priority-setting 
framework developed in this chapter will help policy-makers and researchers to incorporate 
the multi-dimensional nature of NCDs when evaluating their priority for health research 
funding. 
3.1 Introduction  
As explained earlier in Chapter 1, NCDs contribute to high rates of mortality, morbidity and 
health care expenditure in NZ and many other countries (Alwan 2011; Bullen et al. 2015). NZ, 
like many other countries, is struggling with the allocation of scarce health research resources 
across health conditions, including NCDs. It is argued that the burden of NCDs cannot be 
reversed without systematically allocating funding sources for research into NCDs (Frumkin 
& Haines 2019). There is a strong argument that health research systems need to be in tune 
with the needs of patients and research funding should be allocated in proportion to need (Allen 
2017a). The WHO GFHR also emphasises the importance of using structured priority-setting 
frameworks to direct investment into areas of greatest need to improve health equity and 
support vulnerable population groups (Viergever 2010).  
Allocating limited resources across competing alternatives is taking place every day in many 
different areas. However, it is more challenging for health policy-makers to make the right 
decisions (Marsh et al. 2017), as “health is seen as an irreplaceable commodity” [p. 36] 
(Stanhope & Lancaster 2017). Limited health research resources need to be prioritised and 




in many countries, the decisions regarding health research resource allocation often rely on the 
analysis of historical data, which has led to suboptimal use of scarce health resources 
(Knottnerus & Tugwell 2017). As a result, adopting methods such as MCDA to support health 
research priorities and more effectively allocate limited research funding across NCDs has 
become increasingly important.  
PAPRIKA17 – an MCDA method – is used in this chapter to build a priority-setting framework 
to support and guide health research funding across NCDs. As mentioned earlier, the 
PAPRIKA method has been recently used by the WHO to implement a health research priority-
setting framework to create a priority list of antibiotic-resistant bacteria to guide research 
funding into new antibiotics (Tacconelli et al. 2018). ‘1000minds software’ is abbreviated as 
‘1000m’ in the rest of the thesis to preserve space. 
3.2 Method 
The priority-setting framework developed in this thesis involved the following seven steps, as 
presented in Table 3.1 and explained thoroughly in the following subsections. These steps are 
recommended by reports of the MCDA Emerging Good Practices Task Force of the 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and 
commonly used in MCDA studies (Hansen & Devlin 2019; Thokala et al. 2016).  
3.2.1 Step 1: Specifying the decision problem 
A priority list of NCDs to be created based on an MCDA framework to support health research 
funding decision-making in the NZ context. The literature (English language) was searched to 
identify NCDs responsible for large health burdens and spending in NZ and that 
disproportionately affect vulnerable groups such as children, poor people, Māori (NZ’s 
indigenous people) and other ethnic minorities. This literature – academic and grey – included 
                                                 
17 The PAPRIKA method is described briefly in Subsection 3.2.4. Chapter 4 provides more detail about main 




published articles, papers, reports, health system reviews and the websites of major 
international and national organisations such as WHO, World Bank, Institute for Health 
Metrics and Evaluation (IHME), OECD, NZ MOH and HRC. Experts (Blakely et al. 2019; NZ 
MOH 2009, 2016b). In addition, experts in NCDs from a wide range of clinical, research and 
policy-making backgrounds were also consulted to corroborate the interpretation and improve 
the understanding of the information gained from the literature search.  
Table 3.1: General steps for designing and implementing the NCD survey 
Step Title Description  
1 Specifying the decision problem 
A priority list of NCDs to be created based on a priority-
setting framework to guide health research funding in NZ. 
2 Defining the prioritisation criteria 
Informed by the earlier literature, the prioritisation criteria 
were initially specified and then validated by in-depth 
interviews with experts. 
3 
Measuring and rating the alternatives’ 
performance based on the criteria 
NCDs were assessed and rated based on the criteria using 
the available evidence in the NZ context. 
4 & 5 
Weighting the prioritisation criteria & 
scoring the decision alternatives 
The PAPRIKA method asked New Zealanders to pairwise 
compare two hypothetical NCDs described based on two 
prioritisation criteria at-a-time. 
6 
Ranking the alternatives based on 
steps 3, 4 and 5 
NCDs were ranked by applying the ratings from step 3 and 
the mean weights from steps 4 and 5. 
7 
Supporting the results given by the 
MCDA process 
The results given by PAPRIKA was examined and 
supported by checking the consistency and performing the 
sensitivity analysis, test-retest reliability and cluster 
analysis. 
 
3.2.2 Step 2: Defining the prioritisation criteria 
Setting research priorities for NCDs involves making complex trade-offs based on multiple 
considerations or criteria (Angelis & Kanavas 2017). Selecting the criteria and developing a 
conceptual framework for selected criteria is important as it helps MCDA practitioners identify 
certain features – or criteria – of the alternatives, prevent criteria overlapping and ensure they 
are well-defined (Tromp & Baltussen 2012). This study is the first attempt to prioritise a 
priority list of NCDs. The criteria were then specified and guided by the relevant priority-




validated by in-depth interviews with experts and pilot-testing of the framework among key 
stakeholders with varied health backgrounds. 
Before specifying the prioritisation criteria, there are at least three considerations that need to 
be taken into account for prioritising NCDs to guide health research needs and funding. First, 
it is important to develop a clear framework to form a set of relevant criteria, reach consensus 
on definitions and rationale for selected criteria (Tromp & Baltussen 2012). Selecting multiple 
criteria helps researchers and policy-makers assess the multi-dimensional burden of NCDs and 
make the best choice between them. 
Second, there are some similarities and differences between priority-setting studies for health 
conditions, including NCDs and health interventions18 (Viergever et al. 2017). Both fields 
follow key steps of MCDA – e.g. identifying criteria, choosing decision-makers, aggregating 
the stated preferences19. However, there is more uncertainty about the potential benefits that 
may be gained from prioritising health conditions (and consequently reducing the burden of 
NCDs). This uncertainty is associated with envisaging and meeting both present and future 
needs (Callahan 1999; Viergever et al. 2017). Therefore, it is difficult to determine and measure 
the benefits gained from prioritising health research funding across NCDs and reducing their 
burden in society. 
Third, previous priority-setting practices have used a variety of qualitative methods, to set a 
list of prioritisation criteria, such as focus group discussions (FGDs), workshops and ad hoc 
meetings, Delphi and expert opinion and existing literature (Tromp & Baltussen 2012; 
Viergever et al. 2017). The reports of the ISPOR’s MCDA Emerging Good Practices Task 
Force also suggest that prioritisation criteria can be identified in several ways, ranging from 
reviews of previous studies to focus groups and facilitated workshops (Marsh et al. 2016; Reed 
et al. 2013; Thokala et al. 2016). 
                                                 
18 Examples of health interventions include health technologies and treatments (Golan & Hansen 2012; Sullivan 
& Hansen 2017). 




The relevant literature was reviewed to create a list of prioritisation criteria. PubMed and 
Google Scholar were the main search engines used to find the relevant articles, reports and 
grey literature for the period 1990 to 2019. Articles and reports were restricted to the English 
language. Various combinations of these keywords were used: priority-setting, prioritisation, 
criteria, ethics, decision-making, research need, health research funding/spending and/or non-
communicable disease(s) and NCD(s).  
3.2.3 Step 3: Rating NCDs on the criteria20 
A structured ‘health vignette’21 – i.e. a brief but thorough description – was developed for 
compiling information about each NCD. Vignettes were prepared using relevant information 
available from the literature – e.g. reviews, national reports and cost of illness (CoI) studies. 
Each vignette included statistical, epidemiological, economic and general information about 
NCDs such as disease definition, risk factors, co-morbidities, prevalence, mortality, YLL (i.e. 
premature deaths), YLD (i.e. disability and pain) and direct health care cost in the NZ context. 
Note that that the vignettes are used, in this chapter, to compile the information about NCDs, 
not to specify the prioritisation criteria nor to prioritise the NCDs. Figure 3.1 presents an 
example of a vignette designed for compiling information about diabetes mellitus. The 
vignettes for other NCDs are available in Appendix 3.8.1. 
NCDs were initially rated on criteria using the latest information in NZ. Expert opinion was 
sought to assist with this rating exercise. The rest of this subsection provides detailed 
information about how NCDs were rated. To rate each NCD with respect to the first two criteria 
– i.e. deaths and loss of QoL – representing fatal and nonfatal burdens of NCDs, two 
components of DALY, i.e. YLL and YLD, were used. The latest data available for NZ were 
2017 data collected from the IHME website. Reports and papers described NCDs for the NZ 
                                                 
20 This way of ranking the alternatives is more convincing because the scored alternatives are a reflection of the 
data (Kao 2010). 
21 A vignette is defined as a brief and carefully structured description of a situation or an individual, providing 
precise information and measurement scales about the most important variables that need to be considered by 
decision-makers when making decisions (Atzmüller & Steiner 2010). Health vignettes are increasingly designed 




context were qualitatively reviewed to identify whether an NCD disproportionately affects 
vulnerable groups. The rated NCDs are reported in Figure 3.2. 
Figure 3.1: Vignette designed for compiling information about ‘diabetes mellitus’ 
Disease: Diabetes mellitus (DM) 
Definition: DM, a group of metabolic disorders, is characterised by high levels of blood sugar over a long time 
(Abiola et al. 2016). 
ICD (International Classification of Diseases): E10-E14 (NZ MOH 2016b). 
Major risk factors: Obesity, physical inactivity and genetics (Athyros et al. 2010). 
The total number of cases with DM: 256,500 (2016) (mainly type 2 diabetes) (NZ MOH 2017d). There are 
approximately 100,000 people with diabetes in NZ, but have not been diagnosed (Bullen et al. 2015; NZ MOH 
2010a, 2014a). 
The number of new cases with DM: 11,000 (2011) (NZ MOH 2002). 
The number of deaths: 4,500 each year (2005) (Kedgley 2007), 768 (2010). Diabetes was the sixth main cause 
of death among all New Zealanders and the fourth among Māori (2009) (Coppell et al. 2013). 
DALYs (health loss or total DALYs (%), in total population, by gender): 1.5 in males and in 1.5 females (1990); 
2.9 in males and 2.6 in females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 3.27 (2017) (IHME 2019). 
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 1.7 (2017) 
(IHME 2019). 
Disproportionately affecting vulnerable groups: Highly prevalent in Māori and Pacific populations (three 
times higher than other New Zealanders). The rate of mortality is 6.5 times more among Māori males and 10 
times more among Māori females (Kedgley 2007). Both types of diabetes (1&2) are increasing in children as 
well (NZ MOH 2002, 2007). There are also ethnic inequalities in access to health care services (Harwood & 
Tipene-Leach).  
Total direct health care cost to the health system, individuals and families: Direct health care costs (hospital 
admission bed costs) was NZ$1.4 million for diabetes (type 2) in 1982, and direct costs of NZ$250 million to 
NZ$600 million for type 2 diabetes in 1996 (costs included scripts, shoes and clinic and general practice visits). 
Direct medical costs of NZ$247 million for diabetes (type 2) in 2001, NZ$540 million in 2006-2007 (Kedgley 
2007) and NZ$600 million (2008) to NZ$1,310 million (2016) (NZ Diabetes 2016; NZ MOH 2009). Publicly-
funded expenditure by type 2 DM (including hospitalisation, outpatient, pharmaceutical, laboratory testing, and 
primary care) was estimated at around NZ$7,563 million in 2016 (Blakely et al. 2019). 
Co-morbidity with: Cardiovascular diseases, depression, dementia and chronic kidney disease and 










CoI studies were reviewed to distil the relevant data and estimate health care costs associated 
with each NCD. Due to a scarcity of information, only direct health care expenditures incurred 
by the NZ Government and patients (and families) were considered in the analysis. According 
to Blakely et al. (2018), approximately 82% of health care costs are publicly paid by the NZ 
Government, and the remaining 18% is paid by individuals in terms of co-payment and out-of-
pocket money or private health insurance. Due to lack of detailed information about health care 
costs incurred by the Government and patients separately, this proportion was used as the best 
available estimate to roughly calculate direct health care costs to the Government and patients 
for each NCD. Costs were adjusted for inflation by the NZ general consumer price index (CPI) 
for 2017 using the Reserve Bank of NZ inflation calculator.22 
3.2.4 Steps 4 and 5: Weighting the criteria and scoring NCDs23 
Before distributing the survey, it was extensively pilot-tested and refined using several 
convenience samples drawn mainly from the author’s personal and professional networks to 
check the understandability and accuracy of the criteria, levels and the survey instruction. The 
weights were calculated by surveying people from three health sector groups: (1) patients or 
members of the general public; (2) health workforce (e.g. nurses or doctors); and (3) health 
policy-makers or researchers. Consistent with the literature, patients and the general public 
were included as they are considered the ultimate beneficiaries of health research. The other 
two groups were included because of their expert knowledge and interest in NCDs.  
The online survey implemented the PAPRIKA method24 via 1000m. PAPRIKA involves each 
participant being asked to pairwise rank hypothetical NCDs defined on two criteria at-a-time, 
which consists of a trade-off in terms of their priority for research funding. Figure 3.3 presents 
an example of a pairwise-ranking question from 1000m. 
                                                 
22 The Reserve Bank of NZ inflation calculator is available at https://www.rbnz.govt.nz/monetary-
policy/inflation-calculator.  
23 Steps 4 and 5 “can be performed sequentially, simultaneously, or iteratively, depending on the MCDA method” 
[p. 12] (Hansen & Devlin 2019). For example, as briefly will be discussed in Subsection 3.2.4, PAPRIKA asks 
participants to prioritise two hypothetical alternatives defined on two criteria at-a-time (Hansen & Ombler 2008). 




Each time a participant answers a pairwise-ranking question, the method applies the logical 
property of transitivity to automatically identify all other pairs of hypothetical NCDs defined 
on two criteria at-a-time that are pairwise ranked. For example, if a participant ranks NCD A 
ahead of NCD B and NCD B ahead of NCD C, then A is ranked ahead of C – by the logic of 
transitivity. The software eliminates the implicitly ranked questions and thereby reduces the 
number of questions and mitigates the cognitive burden of decision-making for participants 
(Hansen & Ombler 2008). 
From each participant’s answers, the software applies mathematical methods based on linear 
programming to determine the weights on the criteria (and for the levels within each criterion), 
representing their relative importance, which are normalised to sum to unity across the criteria. 
In addition, a Qualtrics survey was embedded in the 1000m survey. Participants were asked 
general questions relating to their backgrounds, such as gender, age, region, ethnicity and 
education, in order to correlate participants’ stated preferences according to their background 
characteristics (explained shortly in Subsection 3.2.6). Participants were asked about how easy 
or difficult they found the survey and answering the questions. A copy of the demographic part 
of the survey is available in Appendix 3.8.2. Ethical approval for the survey was obtained from 
the University of Otago Human Ethics Committee (Reference: D17/169).  




Sampling and contacting the survey participants 
Naturally, different individuals and groups have different experiences and perspectives with 
respect to evaluating NCDs priorities to guide health research funding.25 As explained earlier, 
in particular, the viewpoints of patients was included in the priority-setting exercise because 
they are the ones most directly affected by NCDs (Marsh et al. 2017). In this study, the 
convenience sampling method was used for pilot-test surveys. In addition, snowball sampling 
and stratified purposeful sampling were used to expand maximum variation sampling and 
ensure a diverse range of key stakeholders in the main survey. The stakeholders in this study 
fall into three main categories: (1) patients or the general public;26 (2) health workforce – e.g. 
nurses or physicians; and (3) health policy-makers or researchers. 
Contact details of individuals who were eligible27 to participate in the survey were identified, 
and they were invited to take part in the survey. In addition, a general invitation email was 
distributed within different entities such as universities, MOH, HRC and other health research 
units, DHBs, hospitals, Cancer Society and other relevant entities. Contacted individuals were 
asked to forward the survey link to other interested and eligible people. They were initially 
given two weeks to complete the survey, with a reminder email sent out after 10 days. An 
example of the invitation email is provided in Appendix 3.8.4. 
3.2.5 Step 6: Ranking NCDs based on steps 3, 4 and 5 
As explained earlier, from each participant’s answers, 1000m applies linear programming 
methods to estimate the weights on the criteria (and the levels within each criterion), 
representing their relative importance. The rated NCDs on the criteria in step 3 and the criteria 
weights calculated via steps 4 and 5 are used to rank the NCDs in the survey. The weights were 
                                                 
25 This subject is discussed more fully in Appendix 3.8.3. 
26 The participants were mostly targeted from educated population as education and skill are considered important 
to meaningfully engage patients or general public in the priority-setting and decision-making process (Kapiriri 
2018). Engaging a broader representative group of patients required time, effort and funding to train them. 
27 As mentioned above, key stakeholders, were mainly recruited from the educated population. In addition, eligible 
participants were 18 years and over, New Zealanders or working in NZ, likely to have experience with NCDs – 
e.g. researching in areas related to NCDs, working in the health system (such as nurses and physicians) and being 




summed across the criteria to get a total score for each alternative, via which all alternatives 
were finally ranked. The scientific evidence used to populate the priority-setting framework 
needs to be kept under continuous review and thus must be updated when new information is 
available. For example, the YLL and YLD data used in this study were updated from IHME 
after the 2017 version of data for NZ was released (IHME 2019). 
3.2.6 Step 7: Supporting the participant’s stated preferences and PAPRIKA results  
Although ‘step 7’ is optional, it is considered to perform further procedures and tests at different 
stages of the priority-setting process. This step helps check the consistency of participants’ 
stated preferences and support the PAPRIKA results. Additional tests that are performed in this 
framework are as follows. (1) the consistency check for PAPRIKA (and 1000m); (2) Kendall’s 
Concordance Coefficient; (3) interpolating additional levels among the pre-defined levels on 
quantitative criteria; (4) sensitivity analysis; (5) test-retest reliability of the survey; and (6) 
cluster analysis. These procedures and checks are explained in more detail in the rest of this 
subsection.  
Consistency check28 and Kendall’s Concordance Coefficient29 
A consistency check was performed during the survey to check the consistency of each 
participant’s answers. Consistency checking involves choosing a few questions – e.g. one, two 
or three – to repeat during the survey and checking each participant’s consistency with their 
previous responses (Hansen & Ombler 2008). Three random questions were repeated during 
the online survey to evaluate each participant’s consistency with their preceding answers. The 
results of the consistency checks were used to remove participants with three inconsistent 
answers to improve the robustness of the results.  
In addition, Kendall’s Coefficient of Concordance was calculated to measure the extent of 
agreement between the ranking results given by participants. Kendall’s Coefficient ranges from 
                                                 
28 Consistency check is also called test-retest stability (Mühlbacher & Johnson 2016). 
29 It is also known as Kendall’s W, which is used to assess the conformity of the participants in a given decision 




0 (perfect disagreement) to 1 (perfect agreement). A value of 0 (or close to 0) indicates a low 
level of agreement across the participants and that participants’ stated preferences are very 
close to random. Values close to 1 demonstrate a higher degree of unanimity across the 
participants (Azevedo et al. 2017; Ivlev et al. 2015). 
Interpolating30 additional levels of performance 
The software uses the Bézier spline (smoothed or non-linear) interpolation to construct (or 
interpolate) additional levels between each successive pair of pre-defined levels on the 
quantitative criteria to more accurately rate the NCDs based on criteria levels and improve the 
sensitivity (interpolated levels are shown in Appendix 3.8.5). Unlike the linear (unsmoothed) 
interpolation method, spline interpolation increases the smoothness and creates a better fit for 
a continuous31 function (and variables) (Burden & Faires 1993; Farin et al. 2002; Johnson et 
al. 1993; Kananenka et al. 2016).  
Sensitivity analysis 
It is recommended to include uncertainty as a criterion in the MCDA process or conduct a 
sensitivity analysis to find out the likely resources of uncertainty and support the robustness of 
results (Feizizadeh et al. 2014; Hansen & Devlin 2019; Marsh et al. 2016). A one-way 
sensitivity analysis was performed by the software to find out whether the overall ranking of 
NCDs can be influenced by any changes in the criteria (levels or weights). One-way sensitivity 
analysis, which is a deterministic sensitivity analysis, changes one variable at-a-time and holds 
all others constant. A common way to provide a graphical visualisation for one-way sensitivity 
analysis is the so-called tornado chart,32 a type of bar chart with horizontal bars, where the 
changing variable – i.e. criteria – are presented on the X-axis and the output – i.e. NCDs – is 
observable on the Y-axis (Borgonovo 2017). The variables are plotted in a descending order 
where the top variables, with larger bars, drive the largest impact on uncertainty in ranking 
                                                 
30 Interpolating is useful where there are different levels of performance defined on each criterion. In addition, 
interpolation only works when the levels are in a descending or ascending order. 
31 A continuous function is a function for which small changes in the input variable result in small changes in the 
output variable. A continuous variable can take any integer or non-integer values. 




results. The decision analysts then need to focus on the top variables with larger bars (Benke 
et al. 2011; Wang et al. 2017). 
Test-retest reliability of the survey  
The so-called test-retest reliability of the survey measures the extent to which a survey can be 
replicated over time (Koo & Li 2016). It demonstrates the credibility of a survey to accurately 
capture stated preferences of the same participants assuming that participants’ actual choices 
are fairly stable over time (Carlsson et al. 2014; Morkbak & Olsen 2015). The survey is 
considered reliable when it accurately captures participants’ stated preferences, and reveals the 
same results for the same participants over time (Liebe et al. 2012). The time interval between 
the two surveys has an impact on test-retest reliability. A very short time frame may increase 
the possibility of carryover effects – i.e. the conditions that may carry over from one empirical 
condition to another – due to memory, practice or mood; whereas with a longer period, the 
chance of changes in participants’ stated preferences may rise over time. Most studies consider 
a time lag of about two weeks suitable (Bryan et al. 2000; Morkbak & Olsen 2015; Tony et al. 
2011b). 
A convenience sample of 40 people completed the survey twice, almost two weeks apart, in 
order to check the test-retest reliability of the survey. Both parametric (i.e. paired sample t-
test)33 and non-parametric (i.e. Wilcoxon signed-rank test) tests were performed to check for 
statistically significant differences of the criteria mean weights from the two surveys. The 
Wilcoxon signed-rank test (the non-parametric version of paired sample t-test) was used to 
assess whether the relative rankings (or the order) of the criteria are different between the test 
and retest surveys. 
 
                                                 
33 There are a few assumptions that need to be considered before using the paired sample t-test. First, the 
observations need to be continuous and approximately normally distributed. Shapiro-Wilk test was used to test 
the normality of the sample for the paired sample t-test. Second, observations need to be independent of one 
another. The participating individuals in this survey were independent of one another, resulting in independent 




Cluster analysis  
The PAPRIKA method generates both aggregated and individual-level data. Individual-level 
data enables additional analyses such as cluster analysis34 to identify clusters of participants 
with similar patterns of preferences that may exist. Then other tests – i.e. Pearson’s chi-squared 
test and Cramér’s V – can be conducted along with cluster analysis to examine whether (and 
the extent to which) participants’ stated preferences within each cluster are correlated with their 
background characteristics such as gender, ethnicity, occupation. 
A two-step cluster analysis with a log-likelihood35 measure was used to identify natural clusters 
of participants to reveal response patterns that were very similar. There are three advantages to 
using a two-step clustering method. First, it automatically determines the optimal number of 
clusters and provides a Silhouette measure36 of goodness-of-fit and the quality of the clusters. 
Second, this method uses a combination of both hierarchical and non-hierarchical approaches 
to form the clusters. Third, unlike other clustering methods, the two-step method handles both 
continuous and categorical variables simultaneously (Chiu et al. 2001; Kaye & Johnson 2011).  
Pearson’s chi-squared test examines the associations that may exist between participants’ stated 
preferences and their background characteristics in each cluster by calculating standardised 
residuals, which are presented in a contingency table. A standardised residual37 shows the 
                                                 
34 Cluster analysis is widely used in data mining to identify homogenous clusters (or groups) of data for 
subsequent analyses. Clustering methods are divided into hierarchical, non-hierarchical (or mainly partitioning, 
e.g. K-means) and two-step clustering (a valuable alternative that combines the principles of both hierarchical and 
non-hierarchical methods) methods (Sarstedt & Mooi 2019). Hierarchical cluster analysis constructs 
homogeneous clusters by sequentially merging the observations together one step at-a-time. Non-hierarchical 
techniques, however, build a primary set of cluster means and allocate each observation to the nearest cluster 
mean. Both hierarchical and non-hierarchical clustering methods aim to increase homogeneity within the group 
and heterogeneity between groups (Blei & Lafferty 2009). They rely on using distance measurements that 
demonstrate the (dis)similarity between pairs of observations. The number of clusters has to be pre-determined 
for non-hierarchical methods, whereas it is not a case for hierarchical methods. Pre-determining the optimal 
number of clusters differentiates non-hierarchical clustering from hierarchical clustering methods (Norusis 2010). 
35 Two-step cluster analysis constructs the clusters using log-likelihood or Euclidean distance measurements. The 
log-likelihood measure places a probability distribution on both continuous and categorical variables and assumes 
that all variable are independent, whereas the Euclidean distance measurement can be used only for continuous 
variables (Sarstedt & Mooi 2019). 
36 The Silhouette measure is based on the average distances between the observations and varies between −1 and 
+1. Any values less than 0.20 suggests that the quality of the clusters is poor, values between 0.20 and 0.50 state 
fair and a value higher than 0.50 indicates good quality clusters (Sarstedt & Mooi 2019). 
37 It shows how well the observed distribution of the demographic characteristics, in each cluster, fits with the 




difference between observed and expected values and thus identifies those characteristics – i.e. 
background characteristics within a cluster – that may contribute more to the chi-squared value 
(Hess & Hess 2017). A standardised residual of greater than ±1.9638 is considered significant 
at a p-value of 0.05 (Brown et al. 2016). 
Pearson’s chi-squared test investigates whether there are any relationships between 
participants’ stated preferences (within each cluster) and their background characteristics. If 
the chi-squared test is statistically significant, the strength of the relationship between the 
variables39 is determined by calculating the effect size (Ellis 2010). The size of the effect can 
be interpreted using Cramér’s V, as indicated in Table 3.2. Cramér’s V is one of the most 
commonly used tests to measure the effect size, and that is suitable for large contingency tables 
(Kim 2017). The analyses were conducted in SPSS version 24. 
Table 3.2: Cramér’s V used to interpret the effect size for the chi-squared test 
df 40 Small  Medium Large  
1 0.10 0.30 0.50 
2 0.07 0.21 0.35 
3 0.06 0.17 0.29 
4 0.05 0.15 0.25 
5 0.04 0.13 0.22 
                                                 
38 A positive value shows greater observed frequencies than expected and a negative value, fewer observed counts 
than expected. 
39 That shows the extent to which identified clusters are correlated with participants’ characteristics. 
40 Degree of freedom (df) indicates the number of values that can vary in an analysis and it is calculated using the 





3.3.1 General findings  
NCDs to be prioritised 
Twenty-one NCDs were initially identified. However, two of them – anxiety and dental 
disorders – were excluded due to a paucity of information suitable for the study, resulting in 
19 NCDs being included in the prioritisation exercise. These NCDs, in alphabetical order, are: 
addictive (drug and alcohol use) disorders, arthritis, asthma, back and neck pain, breast cancer, 
chronic kidney disease, chronic obstructive pulmonary disease, colon and rectum cancer, 
coronary heart disease, dementia and Alzheimer’s disease, depressive disorders, diabetes 
mellitus (mainly type 2), headaches, hearing loss, lung cancer, melanoma skin cancer, non-
melanoma skin cancer, prostate cancer and stroke. 
Prioritisation criteria 
As explained earlier, the criteria were specified and guided by relevant priority-setting 
exercises in the literature, as indicated in Table 3.3. According to the literature, three main 
groups of criteria could be used to prioritise chronic NCDs to guide health research funding. 
They include: (1) need, magnitude of the health problem and disease burden, e.g. morbidity 
and mortality; (2) consumed resources, cost burden and efficiency; and (3) additional 
consideration such as ethical and social values (IJzerman et al. 2014; Regier & Peacock 2017; 
Thokala et al. 2016; Tromp & Baltussen 2012). These categories are relatively consistent with 




Table 3.3: Examples of relevant studies used to specify a set of criteria for the NCD survey 
Authors (year) Scope of study Criteria 
Methodology: 
Participants 
Potential criteria for the study 




1. Lives saved, including ‘statistical’ lives 
(i.e. reduced risk of death) 
2. Life-prolongation benefits – in terms of 
the increase in life expectancy and its 
quality-of-life and the number of patients 
affected 
3. Quality-of-life (QoL) gains – in terms of 
baseline QoL, size of QoL gains and 
duration and number of patients affected 
4. Other important ethical/social benefits, 
e.g. targeted to minorities; reduces health 
gaps, etc. 
PAPRIKA: Consensus 
and vote within a 
group of 61 experts 
1. Deaths, rate of mortality (i.e. YLL). 
 










A review of criteria for 
health intervention 
priority-setting 
1. Patients reported health status 
2. Burden of disease 
3. Catastrophic health expenditure 
4. Economic productivity& care for others 
 
5. Size of the target population 
― 1. Mortality (i.e. YLL) and morbidity (i.e. YLD). 
2. Mortality (i.e. YLL) and morbidity (i.e. YLD). 
3&4. It can be defined in terms of two criteria: (1) cost 
incurred by patients, family and community and (2) cost 
incurred by the health system. 
5. Rate of prevalence alone is not a good indicator. It needs 
to be combined with two criteria of deaths and loss of 
quality-of-life. 
Jo et al. (2015) National priority-setting 
of clinical practice 
guidelines development 









AHP: 36 experts 1. Rate of prevalence alone is not a good indicator. It needs 
to be combined with two criteria of deaths and loss of 
quality-of-life. 
2. It can be defined in terms of two criteria: (1) cost 
incurred by patients, family and community and (2) cost 
incurred by the health system. 




Authors (year) Scope of study Criteria 
Methodology: 
Participants 
Potential criteria for the study 
4. Mortality (i.e. YLL) is considered when calculating 
DALYs. Considering both the criteria of DALYs and 
mortality is a double-up. 




prevention and control in 
NZ (a theoretical study) 
1. Likely contribution to the overall NCD 
mortality target 
2. Impact of achieving the target on ethnic 
inequalities in NCD mortality 
― 
1. Mortality (i.e. YLL), failed to consider nonfatal aspects 
of NCDs, morbidity (i.e. YLD). 





1. Patient’s health before treatment 
2. Benefit to patient (i.e. length and/or 
quality of life) 
3. Benefit to others (e.g. family or society) 
PAPRIKA: Online 
survey with 322 adults 
1. Mortality (i.e. YLL) and morbidity (i.e. YLD). 
1, 2&3. Health gains and disease severity should not be 
considered together in the same list of prioritisation 
criteria. Decision analyst can consider either benefit or cost 
later as additional factors in the priority-setting framework. 
A set of prioritisation criteria should reflect either the 
positive aspects (benefit) or the negative aspects (need) of 
the alternatives (Phelps et al. 2018). 
Tacconelli et al. 
(2018) 
Global priority list of 
antibiotic-resistant 
bacteria to guide research, 
discovery and 
development of new 
antibiotics  
1. Mortality PAPRIKA: 70 experts 
with different 
backgrounds 
1. Mortality (i.e. YLL). 
2. Loss of quality-of-life, morbidity (i.e. YLD). 
3. The rate of prevalence alone is not a good indicator. It 
needs to be combined with two criteria of deaths and loss 
of quality-of-life. 
4. NCDs are mostly preventable. 
5. NCDs are mostly treatable. 
2. Healthcare burden 








Need, Magnitude of Health Problem and Burden of Disease 
This category contains the most important descriptive criteria mentioned in many priority-
setting studies. The severity of the health problem has been the primary criterion in most 
prioritisation exercises (Golan et al. 2011). This criterion has been expressed in different forms 
based on the scope of the study as well as the methodology used for assessing the health 
problems (Hoedemaekers & Dekkers 2003; Mobinizadeh et al. 2016). 
In priority-setting exercises for health interventions, ‘need’ is defined in terms of the benefits 
– e.g. saving and prolonging lives – patients would gain from a health intervention. Therefore, 
metrics such as Health-Related Quality of Life (HRQoL) or Quality Adjusted Life Years 
(QALYs) are usually used to measure the effectiveness of health interventions (Golan et al. 
2011). In disease prioritisation studies, however, ‘need’ is interpreted as the burden of disease 
and can be measured in terms of mortality, i.e. fatal aspect; morbidity, i.e. nonfatal aspect; or 
a combination of both. DALYs, or its two components, are widely used to estimate the health 
loss caused by health conditions such as NCDs (Tromp & Baltussen 2012; Vos et al. 2016). 
The burden of disease from NCDs is multi-dimensional. According to Burden of Disease 
(BoD) studies, the rate of disability caused by NCDs is escalating faster than the rate of 
mortality (Vos 2015; Vos et al. 2016). NCDs then cannot be truly represented by only death 
outcomes. However, many systems measure and judge improvement solely on rates of 
mortality (Duttine 2016). This has led to neglecting some of the highly prevalent NCDs that 
cause high rates of disability in many nations. Therefore, considering both fatal and nonfatal 
aspects of NCDs is important when assessing and prioritising them. Two separate criteria were 
considered to reflect both fatal and nonfatal aspects of NCDs in this priority-setting framework. 
The two criteria are (1) deaths across the population – i.e. reduced life expectancy; and (2) loss 
of quality-of-life across the population – i.e. disability and pain, as shown in Table 3.4. The 




Table 3.4: List of criteria (and levels of performance) used in the NCD survey 
Criterion Definition Level 
Health system goal to be 
addressed 
Data source 
Deaths across the 
population – i.e. reduced 
life expectancy Need and the magnitude of health problems 
across the population. This first criterion 
shows fatal aspects of NCDs (i.e. mortality) 
and the second criterion, nonfatal aspects of 
NCDs (i.e. morbidity) across the population. 




Saving lives in short-run Latest NZ YLL data (2017) extracted from the IHME website.  
Loss of quality-of-life 
across the population – 




Improving overall health 
status in medium and 
long-run 
Latest NZ YLD data (2017) extracted from the IHME website. 
Cost of the disease to the 
health system – i.e. 
publicly-funded health 
care 
Costs incurred by the health system to 
provide health care services at different levels 





Improving efficiency and 
value 
 
CoI studies, reports and papers – e.g. from MOH, BODE3 and 
PHARMAC. 
Cost of the disease to 
patients, families and 
community – e.g. unpaid 
family support 
Costs incurred by patients, family and friends 
e.g. productivity loss, out-of-pocket expenses 





from catastrophic costs 
Disproportionately affects 
vulnerable groups – e.g. 
Māori, children, poor 
people 
Other social and ethical considerations to 






Reports and papers –e.g. from WHO, IHME, OECD, MOH, 
HRC, DHBs. 
BODE3: Burden of Disease Epidemiology, Equity & Cost-Effectiveness Programme (BODE3 is a funded program by HRC (Health Research Council) of NZ (New Zealand) to provide data for 
health economics studies); DHBs: District Health Boards (as explained earlier, DHBs in NZ are responsible for providing health care services within their districts); IHME: Institute for Health 
Metrics and Evaluation; MOH: Ministry of Health; OECD: Organisation for Economic Co-operation and Development; PHARMAC: Pharmaceutical Management Agency (PHARMAC is one 
of the leading organisations in the NZ health system that decides which pharmaceutical products are publicly-funded); YLL: Years of Life Lost due to premature deaths; YLD: Years Lived with 





Consumed Resources, Cost Burden and Efficiency 
NCDs pose a heavy financial burden on everyone (Kankeu et al. 2013). Golan et al. (2011) 
indicate that most studies have considered the effect of costs and budgetary limitations in the 
decision-making process. Cost considerations are essential as the process of evaluating ‘needs’ 
remains incomplete without considering its ‘financial issues’ (Drummond et al. 2015; Golan et 
al. 2011; Shmueli et al. 2017). Two relevant categories of costs proposed by Drummond et al. 
(2015) and used in many economic evaluation studies are the publicly-funded health care costs 
and expenses incurred by patients and families including out-of-pocket expenses as well as the 
value of unpaid and informal family support. In this study, two criteria were defined to reflect 
the overall health care expenditure associated with NCDs. They include: (1) cost of the disease 
to the health system – i.e. publicly-funded health care; and (2) cost of the disease to patients, 
families and communities, as indicated in Table 3.4. 
Equity, Ethical and Social Values and Other Considerations 
Improving society’s well-being and bridging health inequality gaps are the primary aims of 
priority-setting studies as well as the main principle of distributive justice in decision-making 
procedures (Hoedemaekers & Dekker 2003). Golan et al. (2011) mention that many studies 
take into account additional considerations such as patients’ affordability and accessibility to 
the health care services especially among vulnerable groups, which focus on improving the 
distribution of health equity across society. The World Bank argues that health priorities 
usually reflect the needs of the majority and fail to consider the particular demands of 
vulnerable groups – e.g. children, poor people and certain ethnicities – who are usually the 
minorities in society. These groups take a higher share of the disease burden and are affected 
disproportionately in most societies (WHO 2002).  
As mentioned above and according to evidence, NCDs may disproportionately affect 
vulnerable groups such as children, poor people, Māori and other ethnicities in NZ (NZ MOH 
2016b). Similarly, studies report that a significant proportion of NZ families experience unmet 




was specified to assess whether an NCD disproportionately affects vulnerable groups – e.g. 
Māori, children and poor people – to take into account additional considerations. 
Table 3.4 presents information about the criteria (and their levels) and the data source used to 
assess each NCD with respect to each criterion. The prioritisation criteria specified in this 
priority-setting framework are linked to (and supported by) the main goals the health systems 
are tasked to achieve. As can be seen in Table 3.4, these goals include ‘improving overall health 
status in society’, ‘improving the distribution of health within the society’, ‘reducing financial 
risk, ‘health system’s responsiveness’ and ‘improving efficiency’ (Murray & Frenk 1999; 
Tromp & Baltussen 2012; WHO 2000). Informed by the literature, two to four levels of 
performance41 are considered for the prioritisation criteria (as presented in Table 3.4). 
General information about participants 
Participants were required to answer approximately 20 pairwise-ranking questions on average. 
From 517 participants who completed the survey, participants with zero consistent answers 
(n=27) and those who answered ‘they are equal’ for all questions (n=14) were excluded from 
the survey to improve the robustness of results. The analysis of the preference survey included 
476 participants, of whom almost 31% were patients or general public, 34% health policy-
makers or researchers and 35% health workers, e.g. nurses or doctors. The representativeness 
of the study sample, the background characteristics of the participants – e.g. gender, ethnicity, 
qualification – were compared with the demographic characteristics of the NZ population using 
data from NZ 2013 census in Table 3.5. The consistency check revealed that almost 75% of 
the participants consistently answered at least two of the three repeated questions, and 35% 
consistently answered all three repeated questions.  
                                                 
41 Defining different levels of performance on each criterion increases the measurability of the criteria, explicitly 
assesses and rates alternatives in a systematic way, particularly when no alternatives dominate. It improves the 
sensitivity and transparency of the analysis (Marsh et al. 2017; Thokala 2012). Although there is no best practice 
to specify the efficient numbers of criteria and levels, Marshall et al. (2010) indicate that most studies used three 
to seven criteria with two to four levels of performance. These levels can be nominal (e.g. where an NCD does 
not proportionately affect vulnerable groups), ordinal (e.g. where an NCD with high disability is worse than an 
NCD with moderate disability) or cardinal (e.g. where an NCD with 18 deaths per 100,000 population is twice as 





Table 3.5: Characteristics of survey participants, n=476 
Characteristics n (%) 
NZ 2013 
statistics (%)  
Gender   
Male 201 (42.2) (48.5) 
Female 274 (57.6) (51.5) 
Gender diverse 1 (0.2)  
Age (years)   
18-24 15 (3.2) 
(28.7) 
25-34 62 (13.0) 
35-44 108 (22.7) 
(32.9) 
45-54 129 (27.1) 
55-64 114 (23.9) 
(38.4) 
65 and over 48 (10.1) 
Ethnicitya   
NZ European 302 (63.4) (71.0) 
Māori 45 (9.5) (11.2) 
Chinese 42 (8.8) (11.0) 
Pacific 18 (3.8) (9.5) 
Indian 29 (6.1) 
(3.0) 
Others 40 (8.4) 
Qualification   
No qualification 30 (6.3) (20.9) 
Secondary school 47 (9.9) (40.0) 
Post-secondary school qualification 72 (15.1) (19.1) 
University degree equivalent 327 (68.7) (20.0) 
Region   
North Island 325 (68.3) (75.5) 
South Island 151 (31.7) (24.5) 
Work situation   
Working 312 (65.5) (62.3) 
Not working 73 (15.3)  
Retired 91 (19.1)  







Using health care services  
Never 4 (0.8)  
Occasionally  373 (78.4)  
Frequently 99 (20.8)  
Participants from varied sectors of the health system  
Health policy-makers or researchers 161 (33.8)  
Health workers such as nurses or doctors 166 (34.9)  
Patients or the general public 149 (31.3)  
Easiness of making hypothetical choices   
Relatively easy 250 (52.5)  
Relatively difficult 226 (47.5)  







Approximately 68% of participants had a tertiary qualification and over. Around 78% of 
participants had someone in their family with an NCD. Almost 53% of the participants found 
making hypothetical choices in the survey relatively easy. In terms of age, compared with the 
NZ statistics, the study sample has more participants in the 35-54 age group and fewer in the 
younger age groups. Chinese and Pacific populations were underrepresented. In terms of 
qualifications, participants with ‘no qualification’ and ‘secondary school’ were 
underrepresented, and those with ‘university degree’ were overrepresented.42 Male participants 
were also underrepresented. In terms of region, ‘North Island’ was underrepresented. 
3.3.2 Criteria weights 
The survey for calculating the mean criteria weights required participants to answer 20 
pairwise-ranking questions each on average, taking 15-20 minutes in total. Table 3.6 shows the 
mean weights on the five prioritisation criteria and their levels, representing their relative 
importance to participants, with their standard deviation (SD). The weights on criteria (and 
their levels) are the averages across all participants.  
As shown in the table, the most important criterion with respect to prioritising NCDs in terms 
of their overall burden to society (and hence their importance for health research funding) is 
‘deaths across the population’ (mean weight = 27.7%), followed by ‘loss of quality-of-life 
(QoL) across the population’ (23.0%), then ‘cost to patients, families and community’ (18.6%), 
‘cost to the health system (17.2%) and the least-important criterion is ‘disproportionately 
affects vulnerable groups’ (13.4%). Criteria weights indicate the relative strength of 




                                                 
42 As stated earlier, the participants were mainly targeted from educated population as education and skill are 




Table 3.6: Sample mean weights on criteria and their levels (%), n=476 
Bolded values show the relative importance – i.e. weight – of the criteria and sum to unity. 
Additional levels were interpolated to rate NCDs more accurately on the criteria and improve 
the sensitivity of the ranking results. For example, with the ‘deaths across the population’ 
criterion, three additional levels could be interpolated: ‘none (or low) - moderate’ with the 
score of 6.9% (which is the interpolated level between the ‘none (or low)’ and ‘moderate’ 
levels) and ‘moderate - high’ with the score of 17.0% (interpolated level between the 
‘moderate’ and ‘high’ levels) and ‘high - very high’ with the score of 24.1% (interpolated level 
between the ‘high’ and ‘very high’ levels). The interpolated levels are shown in Appendix 
3.8.5. 
Criteria and levels Weight (SD) 
Deaths across the population – i.e. reduced life expectancy 
None (or low) 0.0 (0.0) 
Moderate 12.7 (5.0) 
High 20.4 (6.5) 
Very high 27.7 (8.1) 
Loss of QoL across the population – e.g. pain, disability 
Low  0.0 (0.0) 
Moderate 11.9 (4.8) 
High 23.0 (6.3) 
Cost of the disease to the health system – i.e. publicly-funded health care 
Low  0.0 (0.0) 
Moderate 9.0 (4.7) 
High 17.2 (6.7) 
Cost of the disease to patients, families and community – e.g. unpaid family support 
Low  0.0 (0.0) 
Moderate 9.2 (4.2) 
High 18.6 (6.3) 
Disproportionately affects vulnerable groups – e.g. Māori, children, poor people 
No 0.0 (0.0) 




As can be seen in Figure 3.4, 75% of the participants consider ‘deaths’ as the first (48%) and 
second (27%) most important criterion; 67% of participants prioritised ‘loss of QoL (quality-
of-life)’ in the first (17%) and second (50%) place; whereas 74% ranked ‘vulnerable groups’ 
as the least (40%) or second least important criterion (34%). 




Figure 3.5 presents the preference-based marginal rates of substitution (MRS) for each pair of 
criteria, where the relative importance – i.e. weight – of the column criterion is compared with the 
relative importance of the row criterion. “MRS is the magnitude that characterizes preferences and 
it quantifies the trade-offs that individuals are willing to make” [p. 1] (Benjamin et al. 2014). As 
shown in the figure, MRS demonstrates the highest level of a criterion that the survey participants 
are willing to give up for another criterion. As criteria weights represent the relative importance of 
the criteria, the rate of any two criteria weights can be interpreted as an estimate of the average 
preference-based MRS between the criteria. For example, the preference-based MRS between 
‘deaths’ and ‘loss of QoL’ is 1.2 (i.e. 
27.7
23.0
), which means, in general, participants rate ‘deaths’ to be 
1.2 more important than ‘loss of QoL’. 




3.3.3 The priority list of NCDs43 
The value of Kendall’s W was 0.95,44 indicating a high level of agreement – unanimity – among 
the rankings given by the survey participants. Applying the criteria weights to the NCDs’ 
ratings resulted in a priority score in the range of 0-100% for each NCD, by which they are 
ranked, as shown in Figure 3.6. With a total score of 77%, coronary heart disease (CHD) is the 
top-ranked NCD, followed by back and neck pain (72%) and diabetes mellitus (68%). There 
was no NCD obtaining a total score of 100% since no NCD was rated with the highest level 
for all prioritisation criteria. 
Consistent with the presentational style and terminology used by the WHO for its priority list 
of antibiotic-resistant bacteria (Tacconelli et al. 2018) and to simplify the presentation of the 
final priority list of NCDs to better communicate with policy-makers, the list was categorised 
into four tiers of priority: ‘very critical’, ‘critical’, ‘high’ and ‘medium’ that could be used to 
support health research funding decision-making into NCDs (Table 3.7). The four tiers are 
(total score range in parentheses): ‘Very critical’ priority (68-77%): coronary heart disease, 
back and neck pain, diabetes mellitus; ‘Critical’ priority (54-59%): dementia and Alzheimer’s 
disease, stroke; ‘High’ priority (35-44%): colon and rectum cancer, depressive disorders, 
chronic obstructive pulmonary disease, chronic kidney disease, breast cancer, prostate cancer, 
arthritis, lung cancer; and ‘Medium’ priority (12-29%): asthma, hearing loss, melanoma skin 
cancer, addictive disorders, non-melanoma skin cancer, headaches. 
                                                 
43 NCDs were re-ranked based on the preferences of participants in each cluster as well as the participants in three 
groups of stakeholders in Appendix 3.8.6. There were no clear differences in NCDs weights and their relative 
rankings across different clusters or three groups of stakeholders. 
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Deaths across the population – i.e., reduced life expectancy
Loss of quality-of-life across the population – e.g., pain, disability
Cost of the disease to patients, families and community – e.g., unpaid family support
Cost of the disease to the health system – i.e., publicly-funded health care




Table 3.7: Priority list of NCDs to support health research funding decision-making 
NCD Priority tier Policy target 
Coronary heart disease, back and neck pain, diabetes mellitus.  Very Critical 
Immediate targets 
Dementia and Alzheimer’s, stroke. Critical  
Colon and rectum cancer, depressive disorders, chronic 
obstructive pulmonary disease, chronic kidney disease, breast 
cancer, prostate cancer, arthritis, lung cancer. 
High  Medium-term targets 
Asthma, hearing loss, melanoma skin cancer, addictive 
disorders, non-melanoma skin cancer, headaches. 
Medium  Long-term targets 
 
NCDs in the (top) ‘very critical’ tier – coronary heart disease, back and neck pain and diabetes 
mellitus – have high rates of YLL or YLD and high health system costs, whereas, in contrast, 
NCDs in the (bottom) ‘medium’ tier – asthma, hearing loss, melanoma skin cancer, addictive 
disorders, non-melanoma skin cancer and headaches – have the lowest burden. The NCD 
included in the ‘very critical’ tier is consistent with the findings from GBD studies in terms of 
research funding (Vos et al. 2017; Roth et al. 2018). Blakely et al. (2019) point out that “in 
GBD 2016, New Zealand had 1.31 times higher morbidity burden for back pain than expected 
based on its level of sociodemographic development” [p. 17]. As well having high rates of YLL 
or YLD, back and neck pain is associated with high health care costs – reflecting the correlation 
between YLD and health care costs, a common finding in other studies (Fun et al. 2019; Kinge 
et al. 2017; Wieser et al. 2018). For example, Blakely et al. (2019) found in NZ that 
neurological and musculoskeletal disorders were the main drivers of high health care 
expenditure.  
3.3.4 Results of sensitivity analysis 
Figure 3.7 presents the sensitivity analysis using the tornado charts for all NCDs in the study. 
The figure demonstrates the most influential criteria that could be a source of uncertainty and 
the degree to which they could result in possible changes in the final ranking of the NCDs. 
Tornado charts show the effects on rankings of varying each criterion one level at-a-time, 
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to their impact using a horizontal bar diagram. The sensitivity to changes was considered based 
on interpolated levels.  
NCDs are compared (and evaluated for their priority for research funding) based on the total 
utilities (i.e. the preferences to reduce the burden of NCDs) disaggregated across five criteria, 
as shown in Figure 3.7. The tornado charts provide information on how a particular NCD – for 
example, stroke – would become a top priority for research funding by making predictions 
based on the results – i.e. utilities – from the survey. In other words, what would happen if, for 
instance, stroke’s attributes – i.e. criteria – were changed? (As explained before, bear in mind 
that there might be other additional factors to be considered in the next steps to evaluate the 
feasibility and value for money of conducting a health intervention to address the burden of 
NCDs). For example, relative to diabetes mellitus, stroke has a lower priority for research 
funding due to a lower rate of morbidity – i.e. loss of QoL – and lower health care costs (on 
the other hand, stroke has a higher rate of mortality compared to diabetes mellitus). Based on 
this example, with an increase in the rate of mortality and health care costs for stroke, this 
disease would overtake diabetes mellitus in terms of priority for health research funding. 
As can be observed in Figure 3.7, ‘disproportionately affecting vulnerable groups’ is placed on 
the top, followed by ‘deaths’, ‘loss of QoL’ and ‘cost to patients’ as the next most important 
criteria. These criteria have the potential to change the decision policy. Overall, the results of 
changing the criteria levels on NCDs suggests that NCDs are sensitive to changing the criteria 
interpolated levels. For example, if dementia and Alzheimer’s deaths were reduced from 
‘moderate - high’ to ‘moderate’, dementia and Alzheimer’s would receive a score of 12.7% 
instead of 17.0% on deaths, changing its ranking from the fourth to fifth place.  
3.3.5 Results of the test-retest reliability 
As explained earlier, the reliability of the survey results can be measured by finding out whether 
there are statistically significant differences between the means of the original and retest 
surveys. Overall, there are no statistically significant differences between the criteria mean 




changes in the criteria (and levels) weights, the minimal differences (that were statistically 
insignificant) in criteria weights from original and retest surveys did not affect the ranking 
results of NCDs. Table 3.8 presents the criteria weights for both the original and retest surveys.  
Table 3.8: Criteria mean weights (%), original and retest surveys, n=40 
Criteria Original survey Retest survey 
Deaths   
None (or low)  0 0 
Moderate 13.6 13.9 
High 21.4 21.6 
Very high  29.7 28.4 
Loss of QoL   
Low 0 0 
Moderate 11.8 11.8 
High 21.8 23.9 
Cost to patients   
Low 0 0 
Moderate 9.1 10.0 
High 18.9 19.9 
Cost to the health system   
Low 0 0 
Moderate 9.7 8.6 
High 16.6 14.2 
Vulnerable groups 
No 0 0 
Yes 13.0 13.6 
Before conducting the paired sample t-test, Shapiro-Wilk was used to test whether the 
observations were normally distributed (approximately) for both the original and retest surveys. 
The results of the Shapiro-Wilk test (p-value> 0.05)45 presented in Table 3.9 demonstrates that 
the observations are normally distributed. 
Table 3.9: Results of Shapiro-Wilk test, original and retest surveys, n=40 
 Original survey Retest survey 
Statistic Df p-value Statistic Df p-value 
Deaths 0.97 40 0.49 0.97 40 0.39 
Loss of QoL 0.95 40 0.07 0.94 40 0.06 
Cost to patients 0.98 40 0.74 0.96 40 0.22 
Cost to health system 0.96 40 0.22 0.94 40 0.06 
Vulnerable groups 0.94 40 0.06 0.90 40 0.06 
 
The paired (dependent) sample t-test compares the criteria means and determines whether the 
mean differences are significantly different from zero. As shown in Table 3.10, the results of 
                                                 




the paired sample t-test show no statistically significant difference between the mean criteria 
weights in the original and retest surveys as all p-values are higher than 0.05.  
Table 3.10: Results of paired sample t-test, n=40 
 Paired differences 
T Df p-value Mean (SE) 
95% CI of difference 
Lower Upper 
Pair 1 Deaths1 - Deaths2 0.013 (0.01) -0.031 0.057 1.94 39 0.06 
Pair 2 LossofQoL1 - LossofQoL2 -0.021 (0.01) -0.122 0.080 -.24 39 0.81 
Pair 3 Costtopatients1 - Costtopatients2 -0.010 (0.01) -0.030 0.010 -1.25 39 0.09 
Pair 4 Costtohealth1 - Costtohealth2 0.024 (0.02) -0.003 0.051 1.69 39 0.21 
Pair 5 Vulnerable1 - Vulnerable2 -0.006 (0.01) -0.015 0.003 -1.78 39 0.08 
 
In addition, the results of the Wilcoxon signed-rank test (the non-parametric alternative to the 
paired sample t-test) demonstrate that there is no significant difference (p-value>0.05 as shown 
in Table 3.11) between the rankings (or the order) of the criteria weights across the original 
and retest surveys. 
Table 3.11: Results of Wilcoxon signed-ranks test, n=40 










Z -1.600 -.335 -1.535 -1.223 -1.022 




3.3.6 Results of cluster analysis 
Cluster analysis was performed along with other tests (Pearson’s chi-squared and Cramér’s V) 
to support the results generated by PAPRIKA and identify correlations between participants’ 
stated preferences and their backgrounds characteristics. The two-step clustering method 
identified a four-cluster model. The clusters are reasonably sized with relatively good quality, 
as presented in Figure 3.8. The average Silhouette measure of cohesion was 0.4 suggesting a 
fair cluster quality. Cluster 1 contains 94 (19.7%) participants; cluster 2, 139 (29.2%); cluster 
3, 157 (33.0%); and cluster 4, 86 (18.1%).  
Table 3.12 shows the four clusters of participants with similar patterns of preferences (i.e. the 
criteria mean weights and their relative ranking in each cluster). The relative rankings of criteria 
and their overall weights in the largest cluster, i.e. cluster 3 (n=157), are relatively consistent 
with the results obtained from the main survey with ‘deaths’ as the most important criterion, 
followed by ‘loss of QoL’, ‘cost to patients’, ‘cost to the health system’ and ‘disproportionately 
affects vulnerable groups’. 
 
 




Table 3.12: Criteria mean weights (%) based on four clusters, n=476 
Criteria 
Cluster 1 n=94 
Weight 
Cluster 2 n=139 
Weight  
Cluster 3 n=157  
Weight 
Cluster 4 n=86 
Weight 
 
Deaths 38.31 26.20 26.75 21.21  
Loss of QoL 21.88 23.91 25.78 18.12  
Cost to patients 15.24 15.31 22.04 19.86  
Cost to the health system 11.59 24.76 14.43 17.44  
Vulnerable groups 12.97 9.83 10.99 23.36  
 
Compared to other clusters, participants in the second largest cluster, i.e. cluster 2 (n=139), 
place higher importance on ‘cost to the health system’ than ‘cost to patients’. Cluster 4 (n=86), 
the smallest cluster, is the only cluster that considers ‘disproportionately affects vulnerable 
groups’ as the most important criterion with a mean weight higher than other clusters. In 
addition, participants place higher importance on ‘cost to patients’ than ‘loss of QoL. In cluster 
1 (n=94), the third-largest cluster, the mean weight of ‘deaths’ is much higher than other 
clusters with a large difference from the second most important criterion, ‘loss of QoL’ and the 
relative importance of ‘vulnerable groups’ is comparatively higher than ‘cost to the health 
system’. 
Table 3.13 provides the results of the consistency check for all four clusters to test the 
robustness of the survey’s results. As can be seen in Table 3.13, most participants consistently 
answered at least two of the three questions in all four clusters.  











1  26 (27.66) 35 (25.18) 41 (26.12) 17 (19.77) 
2  35 (37.23) 61 (43.88) 61 (38.85) 31 (36.05) 
3 33 (35.11) 43 (30.94) 55 (35.03) 38 (44.18) 
 
Tables 3.14 and 3.15 display two examples of the contingency tables, the Pearson’s chi-squared 
and Cramér’s V tests for gender and age variables, respectively. As indicated in the third 
section of Table 3.14, 275 (57.8%) of participants are female and 201 (42.2%) are male in the 




cluster. In cluster 1 the expected frequency of females is 54.3 (57.8% of 94) and the expected 
frequency for males is 39.7 (42.2% of 94), as presented in the first section of the table. But the 
actual observed frequency of the females and males are 56 and 38 in cluster 1. As shown in the 
last section of Table 3.14, the likelihood ratio indicates that no association has been detected 
between cluster 1 and gender at the 0.05 level of significance. However, with a larger sample 
size, there might be an association with the p-value=0.06. Nevertheless, this association (i.e. 
size effect) is not large according to the Cramér’s V score, as explained shortly. 
Table 3.1: Example of a 2×2 contingency table for ‘gender’ in Cluster 1 
   Gender 
Total 
   Female Male 
Cluster 1 Within 
cluster 
Observed frequency 56 38 94 
Expected frequency 54 40 94.0 
Standardised residual  1.1 1.3 2.4 
% within cluster 59.57 40.43 100.0 
% within gender 20.36 18.91 19.74 
% of total  11.76 7.98 19.74 
Outside 
cluster 
Observed frequency 219 163 382 
Expected frequency 221 161 382.0 
Standardised residual 0.13 0.15 0.28 
% within cluster 57.33 42.46 100.0 
% within gender 79.63 81.09 80.25 
% of total  46.01 34.24 80.25 
Total 
 Observed frequency 275 201 476 
Expected frequency 275.0 201.0 476.0 
% within cluster 57.8* 42.2* 100.0 
% within gender 100.0 100.0 100.0 
% of total  57.8 42.2 100.0 
Chi-squared 3.61 
Likelihood ratio  
(p-value) 
0.06  Cramér’s V 0.17 
*The observed frequency for females and male participants are 57.8% and 42.2% respectively. As gender is not 
divisible, the actual observed and expected frequency should be 58% and 42% for females and males respectively.  
 
In Table 3.15, the contingency table for cluster 2 for age groups is presented. As can be seen 
in the table, the likelihood ratio (p-value) is less than 0.05, and therefore, the chi-squared test 
is statistically significant, suggesting that there is an association between cluster 2 and age 
groups. The level of association (Cramér’s V is 0.17) is medium (Cramér’s V score 




When the chi-squared test is significant, the standardised residual can be used to identify the 
cells/groups that make a greater contribution to the chi-squared test results. In the first section 
of Table 3.15, the calculated residuals for the age groups of 55-65 years (that is 2.1) are higher 
than 1.96, indicating that this age group is overrepresented in cluster 2.  
Table 3.2: Example of a 2×6 contingency table for ‘age’ in Cluster 2 




















Observed frequency 5 19 41 35 21 18 139 
Expected frequency 4.38 18.11 31.53 37.67 33.29 14.01 139.0 
Standardised residual 0.3 0.2 1.7 0.4 2.1 1.1 5.8 
% within cluster 3.6 13.67 29.50 25.18 15.11 12.95 100.0 
% within age 3 30.65 37.96 27.13 18.42 37.5 29.20 
% of total  1.05 3.99 8.61 7.35 4.41 3.78 29.20 
Outside 
cluster 
Observed frequency 10 43 67 94 93 30 337 
Expected frequency 10.62 43.91 76.47 91.33 80.71 33.97 337.0 
Standardised residual 0.2 0.1 1.1 0.2 1.3 0.6 3.5 
% within cluster 2.97 12.76 19.88 27.89 27.60 8.90 100.0 
% within age 66.67 69.35 62.03 72.87 81.58 62.5 70.80 
% of total  2.10 9.03 14.08 19.75 19.54 6.30 70.80 
Total  Observed frequency 15 62 108 129 114 48 476 
Expected frequency 15.0 62.0 108.0 129.0 114.0 48.0 476.0 
% within cluster 3.15 13.03 22.69 27.10 23.95 10.08 100.0 
% within age 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
% of total  3.15 13.03 22.69 27.10 23.95 10.08 100.0 
Chi-squared 13.72 
Likelihood ratio  
(p-value) 
0.01 Cramér’s V 0.17 
 
Due to small numbers in some of the demographic groups, e.g. region, small groups were 
merged into larger ones (for instance, instead of using 14 regions, these were combined into 
two groups: North Island and South Island). The results of the chi-squared tests are provided 
in Table 3.16 along with the relationship (and the size effect) between each cluster and 
participants’ background characteristics. In cluster 2, the second-largest cluster, the relative 
importance of ‘cost to the health system’ is higher than ‘cost to patients’ compared to other 
clusters. This cluster indicates an association with the following characteristics: participants in 
55-64 years age group (with medium effect), participants with no NCDs (with small effect) and 
participants who frequently use health care services (with small effect). There is no association 
found between participants’ characteristics and the other three clusters. The results of clustering 
and chi-squared tests showed that participants’ stated preferences are not affected by their 
background characteristics such as age, gender, ethnicity. Individuals’ results are associated 




Table 3.3: Results of the chi-squared test (χ2) and the effect size of participants’ characteristics within 
each cluster 
Cluster (n, %) Participants’ characteristics  
Significance of χ2 (at the 
significance level of 0.05) 
Effect size 
Contribution of group 
(Standardised residual > ±1.96) 
Cluster 1 
 (n=94, 19.7%) 
Gender χ2=3.61; p-value=0.06 - - 
Age groups χ2=3.19; p-value=0.67 - - 
Qualification χ2=5.72; p-value=0.126 - - 
Region χ2=0.01; p-value=0.90 - - 
Work situation χ2=2.91; p-value=0.23 - - 
Participant or a family member has 
an NCD 
χ2=0.55; p-value=0.45 - - 
Using health care services χ
2=1.15; p-value=0.56 - - 
Key groups of stakeholders χ2=1.64; p-value=0.44 - - 
Ethnicity χ2=1.60; p-value=0.90 - - 
Cluster 2 
 (n=139, 29.2 %) 
Gender χ2=1.70; p-value=0.19 - - 
Age groups χ2=13.72; p-value=0.01 Medium Participants in the age group 
55-64 years (2.1) are 
overrepresented 
Qualification χ2=3.90; p-value=0.27 - - 
Region χ2=0.90; p-value=0.34 - - 
Work situation χ2=0.99; p-value=0.60 - - 
Participant or a family member has 
an NCD 
χ2=3.91; p-value=0.04 Small Participants with no NCDs 
(2.2) are overrepresented  
Using health care services χ
2=7.62; p-value=0.02 Small Participants frequently (4.0) 
using health care services are 
overrepresented 
Key groups of stakeholders χ2=2.54; p-value=0.281 - - 
Ethnicity χ2=8.95; p-value=0.11 - - 
Cluster 3 
 (n=157, 33%) 
Gender χ2=2.12; p-value=0.14 - - 
Age groups χ2=8.34; p-value=0.13 - - 
Qualification χ2=4.27; p-value=0.23 - - 
Region χ2=1.51; p-value=0.21 - - 
Work situation χ2=1.19; p-value=0.55 - - 
Participant or a family member has 
an NCD 
χ2=1.41; p-value=0.23 - - 
Using health care services χ
2=0.97; p-value=0.61 - - 
Key groups of stakeholders χ2=2.58; p-value=0.27 - - 
Ethnicity χ2=6.55; p-value=0.25 - - 
Cluster 4 
 (n=86, 18.1%) 
Gender χ2=2.99; p-value=0.08 - - 
Age groups χ2=2.43; p-value=0.78 - - 
Qualification χ2=1.56; p-value=0.66 - - 
Region χ2=0.06; p-value=0.79 - - 
Work situation χ2=2.77; p-value=0.25 - - 
Participant or a family member has 
an NCD 
χ2=0.01; p-value=0.91 - - 
Using health care services χ
2=1.32; p-value=0.51  - 
Key groups of stakeholders χ2=1.72; p-value=0.42 - - 




3.4 Discussion  
Despite the rising burden of NCDs in NZ and many other countries, systematic priority-setting 
studies to guide health research funding across NCDs are rare, and there is a paucity of research 
in this area (Allen 2016, 2017a; Terry et al. 2018). As discussed earlier, a review of MCDA 
methods undertaken by Marsh et al. (2014) and (2017) showed MCDA was widely used to 
support health intervention prioritisation studies, but very few studies MCDA to prioritise 
health conditions, including NCD (Marsh et al. 2017; Marsh et al. 2014). The intended use of 
such a priority list is to support health research funding decision-making. Additional 
considerations such as the cost of the research and its likelihood of success would also need to 
be included when research projects are being assessed and funds are being allocated in pursuit 
of ‘value for money’. 
In this chapter, an MCDA-based framework was developed and conducted to incorporate both 
stakeholders’ views and scientific evidence to guide research funding across NCDs in NZ. 
Stakeholders’ views were elicited via an MCDA method, i.e. PAPRIKA that is a well-
established decision-making method used to elicit and aggregate stakeholders’ views and set 
priorities within the health care system (Drake et al. 2017; Marsh et al. 2017). As mentioned 
earlier, the WHO has recently implemented the PAPRIKA method to create a priority list of 
antibiotic-resistant bacteria to guide global research into new antibiotics (Tacconelli et al. 
2018), indicating the importance of setting explicit priorities and guiding health research 
funding through using explicit decision-making methods (Tripathy 2018). 
Five criteria were specified (as presented in Table 3.4) to establish a multi-criteria approach in 
this chapter to understand the multi-faceted burden of each NCD, make trade-offs between 
hypothetical NCDs in terms of their priority for research funding and develop a priority list of 
them. The prioritisation criteria specified in this chapter are more or less reflected in other 
similar studies (Golan et al. 2011; Jo et al. 2015; Tromp & Baltussen 2012). These criteria are 
also reinforced with the goals health systems are tasked to achieve, as a rationale behind their 




the health system – are neglected in many priority-setting studies. As NCDs impose a high 
financial burden to patients and health providers, ‘cost’ was considered in this priority-setting 
exercise. In addition, vulnerable or disadvantaged groups can be worse affected by NCDs, and 
their health needs are often overlooked. Therefore, additional social and ethical considerations 
were taken into account to determine whether an NCD disproportionately affects vulnerable 
groups. The latter criterion is consistent with the egalitarian principles of distributive justice, 
which were considered by Golan et al. (2011) in their priority-setting framework. 
The main difference between priority-setting studies for health conditions, including NCDs 
(the subject of this study) and interventions is that there is more uncertainty about the values 
(benefits) that would be gained from prioritising NCDs for research funding (and consequently 
reducing the burden of each NCD). This uncertainty is associated with envisaging and meeting 
both present and future needs (Callahan 1999; Viergever et al. 2017). It is not easy to measure 
the amount of potential public health benefits from addressing NCDs. In the absence of data 
and published information about the benefits gained from reducing the burden of NCDs, 
several studies have highlighted the role of proportional resource allocation according to the 
need and based on need assessment (Allen 2016). Thus, given the above-mentioned reasons, 
the benefit was not considered in this priority-setting framework despite being an important 
factor in real-world priority-setting. In addition, there might be uncertainty about the difficulty 
that participants might have had in thinking about prioritising NCDs for research funding 
compared to health interventions for public or research funding. Participants may find 
prioritising health interventions easier than health research funding. However, there is a paucity 
of literature on the uncertainty about difficulty prioritising health conditions and interventions 
to support health funding. 
Answering the survey questions (an example of questions in 1000m is presented in Figure 3.3) 




differences. The levels within each criterion were specified based on ordinal measurements46 
and in general terms, e.g. low, moderate or high, without much detail and explanation. Findings 
from pilot-testing the survey demonstrated that many participants, particularly those with non-
health backgrounds, found pairs of questions containing any qualitative or quantitative forms 
of YLD,47 YLL or health care cost48 ambiguous or confusing. 
As recommended by many priority-setting studies for health research funding, the study 
participants were mainly targeted through purposeful stratified and snowball sampling. These 
sampling methods aim to improve the priority-setting frameworks through engaging a diverse 
range of suitable stakeholders – e.g. patients, the general public, policy-makers, researchers 
and health workforce – stratified by different characteristics, health backgrounds and 
perspectives with respect to setting health research priorities across NCDs (O’Haire et al. 2011; 
Street et al. 2014; Sutherland et al. 2011). It was not possible to measure the response rate due 
to the way participants were recruited. As mentioned earlier, the contact details of individuals 
who were eligible to participate in the survey were identified, and they were invited to take part 
in the survey. In addition, a general invitation email was distributed within different entities. 
The number of participants included in the survey (n=476) that was relatively large compared 
to other priority-setting studies on health research that conducted online surveys (Yoshida et 
al. 2016). 
Many health research prioritisation studies mainly involve (and recommend to involve) 
researchers and policy-makers (Thakkar & Sullivan 2017). But there is a lack of consensus on 
involving (and how to involve) patients and the public in the health care research priority-
setting. There is also very limited evidence on the actual impact of patient and the public 
                                                 
46
 In addition, judgements based on ordinal (categorical) measurements “have gained popularity because of 
reduced cognitive burden, lower degree of abstract reasoning, reduced measurement error, ease of administration 
and ability to use both health and non-health outcomes” [p. 21] (Ali & Ronaldson 2012). 
47 For example, as each NCD was assessed based on loss of QoL using YLD, it was not possible to use any other 
concepts to define a range for each level on this criterion. Levels containing any qualitative or quantitative forms 
of YLD values were found confusing or mystifying by most participants. This may be a shortcoming of the present 
study with respect to the criteria and their levels being specified in general terms. 
48 Participants also found the pairs of questions containing the amount of health care costs posed by NCD, 




engagement in prioritisation studies for health research (Gray-Burrows et al. 2018). It may be 
practically difficult and expensive to train and engage large representative groups of patients 
and public that could positively and meaningfully engage in the health priority-setting process 
(Yoshida et al. 2016). Blind recruitments of patients and the public (without considering their 
educational level, knowledge and understanding of the subject) will negatively influence the 
acceptability and legitimacy of the collectively made decisions as each participant affects the 
aggregated results (Kapiriri 2018; Manafo et al. 2018). 
Key stakeholders were included in this priority-setting framework because different groups 
may have different perspectives with respect to allocating research funding across NCDs. The 
targeted participant groups in the present priority-setting framework were mainly recruited 
from the educated population. The priority-setting framework might have not sufficiently 
captured the preferences of the lower educated population. Therefore, the study sample is not 
representative of the NZ population, particularly in terms of qualification (i.e. level of 
education), as indicated in Table 3.5 by the NZ 2013 census. The present priority-setting 
framework could be repeated to involve a more representative random sample. As indicated by 
other studies, researchers are expected to use random sampling methods to recruit eligible 
participants. But this approach is costly and time-consuming, and other available sampling 
methods have demonstrated promising results in eliciting and articulating participants’ stated 
preferences that reflect the values/views of the larger community (Valerio et al. 2016). In 
addition, decision analysts need to ensure the targeted general public have a good 
understanding of the terms and concepts used in the survey as it is considered important to 
meaningfully engage the public in the decision-making process (Kapiriri 2018). 
Nineteen NCDs were prioritised based on five prioritisation criteria (with weights determined 
from a survey of NZ health sector stakeholders) and information about their performance on 
the criteria. Like the WHO’s priority list of antibiotic-resistant bacteria (Tacconelli et al. 2018), 
the priority list of NCDs was simplified for ease of communication (e.g. with researchers and 
policy-makers) into four tiers of priority: i.e. ‘very critical’, ‘critical’, ‘high’ and ‘medium’. 




mellitus – have high rates of YLL or YLD and high health system costs, whereas, in contrast, 
NCDs in the (bottom) ‘medium’ tier – asthma, hearing loss, melanoma skin cancer, addictive 
disorders, non-melanoma skin cancer and headaches – have the lowest burden. The findings 
revealed that NCDs with high YLD – i.e. musculoskeletal, mental and neurological disorders 
– are listed in the first and second tiers of priority, demonstrating that NZ, like many other 
countries, is experiencing a disability transition that is also highlighted by other studies (Grosse 
et al. 2009; NZ MOH 2016b; Vos 2015). Blakely et al. (2019) point out that “in GBD 2016, 
New Zealand had 1.31 times higher morbidity burden for back pain than expected based on its 
level of sociodemographic development” [p. 17]. This epidemiologic transition suggests a shift 
to morbidity (not only mortality), affecting both older and younger adults due to population 
ageing and unhealthy lifestyle. As also stated by GBD 2016 studies, YLD rates are increasing 
more rapidly than YLL rates so that nonfatal health loss as a proportion of DALYs is growing 
(Benziger et al. 2016). Long-term conditions such as musculoskeletal, mental and neurological 
disorders are growing rapidly. 
In addition, top-ranked NCDs are mainly associated with high health care costs showing a 
correlation between high health care costs and YLD (disability), which has been found in other 
studies (Blakely et al. 2019; Mitra et al. 2017). A recent study by Blakely et al. (2018) suggests 
that apart from cardiovascular diseases contributing to 21.2% of total NCD expenditure in NZ, 
neurological and musculoskeletal disorders were surprisingly responsible for high health care 
costs making up 22.3% and 20.8% of total NCD expenditure, respectively. There is no doubt 
that some NCDs such as ‘CHD’, ‘back and neck pain’, ‘diabetes’, ‘dementia and Alzheimer’s’ 
and ‘stroke’ remain on top of the priority list due to their higher YLD and/or YLL as well as 
high health care costs to both patients and the health system. For example, ‘back and neck pain’ 
had a higher health loss (7.91% of total DALYs) compared to ‘CHD’ (7.025 of total DALYs) 
in NZ in 2017. Moreover, there has been an annual increase (+0.53%) in health loss caused due 
to back and neck pain compared to a health loss decrease in CHD (-2.71%) (IHME 2019). In 
addition, musculoskeletal, mental and neurological disorders have caused high health care costs 




There are other important NCDs such as anxiety disorders due to medium levels of YLD and 
dental disorders due to and health care expenditures incurred by patients (as health care services 
are not covered for some of the NCDs by the Government) (Exeter et al. 2015; NZ MOH 
2016b). These NCDs are excluded from the priority-setting framework due to a dearth of data; 
however, they are more likely to be placed in the mid-term or long-term priority tiers. The 
percentage of the survey participants who have, or have a family member with, an NCD is 
presented in Appendix 3.8.7. As presented in the table, 29% stated having asthma; 23%, back 
pain; 21%, anxiety disorders; 15%, chronic kidney disease; 11%, coronary heart disease and 
8%, dental disorders.  
The results of the paired sample t-test revealed that there are no significant differences between 
the criteria weights in the original and retest surveys. Therefore, the preference survey 
administered through the PAPRIKA method is likely to be reliable and produces results that 
are replicable over time. This finding is consistent with the findings of Sullivan and Hansen 
(2017), who used PAPRIKA to prioritise health technologies.  
Very few studies have used cluster analysis and MCDA together to explore possible 
correlations between participants’ characteristics and their stated preferences (Kaltoft et al. 
2015; Landau & Chis Ster 2010). Findings from the cluster analysis and chi-squared tests 
revealed very few associations, with the only significant association found to be between 
cluster 2 and criteria – i.e. ‘age group’, ‘participant or a family member having NCD’ and 
‘using health care services’ – demonstrating medium and small effects (as shown in Table 
3.16). The findings indicate that participants’ stated preferences are not associated with their 
personal and background characteristics. This finding is consistent with the findings of Sullivan 
and Hansen (2017) [p. 685], suggesting that “the variation in participants’ preferences is largely 
idiosyncratic and it is related more to their personal preferences than demographic and 
background characteristics”.49 NCDs were also ranked with respect to different clusters of 
participants, as well as different groups of stakeholders, as presented in Tables 3.18 and 3.19 
                                                 
49 Sullivan and Hansen’s study was undertaken on prioritising health technologies based on a different set of 




in Appendix 3.8.6. In general, there were no clear differences in NCDs scores based on 
participants’ stated preferences in different clusters or groups of stakeholders. 
3.5 Strengths of the study 
This study has four main strengths. One, the ranking exercise was performed integrating the 
values of key stakeholders with scientific evidence to guide health research resource allocation 
and policy-making across NCDs. Two, the online survey enabled participants’ stated 
preferences in terms of the relative importance of prioritisation criteria to be elicited, quantified 
and aggregated to set NCDs priorities within health research funding system. Three, the 
PAPRIKA method used in this study performs a consistency check that enables MCDA 
practitioners to remove participants with inconsistent answers and improves the trustworthiness 
of the results. Four, the method generates individual-level stated preferences that enable 
MCDA practitioners to conduct further analysis such as cluster analysis to identify individuals 
with similar patterns of preferences and explore the association between an individual’s 
personal characteristics and their stated preferences. 
3.6 Limitations of the study 
At least five major potential limitations – that could also be recognised as the current research 
gaps in this area – should be acknowledged. One, all the 19 NCDs considered in this chapter 
are rather heterogeneous – e.g. stroke can range from being a mild and transient event to a 
major disabling event requiring nursing home care for the rest of life. However, it was not 
possible to consider the heterogeneity of the NCDs and further classify them in the framework 
due to the lack of detailed information on the heterogeneous health conditions. Two, despite 
contributing to high YLD or health care costs in NZ, NCDs such as anxiety and dental disorders 
were excluded from this framework due to a paucity of data. This not only may affect the results 
but highlights a clear area of future research. Furthermore, due to a lack of detailed data on 
NCDs costs, the proportion proposed by Blakely et al. (2015) – indicating that 82% of all NZ 
health care expenditure is publicly-funded by the Government, and the remaining 18% is 




family) and Government separately50. Three, there was very little evidence on NCDs-related 
health care expenditures by the private sector and non-governmental communities – e.g. Cancer 
Society. But given 82% of the NZ total health care expenses are estimated to be publicly-
funded, this is not considered as a profound limitation (Blakely et al. 2014). Four, it was 
difficult to project and include NCDs’ future trends in the study due to the lack of information 
regarding their likely impact on policy-making. Five, there is uncertainty in setting priorities 
for health research arising from values (benefits) that could be gained from prioritising health 
research funding (and consequently reversing the growth of NCDs). This uncertainty is 
associated with envisaging and meeting both present and future needs (Callahan 1999; 
Viergever et al. 2017).  
3.7 Conclusion 
There is a paucity of research on using MCDA to guide health research funding across health 
conditions such as NCDs. To the best of the authors’ knowledge, the MCDA-based framework 
developed and piloted in this study is the first attempt to prioritise NCDs to support health 
research funding decision-making. More priority actions are required globally and nationally 
to strengthen the health research systems and support the development of sustainable research 
priorities by using explicit and structured priority-setting methods. 
The priority-setting framework developed in this chapter aims to identify the gaps pertaining 
to major NCDs, understand and measure the magnitude of their burden in terms of five criteria 
to inform and support policy decisions across NCDs. In this chapter, the priority-setting 
framework suggests that it is essential to identify and evaluate the multi-dimensional nature – 
e.g. deaths, loss of QoL and health care costs – of NCDs when preparing a priority list of them. 
Ideally, the priority-setting framework established in this chapter will help policy-makers and 
researchers implement systematic frameworks to more effectively allocate health research 
                                                 
50 This proportion, however, should be used with caution across different NCDs – e.g. patients with cancers or 




funding across NCDs. The results from applying the MCDA-based framework for creating a 
priority list of NCDs indicates the framework is feasible and effective. The framework 
developed in this study could also be used for supporting priority-setting for health research 
funding across other health conditions. 
There exists a large body of literature on using explicit decision-making approaches such as 
MCDA to develop structured priority-setting frameworks. But due to the availability of a large 
number of MCDA methods and their diversity, the question is which MCDA methods suit 
MCDA practitioners and the decision problems? What differentiates PAPRIKA from other 





3.8.1 Health vignettes designed for compiling information about NCDs 
Disease: Addictive disorders  
Definition: Addictive disorders are common disorders that involve overuse of alcohol or drugs. Addiction 
develops and gets worse over time (Blanco et al. 2018). 
ICD: Not available (NA) (depends on the specific addictive disorder). 
Major risk factors: Genetic vulnerability, environmental stressors, social pressures and psychiatric problems 
(Blanco et al. 2018). 
The total number of cases with addictive disorders: 34,000 people treated, but 150,000 required treatment 
in 2010-2011 (NZ NHC 2011). 
The number of new cases with addictive disorders: NA. 
The number of deaths: 4,700 deaths from tobacco smoking (1996), 388 from passive smoking (2000), seven 
deaths from cannabis-related conditions (1990-1996) and 142 deaths from alcohol-related conditions (1997) 
(NZ MOH 2001). 
DALYs (health loss or total DALYs (%), in total population, by gender): 2.4 in males (1990); 2.7 in males 
(2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 2.97 (2017) (IHME 
2019). 
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 0.43 
(2017) (IHME 2019). 
Proportionately affecting vulnerable groups: Māori has higher mortality rates due to alcohol-related 
conditions than non-Māori.  
Total direct health care cost to the health system, individuals and families: The health budget for alcohol 
and drug treatment was estimated NZ$120 million in 2011. Only expenditure by MOH was NZ$78.3 million 
in 2016 (NZ MOH 2016a). 




Disease: Arthritis  
Definition: Arthritis is a joint disorder with inflammation and joint pain. Osteoarthritis is considered as the 
most common form of arthritis (Medicinenet 2017). 
ICD: M13 (NZ MOH 2016b).  
The total number of cases with arthritis: 630,000 (2015) (NZ MOH 2015a).  
The number of new cases with arthritis: NA. 
The number of deaths: –  
DALYs (health loss or total DALYs (%), in total population, by gender): 1.6 in females (1990); 2.1 in females 
(2013) (NZ MOH 2016b).  
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 1.67 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 0 (2017) 
(IHME 2019).  
Proportionately affecting vulnerable groups: Women are more likely to get arthritis. The onset of 
rheumatoid arthritis can occur in younger women. In addition, Pacific and Māori men are reported having a 
higher incidence of gout in the world. Children can also get arthritis, i.e. juvenile idiopathic arthritis (JIA). 
Juvenile arthritis affects one in 1000 children. Although it can occur at any age, is commonly seen among 
children between ages one and four years (Medicinenet 2017). 
Total direct health care cost to the health system, individuals and families: NZ$564 million in 2005, health 
sector costs of arthritis were estimated to be NZ$695 million in 2010 and NZ$992.5 million in 2018 (Arthritis 
NZ 2018). The total expenditure (publicly-funded events, including hospitalisation, outpatient, pharmaceutical, 
laboratory testing, and primary care) of musculoskeletal disorders was estimated at around NZ$15,312 million 
in 2016 (Blakely et al. 2019). 






Definition: Asthma is a chronic condition that affects the airways and characterised by recurrent attacks of 
breathlessness and wheezing that vary in severity and frequency among individuals. It may start early in 
childhood. (HQSC 2014). 
ICD: J45, J46 (NZ MOH 2016b). 
Major risk factors: Family history, viral respiratory infections and allergies, smoking, obesity, air pollution 
and occupational exposures (Beasley et al. 2015). 
The total number of cases with asthma: One in seven children (15%, 120,000 children) aged 2–14 years and 
one in nine adults (11%, 401,000 adults) (2014) (HQSC 2014). 
The number of new cases with asthma: NA. 
The number of deaths: 79 deaths (2006), 61 (2007), 65 (2008) and 69 (2011) (HQSC 2014).  
DALYs (health loss or total DALYs (%), in total population, by gender): 2.3 in males and 2.8 in females (1990); 
2.2 in males and 2.7 in females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 1.9 (2017) (IHME 2019). 
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 0.22 
(2017) (IHME 2019). 
Proportionately affecting vulnerable groups: Rate of mortality is higher among Māori (almost 4.8 times) and 
Pacific peoples (5.8 times) than other ethnicities. There are socio-economic differences in asthma mortality 
(HQSC 2014). Most adult asthma develops early in childhood (Beasley et al. 2015). NZ has a higher prevalence 
of asthma than other OECD countries. NZ has the fourth highest hospital admission rates for asthma among the 
OECD countries (HQSC 2014). 
Total direct health care cost to the health system, individuals and families: The direct health care costs 
were NZ$102 million in 1988-1989, including hospital costs (NZ$17 million) and pharmaceutical costs (NZ$85 
million). The direct cost was NZ$125 million in the late 90s. Pharmaceuticals were the main source of direct 
costs. This finding is consistent with the Mitchell (1989) study about asthma costs (NZ MOH 2009). The direct 
costs of asthma in NZ was estimated at NZ$125 million and indirect medical costs, NZ$700 million (e.g. days 
off work, morbidity and mortality) in 2002 (Holt 2002). 
Co-morbidity with: Rhinitis, obstructive sleep apnea, hormonal disorders and psychopathologies (Boulet & 





Disease: Back and neck pain  
Definition: Abnormal strains on the muscles of the vertebral column are the main cause of developing back 
pain. Neck pain occurs because of muscle strain, soft tissue sprain or a sudden force (Linton 2000). 
ICD: F45.4, M53.8, M54.5 (NZ MOH 2016b). 
Major risk factors: Muscle injury, psychological predictors such as stress, distress, or anxiety, as well as 
mood and emotions, cognitive functioning (Linton 2000). 
The total number of cases with back and neck pain: Prevalence of Lower Back Pain (LBP) is 9.1% 
(approximately 305,600 people) of New Zealander adults (2013-2014) (NZ NHC 2014). 
The number of new cases with back and neck pain: NA. 
The number of deaths: – 
DALYs (health loss or total DALYs (%), in total population, by gender): 6.6 in males and 7.9 in females 
(1990); 8.2 in males and 9.7 in females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 17.32 (2017) (IHME 
2019). 
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 0 (2017) 
(IHME 2019). 
Proportionately affecting vulnerable groups: It is more prevalent among women and Māori (McGavock 
2011; Trevelyan & Legg 2010). 
Total direct health care cost to the health system, individuals and families: NZ$215 million per year (by 
Health Vote), NZ$325 million per year (by Accident Compensation Corporation), NZ$795 million (by 
PHARMAC) in 2013-2014 (Harcombe et al. 2009; NZ NHC 2014). The total expenditure (publicly-funded 
events, including hospitalisation, outpatient, pharmaceutical, laboratory testing, and primary care) of 
musculoskeletal disorders was estimated at around NZ$15,312 million in 2016 (Blakely et al. 2019). 






Disease: Breast cancer  
Definition: ‘Breast cancer’ refers to a malignant tumour that develops from cells in the breast. Breast cancer 
starts in the cells of the lobules that are the milk-producing glands (NZ MOH 2017a). 
ICD: C50 (NZ MOH 2011c). 
Major risk factors: Genetic abnormality (Hill et al. 2014).  
The total number of cases with breast cancer: 71,000 (2016) (NZ MOH 2017a).  
The number of new cases with breast cancer: 2,735 (2008) (NZ MOH 2011c). Approximately 400 
NZ females under the age of 44 are diagnosed with breast cancer each year (BCAC 2017; NZ MOH 2017a). 
The number of deaths: More than 600 each year (BCAC 2017) 
DALYs (health loss or total DALYs (%), in total population, by gender): 3.7 in females (1990); 3.4 in females 
(2013) (NZ MOH 2016b).  
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 0.35 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 2.26 
(2017) (IHME 2019). 
Proportionately affecting vulnerable groups: Breast cancer is the most common cancer among women in 
NZ. Māori women are more diagnosed with and die of breast cancer than non-Māori women (NZ MOH 
2011b). Late diagnosis, deprivation and access to and quality of health care services are the main reasons for 
disparities among different ethnicities in NZ (Tin Tin et al. 2018). It is the third most common cancer (Breast 
Cancer Foundation 2017), and after lymphoid and haematological cancer (NZ$38,834 per person), breast 
cancer is the most expensive cancer (NZ$28,074) in 2008 (BCAC 2017). The total cost (publicly-funded 
events, including hospitalisation, outpatient, pharmaceutical, laboratory testing, and primary care) by breast 
cancer was estimated at around NZ$1,481 million in 2016 (Blakely et al. 2019).  
Total direct health care cost to the health system, individuals and families: NZ$76,783,163 (including 
expenses related to testing, treatment, travel to care centre) in 2008 (NZ MOH 2011c).  
Co-morbidity with: NA. 




Disease: Chronic kidney disease (CKD) 
Definition: CKD, also called chronic kidney failure, occurs due to kidney dysfunction (Lights & Boskey 
2017). 
ICD: N18, N18.1, N18.2, N18.3, N18.4, N18.5, N18.9 (NZ MOH 2016b). 
Major risk factors: Older age, low birth weight and family history of CKD, smoking, obesity, hypertension 
and diabetes mellitus (Lights & Boskey 2017). 
The total number of cases with CKD: 210,000 (2015) (NZ MOH 2015b). 
The number of new cases with CKD: NA. 
The number of deaths: NA. 
DALYs (health loss or total DALYs (%), in total population, by gender): 1.3 in males and 1.7 in females 
(1990); 2.1 in males and 2.2 in females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 0.55 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 2.37 
(2017) (IHME 2019). 
Proportionately affecting vulnerable groups: Māori and Pacific are reported with a higher incidence of CKD 
(Collins 2010). 
Total direct health care cost to the health system, individuals and families: The total cost of CKD to the 
health system (publicly-funded events, including hospitalisation, outpatient, pharmaceutical, laboratory 
testing, and primary care) was estimated at around NZ$2,326 million in 2016 (Blakely et al. 2019). 







Disease: Chronic Pulmonary Obstructive Disease (COPD) 
Definition: COPD is an umbrella term used to describe progressive lung diseases including emphysema, 
chronic bronchitis, refractory (non-reversible) asthma and some forms of bronchiectasis. This disease is 
characterised by increasing breathlessness (ALA 2017). 
ICD: J44 (NZ MOH 2016b). 
Major risk factors: Chronic inflammatory airway disease and smoking (ALA 2017). 
The total number of cases with COPD: 200,000 (2003) (Asthma Foundation NZ 2016). 
The number of new cases with COPD: NA. 
The number of deaths: NA. 
DALYs (health loss or total DALYs (%), in total population, by gender): 3.6 in males and 3.4 in females 
(1990); 3.7 in males and 4.1 in females (2013) (NZ MOH 2016b).  
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 2.49 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 5.73 
(2017) (IHME 2019). 
Proportionately affecting vulnerable groups: Hospitalisation rates are the highest for Māori (3.7 times more 
than non-Māori), non-Pacific and non-Asian. Mortality rate is higher among Māori than non-Māori. COPD 
hospitalisation and mortality rates are higher in the deprived areas (Asthma Foundation NZ 2016). 
Total direct health care cost to the health system, individuals and families: Direct health care costs were 
NZ$103 million to NZ$192 million in 2002. Hospitalisations made up the highest proportion, accounting for 
63% of costs. Pharmaceuticals accounted for 15% of costs (NZ MOH 2009). 





Disease: Colon and rectum cancer  
Definition: Colon and rectum cancer (or colorectal cancer) is a malignant growth that develops inside the 
bowel. It is also called the colon, rectal or colorectal cancer (Johnson et al. 2013). 
ICD: C18-C21 (NZ MOH 2011c). 
Major risk factors: Family history, increased body mass index, cigarette smoking, low physical activity, low 
vegetable and low fruit consumption (Johnson et al. 2013). 
The total number of cases with colon and rectum cancer: NA. 
The number of new cases with colon cancer: Almost 2,808 (2008) (NZ MOH 2011c) and 3,030 (2011) (NZ 
MOH 2011a). 
The number of deaths: Around 1,191 (2011) (NZ MOH 2016b). 
DALYs (health loss or total DALYs (%), in total population, by gender): 2.3 in males and 2.4 in females 
(1990); 2.6 in males and 2.3 in females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 0.31 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 4.77 
(2017) (IHME 2019). 
Proportionately affecting vulnerable groups: More NZ women are diagnosed with colorectal cancer than 
other women in the world. Māori people are diagnosed with a lower rate of colorectal cancer than non-Māori, 
but Māori people are more likely to die of this cancer (NZ MOH 2016b). NZ has one of the highest rates of 
colon and rectum cancer in the world (NZ MOH 2011a). 
Total direct health care cost to the health system, individuals and families: NZ$24,824 (that included 
national travel assistance, public hospital discharge excluding palliative care, public inpatient palliative care 
discharge, outpatient attendance, community & hospital pharmacy dispensing, laboratory testing, primary care 
consult) in 2008 (NZ MOH 2011c). It was estimated that the cost of colon and rectum cancer might increase 
from NZ$80 million to NZ$100 million over the next decade (Sheerin et al. 2015). The total cost (publicly-
funded events, including hospitalisation, outpatient, pharmaceutical, laboratory testing, and primary care) was 
estimated at around NZ$1,206 million in 2016 (Blakely et al. 2019). 
Co-morbidity with: Cardiovascular diseases and hypertension (De Marco et al. 2000). 





Disease: Coronary heart disease (CHD) 
Definition: CHD refers to a group of diseases that consists of stable angina, unstable angina, myocardial 
infarction and sudden cardiac death. 
ICD: I20-I25, I30-I52 (NZ MOH 2016b). 
Major risk factors: High blood pressure, family history, diabetes and smoking. 
The total number of cases with CHD: 186,000 (2015) (NZ Heart Foundation 2015). 
The number of new cases with CHD: NA. 
The number of deaths: Around 5,000 (2015) (NZ Heart Foundation 2015). 
DALYs (health loss or total DALYs (%), in total population, by gender): 14.9 in males and 9.2 in females 
(1990); 10.1 in males and 5.8 in females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 0.68 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 18.3 
(2017) (IHME 2019).  
Proportionately affecting vulnerable groups: More Māori males and females die of CHD, and the mortality 
rate for Māori under 65 years of age is higher than for non-Māori in the same age group (Deloitte 2016).  
Total direct health care cost to the health system, individuals and families: The direct cost was NZ$179 
million in 1992 (that included ambulance costs, hospital costs, diagnostic tests, private consultation costs, 
medicine and dispensing costs). Hospital ward stays were the main proportion of the direct costs (NZ MOH 
2009). The total cost (publicly-funded events, including hospitalisation, outpatient, pharmaceutical, laboratory 
testing, and primary care) was estimated at around NZ$7,611 million in 2016 (Blakely et al. 2019). 





Disease: Dementia and Alzheimer’s 
Definition: Alzheimer’s disease and dementia are brain diseases that cause a slow decline in memory, thinking 
and reasoning skills that influence an individual’s ability to do daily tasks (Deloitte 2017). 
ICD: F00, F01-03, G30 and G31 (Deloitte 2017; NZ MOH 2016b).  
Major risk factors: Age is recognised as the most significant risk factor for dementia. Other risk factors 
include a lack of physical activity, smoking and excessive alcohol consumption (NZ MOH 2016b; Deloitte 
2017). 
The total number of cases with dementia Alzheimer’s disease: 62,287 (2016).  
The number of new cases with dementia and Alzheimer’s disease: NA. 
The number of deaths: 1,981 (2013) (Deloitte 2017). 
DALYs (health loss or total DALYs (%), in total population, by gender): 1.2 in males and 2.4 in females 
(1990); 2.4 in males and 4 in females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 1.1 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 9.12 
(2017) (IHME 2019). 
Proportionately affecting vulnerable groups: It is more prevalent among European NZ and expected to 
decrease (from 87.5% in 2016 to 77% in 2038) (Deloitte 2017). 
Total direct health care cost to the health system, individuals and families: Direct health care costs were 
NZ$436 million in 2008. The residential aged care costs (63% of direct costs) made up a large proportion of 
the cost, followed by hospital costs (23% of direct costs) (Deliotte 2012). Direct health costs were NZ$1105.3 
million in 2016 (Deloitte 2017). The total cost of neurological disorders (publicly-funded events, including 
hospitalisation, outpatient, pharmaceutical, laboratory testing, and primary care) was estimated at around 
NZ$15,380 million in 2016 (Blakely et al. 2019). 





Disease: Depressive disorders  
Definition: Depressive disorders are described as the ‘common cold’ of psychiatry (Goodwin 2006). Sadness, 
emptiness, or irritable tempers are the main features along with cognitive changes, which mainly influence the 
individual’s capacity and mood (RANZC 2016). 
ICD: F32, F33, F34.1, F53.0 (NZ MOH 2016b). 
Major risk factors: History, age, gender, diabetes, smoking and blood pressure (Jackson 2000). 
The total number of cases with depressive disorders: Around 648,859 (2005) (Midcentral DHB 2005). 
The number of new cases with depressive disorders: NA. 
The number of deaths: – 
DALYs (health loss or total DALYs (%), in total population, by gender): 2.1 in males and 4.2 in females 
(1990); 2.6 in males and 4.7 in females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 4.21 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 0 (2017) 
(IHME 2019). 
Proportionately affecting vulnerable groups: Māori adults are more likely to have anxiety or depressive 
disorders than non-Māori adults. The NZ MOH has reported that a growing number of young New Zealanders 
(11.8% in 2016) are suffering from psychological distress (i.e. high or very high probability of anxiety or 
depressive disorders). Women are more likely to experience mental disorders than men (NZ MOH 2014b). 
Total direct health care cost to the health system, individuals and families: Direct health costs were around 
NZ$750 million per year (Midcentral DHB 2005).  
Co-morbidity with: Suicide and physical illnesses such as cardiovascular disease and stroke (Barger & 






Disease: Headaches (migraine) 
Definition: Headaches can be severe, recurring and painful. They can be preceded or accompanied by sensory 
warning signs and other symptoms (Webberley 2017). 
ICD: G43.909 (NZ MOH 2016b). 
Major risk factors: Although the causes are not yet known, the following may be considered as likely triggers: 
hormonal changes, emotional triggers, physical causes, medications and diet (Webberley 2017). 
The total number of cases with headaches: 400,000 (NZ MOH 2016b). 
The total number of new cases with headaches: NA. 
The total number of deaths: – 
DALYs in NZ (health loss or total DALYs (%), in total population, by gender): 2.4 in females (1990); 2.4 in 
females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 5.29 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 0 (2017) 
(IHME 2019). 
Proportionately affecting vulnerable groups: Headaches are three times higher in women than in men (NZ 
Neurological Foundation 2017).  
Total direct health care cost to the health system, individuals and families: Direct health costs of headaches 
was estimated around NZ$80 million each year (Hallam 2000). 





Disease: Lung cancer  
Definition: Lung cancer is an uncontrolled growth of abnormal cells that starts in the lungs (Lawrenson et al. 
2018). 
ICD: C33, C34 (NZ MOH 2011c, 2016b). 
Major risk factors: Smoking, family history, exposure to asbestos and other carcinogens (NZ Lung 
Foundation 2013). 
The total number of cases with lung cancer: NA. 
The total number of new cases with lung cancer: 1,871 (2008) (NZ MOH 2011c). 
Total number of deaths: 1,600 each year (NZ Lung Foundation 2013). 
DALYs (health loss or total DALYs (%), in total population, by gender): 3.7 in males and 2.3 in females 
(1990); 3.4 in males and 2.9 in females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 0.098 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 5.55 
(2017) (IHME 2019).  
Proportionately affecting vulnerable groups: Māori people are more likely to be diagnosed and die of lung 
cancer than the general population (NZ Lung Foundation 2013). 
Total direct health care cost to the health system, individuals and families: Direct health care costs were 
NZ$18 million to NZ$28 million in 2002. Hospitalisation costs constituted about two-thirds of the total costs. 
Palliative care costs were more expensive than pharmaceutical costs (NZ MOH 2009). NZ$30.9 million (that 
included national travel assistance, public hospital discharge excluding palliative care, public inpatient 
palliative care discharge, outpatient attendance, community & hospital pharmacy dispensing, laboratory 
testing, primary care consult) for cancers of the trachea, bronchus or lung in 2008 (NZ MOH 2011c). The total 
cost (publicly-funded events, including hospitalisation, outpatient, pharmaceutical, laboratory testing, and 
primary care) was estimated at around NZ$470 million in 2016 (Blakely et al. 2019). 






Disease: Melanoma skin cancer (MSC) 
Definition: It occurs as a changed or new freckle or mole. Often it has an unusual shape or colour, or a variety 
of colours. Some forms might itch, bleed or weep (NZ Health Navigator 2017). 
ICD: C43 (NZ MOH 2011c). 
Major risk factors: Exposure to UV radiation from sun or UV light (NZ Health Navigator 2017). 
The total number of cases with MSC: 4,000 (2008) (NZ Melanoma 2017). 
The total number of new cases with MSC: 18,610 (2005) (NZ MOH 2011c). 
The total number of deaths: 269 (2005) and 292 (2007) (O’Dea 2009). 
DALYs in NZ (health loss or total DALYs (%), in total population, by gender): NA. 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 0.22 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLDs (%), in total population, both sexes, all ages): 1.08 
(2017) (IHME 2019).  
Proportionately affecting vulnerable groups: Māori and Pacific are less likely to get melanoma, but they 
often have thicker (more serious) melanomas. Melanoma is the least common, but the most severe type of skin 
cancer. It spreads quickly and can be fatal if left untreated. The incidence rates of melanoma are the highest in 
both NZ and Australia compared to other countries, around three times the rates in other countries, including 
Europe and America (NZ MOH 2017b). 
Total direct health care cost to the health system, individuals and families: Health care costs (excluding 
GST) was NZ$5.7 million and Lost production was NZ$59.3 million in 2006 (O’Dea 2009). 





Disease: Non-melanoma skin cancer (NMSC) 
Definition: NMSC has two types. Squamous cell carcinoma (SCC), which is common in people over the age 
of 40. It occurs as a raised, crusty, non-healing sore, often found on hands, forearms, face or neck of individuals 
that spend so much time outdoors. SCC can be dangerous if untreated. Basal cell carcinoma (BCC) is the most 
common and the least severe types of skin cancer (as long as they are treated). It appears as a pale, red or pearly, 
smooth lump, usually on the face or neck. It is more prevalent among the older population; however, it can be 
seen in people in their early 40’s and younger (NZ Health Navigator 2017).  
ICD: C44.91 (NZ MOH 2016b). 
Major risk factors: Exposure to UV radiation from sun or UV light (NZ Health Navigator 2017). 
The total number of cases with NMSC: 350,000 (2008). 
The number of new cases with NMSC: 67,000 (2009) (O’Dea 2009) and 80,000 (2010) (Brougham et al. 
2010). 
The number of deaths: 102 (2005) and 122 (2007) (O’Dea 2009).  
DALYs (health loss or total DALYs (%), in total population, by gender): NA. 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 0.12 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 0.49 
(2017) (IHME 2019).  
Proportionately affecting vulnerable groups: The NZ population mainly consists of fair-skinned Europeans 
with a high incidence of NMSC as well as Māori with a lower incidence. But Māori people are more likely to 
die of NMSC. There is a paucity of (up-to-date) information and data on NMSC in NZ (Brougham et al. 2010; 
O’Dea 2009). 
Total direct health care cost to the health system, individuals and families: Health care costs (excluding 
GST) was NZ$51.4 million and Lost production was NZ$6.7 million in 2007 (O’Dea 2009). 





Disease: Prostate cancer  
Definition: The development of cancer in the prostate, a gland in the male reproductive system (Moul 2004). 
ICD: C61 (NZ MOH 2011c). 
Major risk factors: Age, ethnicity, family history, physical activity (Anand et al. 2008; Gann 2002). 
The total number of cases with prostate cancer: 31,00 (2007) (NZ Prostate Cancer Foudation 2017); 2,94 
(2008) (NZ MOH 2011c). 
The total number of deaths: 600 each year (based on statistics from 2007-2009) (NZ MOH 2016b); 670 
(2008) (NZ MOH 2017c). 
DALYs (health loss or total DALYs (%), in total population, by gender): 1.3 in males (1990) and 2.6 in males 
(2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 0.41 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 2.15 
(2017) (IHME 2019). 
Proportionately affecting vulnerable groups: Māori men are more likely to die of prostate cancer than non‐
Māori men (Obertova 2015). NZ has one of the highest rates of incidence of prostate cancer in the world 
(Obertova 2015). 
Total direct health care cost to the health system, individuals and families: NZ$51,969,609 (that included 
national travel assistance, public hospital discharge excluding palliative care, public inpatient palliative care 
discharge, outpatient attendance, community & hospital pharmacy dispensing, laboratory testing, primary care 
consult) in 2008 (NZ MOH 2011c). The total cost (publicly-funded events, including hospitalisation, 
outpatient, pharmaceutical, laboratory testing, and primary care) was estimated at around NZ$1,237 million in 
2016 (Blakely et al. 2019). 







Disease: Stroke (Cerebrovascular) 
Definition: The sudden death of brain cells because of a lack of oxygen, caused by blockage of blood flow or 
rupture of an artery to the brain (Sacco et al. 2013). 
ICD: I60-I69 (NZ MOH 2016b). 
Major risk factors: Obesity, physical inactivity, heavy drinking and using drugs (Ostwald et al. 2006). 
The total number of cases with stroke: 45,000 to 189,000 (2006) (NZ Stroke Foundation 2017). 
The total number of new cases with stroke: 2,500 (2006) (Abubakar & Isezuo 2012). 
The total number of deaths: 2,674 (2006) (NZ Stroke Foundation 2017). 
DALYs (health loss or total DALYs (%), in total population, by gender): 3.5 in males and 4.7 in females 
(1990); 2.7 in males and 3.4 in females (2013) (NZ MOH 2016b). 
Years lived with disability (total YLDs (%), in total population, both sexes, all ages): 1.37 (2017) (IHME 
2019).  
Years of life lost due to premature deaths (total YLLs (%), in total population, both sexes, all ages): 7.51 
(2017) (IHME 2019). 
Proportionately affecting vulnerable groups: Case fatality rates have not improved significantly in ethnic 
groups. The average age at stroke onset is almost 60 in Māori, 62 in Pacific and 68 in Asian/other ethnic groups 
compared to 75 years in NZ Europeans (Fink 2016). 
Total direct health care cost to the health system, individuals and families: Direct costs were NZ$93 
million to NZ$140 million in 1992. Direct costs were about 10 times greater than indirect costs. Hospital and 
continuing care costs constituted 90% of all costs. The indirect costs were estimated at NZ$6 million to NZ$14 
million (lost productivity only) in 1992 (NZ MOH 2009). The cost of acute stroke treatment in the hospital 
was estimated around NZ$700 million in 2017 (Fuatai 2017). The total cost (publicly-funded events, including 
hospitalisation, outpatient, pharmaceutical, laboratory testing, and primary care) was estimated at around 
NZ$2,970 million in 2016 (Blakely et al. 2019). 





















3.8.3 Whose preferences should count? 
Health research decisions may affect many people, involve the interests of many different 
stakeholders and have long-term impacts on future generations. It is important to use decision-
making approaches that reflect the actual choices of key stakeholders. Key stakeholder 
engagement is an essential step in MCDA. “The term ‘stakeholders’ refers to all individuals 
and/or groups who have an interest in the priority-setting process” [p. 619] (Kapiriri et al. 
2007). Stakeholders’ knowledge and values can be combined with evidence to reflect the 
values of main stakeholders, improve the priority-setting process and obtain more legitimate 
outcomes (Yoshida et al. 2016).  
The literature emphasises a broad inclusion of heterogeneous groups of stakeholders involved 
with NCDs – e.g. patients, members of the general public, general practitioners, nurses, 
researchers and policy-makers – who are representatives of a wider population with a wide 
range of experiences, disciplines and expertise in the priority-setting decisions. Involving 
different groups of stakeholders helps incorporate different personal experiences of the issues 
that may not have considered by policy-makers (Tritter & McCallum 2006; Tromp & Baltussen 
2012). In addition, the results of the prioritisation exercise are more likely to be trusted and 
implemented with buy-in from the appropriate stakeholders (Kapiriri 2018; Thokala & 
Madhavan 2018). 
There is a lack of consensus on involving patients and the general public (and their level of 
involvement) in the priority-setting. There is very limited evidence on the actual impact of 
patient and public engagement in the health research priority-setting studies (Gray-Burrows et 
al. 2018). It may be practically difficult and expensive to train and engage large representative 
groups of patients and the public who could positively and meaningfully engage in the health 
priority-setting process (Yoshida et al. 2016). Blind recruitments of patients and the public 
(without considering their educational level, knowledge and understanding of the subject) will 
negatively influence the acceptability and legitimacy of the collectively made decisions as each 




have a good understanding of the main concepts used in the decision survey before recruiting 
them for the survey (Kapiriri 2018; Manafo et al. 2018). 
In addition, the level of stakeholders’ participation varies depending on the scope and aims of 
the priority-setting process. There are different ways to engage key stakeholders and benefit 
from their knowledge and values in different phases of the decision-making process – e.g. 
specifying the criteria, determining their relative importance and assessing alternatives based 
on criteria – ranging from interviews and workshops to focus group discussions and online 
surveys (Bryant et al. 2014; Marttunen et al. 2015; Viergever et al. 2010). In this thesis, key 
stakeholders – e.g. patients, members of the general public, health workforce, health policy-
makers and researchers – are engaged at different stages of the priority-setting frameworks 
from designing the survey to establishing the prioritisation criteria (through pilot-tests and 




3.8.4 Example of the invitation email sent to participants 
 




3.8.5 Interpolated levels among pre-defined levels of performance on criteria  
 




3.8.6 NCDs scores based on four clusters and three groups of stakeholders 
Table 3.4: NCDs scores (%) based on four clusters of participants in the survey, n=476 
NCD Cluster 1 (n=94) Cluster 2 (n=139) Cluster 3 (n=157) Cluster 4 (n=86) 
Addictive disorders 21.36 20.07 21.36 31.80 
Arthritis 32.11 36.14 35.99 46.76 
Asthma 25.39 26.09 26.84 37.41 
Back and neck pain 61.75 73.90 73.33 78.86 
Breast cancer 35.13 26.35 34.60 46.27 
Chronic kidney disease 34.04 35.09 34.57 46.24 
COPD 44.32 40.12 40.94 47.01 
Colon cancer 43.97 41.90 41.52 51.76 
Coronary heart disease 78.12 76.10 74.22 81.87 
Dementia and Alzheimer’s 56.06 62.44 59.66 55.10 
Depressive disorders 37.34 41.85 42.14 51.09 
Diabetes mellitus 60.30 68.43 67.06 75.05 
Headaches 13.62 15.96 16054 12.79 
Hearing loss 26.59 25.78 27.52 36.13 
Lung cancer 38.62 33.88 34.22 44.28 
Melanoma skin cancer 23.31 19.06 19.98 31.31 
Non-melanoma skin cancer 15.65 13.83 14.63 27.07 
Prostate cancer 35.13 26.35 26.75 46.27 
Stroke 55.58 52.18 52.37 59.75 
 








Addictive disorders 22.89 20.56 22.41 
Arthritis 37.63 37.27 36.68 
Asthma 28.41 28.46 27.76 
Back and neck pain 72.70 71.90 72.00 
Breast cancer 37.23 36.90 36.12 
Chronic kidney disease 37.19 36.86 36.08 
COPD 42.82 43.15 42.42 
Colon cancer 44.31 44.18 43.38 
Coronary heart disease 77.50 77.00 76.36 
Dementia and Alzheimer’s 59.48 58.48 59.02 
Depressive disorders 43.01 42.76 42.33 
Diabetes mellitus 68.23 67.37 67.13 
Headaches 14.92 15.01 15.38 
Hearing loss 28.26 28.67 28.06 
Lung cancer 36.95 37.15 36.26 
Melanoma skin cancer 22.49 22.80 21.85 
Non-melanoma skin cancer 17.01 17.16 16.24 
Prostate cancer 37.23 36.90 36.12 




3.8.7 Percentage of participants (or family members) with an NCD 
Table 3.19: Percentage of participants (or family members) with an NCD, n=457 
NCD n (%)* 
Anxiety disorders 96 (21.00) 
Arthritis 72 (15.75) 
Asthma 136 (29.75) 
Back and neck pain 107 (23.41) 
Breast cancer 34 (7.43) 
COPD 17 (3.71) 
Chronic kidney disease 15 (3.28) 
Colon cancer 40 (8.75) 
Coronary heart disease 53 (11.59) 
Dementia and Alzheimer’s 47 (10.28) 
Dental disorders 38 (8.31) 
Depressive disorders 116 (25.38) 
Diabetes mellitus 79 (17.28) 
Headaches 86 (18.81) 
Lung cancer 20 (4.37) 
Melanoma skin cancer 36 (7.87) 
Non-melanoma skin cancer 34 (7.43) 
Prostate cancer 35 (7.65) 
Stroke 48 (10.50) 
Participants without NCDs 100 (21.88) 














With a large number of MCDA methods (and software) available, choosing the best method is 
a multi-criteria problem in and of itself. Given this problem of selection, the question is which 
method better suits MCDA practitioners and their decision situations? Moreover, the associated 
decision-making software package as well as users’ perceptions about the method (and 
software), which can play an essential role in choosing the best method, are not well captured 
in the MCDA evaluation process by many studies. In this chapter, a set of selection criteria is 
specified for the purpose of assessing two prominent examples of MCDA methods – i.e. AHP 
and PAPRIKA – and their associated software – i.e. EC and 1000m. Ideally, the framework 
developed in this chapter will help MCDA practitioners choose a suitable method (and 
software) based on the application of sound theoretical foundations.51 
4.1 Introduction 
As discussed earlier, often supported by specialised decision-making software, a large number 
of MCDA methods has been developed since the 1970s (Saaty & Ergu 2015). The variety of 
MCDA methods has bewildered MCDA practitioners and posed difficulty choosing a suitable 
method. MCDA methods have been extensively used in many various fields due to their ability 
to deal with multi-dimensional decision-making problems (Thokala et al. 2016). The choice of 
an MCDA method (and software) is usually motivated by the decision analyst’s52 familiarity 
and knowledge of the methods (and software) already used in a particular field (Wątróbski et 
al. 2019). Many studies fail to justify the choice of a particular method (and software) over 
others (Cinelli et al. 2014). Roy and Slowinski (2013) indicate that the choice of MCDA is a 
critical part of the decision-making process. Choosing an appropriate method helps find a 
legitimate solution for the decision problem. With an extensive number of MCDA methods 
                                                 
51 In addition, an appropriate MCDA method needs to generate robust results. Evaluating the robustness of the 
selected MCDA results is covered in Chapter 5. 




and their diversity (based on different schools of thoughts), it is challenging for MCDA 
practitioners to select the best method. 
MacCrimmon, as quoted by Saaty and Ergu (2015), has first recognised the importance of 
selecting a suitable MCDA method in 1973 (Zanakis et al. 1998). Since then, there is a large 
body of literature proposing different frameworks to choose a method that suits the MCDA 
practitioner and the decision situation. However, many studies did not examine the associated 
decision-making software as well as the users’ (i.e. MCDA practitioners and participants) 
perception of ease-of-use of the software (Weistroffer & Li 2016; Weistroffer et al. 2005). 
As explained earlier, PAPRIKA is the primary MCDA method used in this thesis to create a 
priority list of NCDs to guide health research funding. In this chapter, PAPRIKA is compared 
with AHP, the most well known and thus the most widely-used MCDA method, to illustrate its 
suitability. AHP is considered a benchmark among MCDA methods by many MCDA 
practitioners. Both AHP and PAPRIKA are two prominent examples of MCDA methods since 
both methods have been used in many different fields and appeared in many publications 
(Belton & Stewart 2002; Marsh et al. 2017; Marsh et al. 2014; Thokala et al. 2016). The two 
MCDA methods survey participants in a way that provides sufficient information to estimate 
the aggregate and individual-level data. These methods, however, are grounded on different 
theoretical foundations and methodologies (Bregar 2018; Drake et al. 2017; Marsh et al. 2014; 
Saaty 1990a). AHP and PAPRIKA differ in the approach taken to keep decision-making burden 
low enough to be practical while still collecting enough information to estimate criteria weights 
and alternatives scores for each individual participants. Therefore, it is worthwhile to compare 
the two methods (and their associated software) further based on their theoretical foundations 
from eliciting participants’ stated preferences to generating the decision results. 1000m is the 
only software package that administers the PAPRIKA method. Expert Choice software is one 
of the several software packages that implements AHP, and it has been cited in numerous 
publications. In addition, it was more convenient for the author to purchase this software at a 





This aim of this chapter is twofold. (1) A checklist of MCDA selection criteria is created to 
help evaluate and select a method (and software) that suits MCDA practitioners and their 
decision situation. (2) Two prominent examples of MCDA – i.e. PAPRIKA and AHP – and 
their associated software – i.e. EC and 1000m – are used to illustrate how the checklist can be 
used. The following sections provide information about AHP (and EC) and PAPRIKA (and 
1000m) and the practical example of how the two methods work. A brief review of the main 
MCDA methods is provided in Appendix 4.10.1. 
4.2 Introduction to AHP and EC 
EC (available at https://www.academic.expertchoice.com), founded by Ernest Forman in 1983, 
is one of the web-based software packages that implements the AHP method. AHP was 
developed by Thomas L. Saaty in the late 1970s with the aim of combining and evaluating both 
quantitative and qualitative criteria. AHP has been widely used for decision-making in many 
fields (Mustajoki & Marttunen 2017; Saaty 1977), and it involves a hierarchy of (at least) three 
layers, as shown in Figure 4.1. 
In AHP, the criteria can be further divided into sub-criteria. AHP asks participants to pairwise 
compare53 criteria (and alternatives) using a (semantic) scale. Each pair can be expressed in 
terms of linguistic phrases such as ‘NCD1 is strongly preferred to NCD2’, or ‘NCD1 and 
                                                 
53 Pairwise comparison is the process of comparing items in pairs to determine which of the items in the pair has 
a greater value or whether they are both equal (Guarini et al. 2018). 
Figure 4.1: Example of decision-making tree for AHP 
Which NCD is more of a problem for society, and therefore, should receive more health 
research funding (to improve health)? 
Cost of NCD to the health system  Loss of QoL Premature deaths 







NCD2 are equally preferred’, or ‘NCD1 is strongly less preferred to NCD2’. The stated 
preference will be quantified on a relative (arbitrary)54 scale of 1 to 9, as presented in Table 4.1 
(Saaty 1977). AHP produces ratio scale measurements from which the relative importance, or 
weight, of the criteria (and alternatives) are calculated. 
 
Table 4.1: Ratio scale measurements used in AHP for pairwise comparisons (Saaty 1977) 
Scale  Definition Reciprocal Definition 
1 Equally preferred 1 Equally preferred 
3 Moderately preferred 
1
3
 Moderately less preferred 
5 Strongly preferred 
1
5
 Strongly less preferred 
7 Very strongly preferred 
1
7
 Very strongly less preferred 
9 Extremely preferred 
1
9
 Extremely less preferred 
2,4,6,8 














Intermediate values between 
adjacent judgments 
Figure 4.2 presents an example of pairwise comparison questions of two criteria at-a-time in 
EC. The number of pairwise questions increases with the number of criteria (and alternatives) 
as shown in Table 4.2. Direct rating55 questions can also be used for evaluating and rating the 
criteria (and alternatives). It is useful, particularly when a large number of alternatives are 
compared with respect to each criterion, as shown in Figure 4.3. AHP is known as a 
compositional method since it elicits participants’ stated preferences on criteria and alternatives 
separately, as depicted in Figures 4.2 and 4.3, suggesting criteria weights are measured 
separately from scoring the alternatives. 
Table 4.2: Number of pairwise comparisons required when using AHP 
Number of criteria/sub-
criteria/alternatives 
1 2 3 4 5 6 7 n 
Number of comparisons 0 1 3 6 10 15 21 
n (n − 1)
2
 
                                                 
54 An arbitrary scale (relative scale), unlike absolute scale, starts at a minimum point e.g. 1 and can progress in 
both directions. 
55 In direct rating questions, alternatives, for example, are evaluated and compared with respect to each criterion 





Figure 4.2: Example of a ratio scale-based pairwise comparison of criteria, NCD survey, from EC 




AHP uses a matrix to compile the participant’s stated preferences (i.e. the ratio scale 
measurements derived from paired comparisons). The structure of a typical decision matrix of 
criteria, A = (aij), is shown in Figure 4.4, where the ratio scales form the entries on and above 
the main diagonal.56 As matrix A is reciprocal, all entries below the main diagonal can be 
calculated using the multiplicative inverse of the derived ratio scales (aji = 
1
aij
). For example, if 
the participant prefers C1 five times greater than C2, the ratio scale derived from this paired 







  C1 C2   Cn  
C1  a11 a12 … a1n  
C2   a22   a2n  
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AHP applies the eigenvector (and eigenvalue)57 method to calculate the criteria weights and 
alternatives scores from the ratio scales,58 using this equation: A × w = λ × w, which shows 
the relationship among a matrix and the associated eigenvalues and eigenvectors. ‘A’ is a 
matrix of order n, ‘w’ is a nonzero vector (also so-called eigenvector, i.e. the matrix that shows 
the criteria weights) and w1, w2, … and wn indicate the weights of criteria C1, C2, …, to Cn, as 
depicted in Figure 4.5. ‘λ’ refers to the eigenvalue (and the number of criteria, which can be 
                                                 
56 In decision matrix A, the main (principal) diagonal consists of the entries that lie on the diagonal starting in the 
upper left corner and proceeding down and towards the right lower corner, where for each entry (aij), the row 
number equals column number (i=j). 
57 A matrix is a collection of numbers and scalar values. It can be used to transform a vector to another. A matrix 
can be understood better by breaking it into eigenvalues and eigenvectors. Eigenvectors and eigenvalues are used 
to reduce noise in data. An eigenvector is a nonzero vector that shows the direction of a matrix. An eigenvalue is 
a scalar that indicates the variance of the data in that direction. Eigen is a German term that means ‘specific, 
characteristic or very own’, denoting a very special relationship between a matrix with its eigenvalues. A matrix 
of n×n has ‘n’ eigenvalues, where each of them is paired with a corresponding eigenvector. 
58 Some studies have used other methods (such as the least squares, additive normalisation and goal programming 
methods) to calculate weights from the ratio scale measurements of the criteria (and alternatives). Interested 
readers are referred to Gao et al. (2010) and Khatwani and Kar (2017) for more information about these alternative 
methods. 




the same when matrix A is perfectly consistent). “Consistency expresses the coherence that 
should (perhaps) exist between judgments about the elements of a set” [p. 4450] (Benítez et al. 
2011). Matrix A is consistent (i.e. ordinally and cardinally transitive), if aijajk = a𝑖𝑘 for i, j, k =
1,2, … , n (Saaty 1997). 
   C1 C2   Cn            
 C1  a11 a12 … a1n    w1      w1  
 C2  a21 a22   a2n    w2      w2  
   
⁝ 
   
⁝ 
 ×  
⁝ 
 = λ ×  
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 Cn  an1 an2 … ann    Wn      Wn  
   Decision matrix of criteria 
(matrix A) 
  Eigenvector Eigenvalue Eigenvector 
Figure 4.5: The eigenvalue (and the eigenvector) method used in AHP to calculate criteria weights 
Saaty indicates that in the decision-making environment, decision-makers may not be precise. 
They may make small errors in judgments, indicating that matrix A may not be consistent 
(Saaty 1990b), and therefore, suggesting that A × w = λmax × w, where λmax is the ‘largest 
eigenvalue’59 when A is no longer consistent. Saaty states a consistency ratio (CR), as will be 
explained shortly in more depth with an example, is calculated by comparing the inconsistency 
of judgments – i.e. participants’ stated preferences – with an average inconsistency for random 
judgments (provided by Saaty by simulating large numbers of matrices of order n based on 
random judgments) (Saaty 1987).  
EC automatically calculates a CR for each participant. Saaty indicates that the results are 
sufficiently consistent if CR ≤ 0.10 (Saaty 1987). Otherwise, the MCDA practitioner needs to 
repeat the survey. Interested readers are referred to Costa and Vansnick (2008), Franek and 
Kresta (2014) and Saaty (1990) for more technical information about eigenvector (and 
eigenvalue) method used in the present context. The next section provides a numerical example 
to explain how AHP works. 
                                                 
59 As explained earlier, an eigenvector shows the direction in which the matrix is transformed and the eigenvalue 
represents the variance of the data in that direction. Each eigenvalue is paired with an eigenvector. The largest 
eigenvalue helps identify the largest eigenvector, which is so-called the first principal components or the priority 




4.3 A real-world example of how AHP works 
Suppose that policy-makers face the problem of prioritising NCDs to support health research 
funding decision-making for the next five years. There are three NCDs: ‘NCD1’, ‘NCD2’ and 
‘NCD3’ to be evaluated based on three criteria: ‘C1’, ‘C2’ and ‘C3’ (a simple decision 
situation). Now, suppose that a participant is asked to pairwise compare two criteria at-a-time 
and indicate the extent to which one criterion is more important than the other one (when 
evaluating different NCDs to prioritise health research funding). For example, based on the 
participant’s stated preferences, C1 is four times less important than C2 (i.e. C1= 
1
4
 × C2), C1 
is two times less important than C3 (i.e. C1= 
1
2
 × C3) and C2 is three times more important 
than C3 (i.e. C2 = 3 × C3) as shown in decision matrix A below.60 The diagonal values of the 
decision matrix are always 1 (since each criterion is compared with itself). 
   C1 C2 C3  
 C1  1 1/4  1/2  
A = C2   1 3  
 C3    1  
 
As explained earlier, the participant stated preferences create the upper triangular matrix. The 
lower triangular matrix can be calculated using reciprocal values of the upper triangular. If ‘aij’ 
is the element of row i column j of the matrix, then its reciprocal value is calculated using the 
following formula, aji =
1
aij
 (all values are positive). 
 
 
  C1 C2 C3  
 C1  1 1/4  1/2  
A = C2  4 1 3  
 C3  2 1/3 1  
The (largest) eigenvalue of the decision matrix is identified using the formula below, as 
explained earlier, to calculate its associated eigenvector (so-called priority vector, i.e. the 
matrix that shows the criteria weights). 
                                                 
60 The judgment values can be expressed in terms of integer (e.g. 3) or non-integer numbers (e.g. 
1
2
) as shown in 




A × w = λ × w, 
A × w − λ × w = 0, 
(A − I × λ) × w = 0,61 
W is a nonzero vector. Therefore, det (A − I × λ) = 0 needs to be solved to find the eigenvalues 


















] = 0 
[
1 − λ 1/4 1/2
4 1 − λ 3
2 1/3 1 − λ
] = 0; 
Expanding the determinant;  
(1 − λ) |
1 − λ 3






2 1 − λ




4 1 − λ
2 1/3
|  = 0 












) − 2(1 − λ)] = 0 
Expanding the brackets, simplifying and solving the equation; 
(1 − λ)(1 + λ2 − 2λ) +
13
6
− 3 (1 −  λ) = 0 
λ1 = 3.0183, λ2 = 0.0091 and λ3 = − 0.0091 
                                                 








Now, given λ1 = 3.0183 is the largest eigenvalue (λmax) of the decision matrix of criteria, 
through which the relative importance of the criteria can be calculated using this formula: A×w 

















 (1 × 𝑤1 ) + (
1
4




(4 × 𝑤1 ) + (1 × 𝑤2) + (3 × 𝑤3)
(2 × 𝑤1 ) + (
1
3





 3.0183 × 𝑤1
 3.0183 × 𝑤2
 3.0183 × 𝑤3
] 
There are three equations to be solved as shown below; 
(1 × w1 ) + (
1
4
× w2) + (
1
2
× w3) = 3.0183 × w1 
(4 × w1 ) + (1 × w2) + (3 × w3) = 3.0183 × w2 
(2 × w1 ) + (
1
3
× w2) + (1 × w3) = 3.0183 × w3 
Then, w1 (i.e. weight of C1) = 0.1999, w2 (i.e. weight of C2) = 0.9154 and w3 (i.e. weight of 
C3) = 0.3493. The normalised62 criteria weights are 0.1365, 0.6250 and 0.2385, respectively. 
The same results (criteria weights and λmax) were obtained using MATLAB version R2018a. 
The so-called priority vector provides the criteria weights, as shown in the table below. The 
CR of the participant’s stated preferences for the criteria, as an example, is calculated by 
measuring the consistency index (CI) using the following formulas.  
 C1 C2 C3 Priority vector 
(i.e. weight) 
C1 1 1/4 1/2 0.1365 
C2 4 1 3 0.6250 
C3 2 1/3 1 0.2385 
λmax = 3.0183; CI = 0.009; CR = 0.015 
                                                 
62 The normalised weights show the values so that they all sum to unity. The normalisation allows comparability 










 = 0.009  
CI of the participant stated preferences needs to be compared with the random consistency 
index (RCI) of a large number of simulated matrices of random judgments undertaken by Saaty. 
The average RCI of matrices of dimension 1 to 15 is provided in Table 4.3. CR is 0.015, which 
is less than 0.10. Therefore, the stated preferences in the example are sufficiently consistent. 
Table 4.3: Random consistency index (RCI) for different number of criteria suggested by Saaty (1987) 
N 1 2 3 4 5 6 7 8 9 10 







 = 0.015  
The stated preferences calculated using AHP are sufficiently consistent as the CR is less than 
0.10, as indicated by Saaty (1987).   
Next, the participant is asked to pairwise compare NCDs with respect to each criterion at-a-
time. Suppose NCD1 is seven times more problematic than NCD2 with respect to C1 (i.e. 
NCD1= 7 × NCD2), NCD1 is five times more problematic than NCD3 with respect to C1 (i.e. 
NCD1= 5 × NCD3) and NCD2 is as problematic as NCD3 with respect to C1 (i.e. NCD2 = 1 ×
 NCD3) as shown below. The relative scores of NCDs with respect to C1 and their 
corresponding λmax, CI and CR are provided below. 
With respect to C1  
 NCD1 NCD2 NCD3 Relative score 
NCD1 1 7 5 0.7470 
NCD2 1/7 1 1 0.1194 
NCD3 1/5 1 1 0.1336 
λmax = 3.0126; CI = 0.006; CR = 0.011 
NCDs are pairwise compared with respect to C2. 
With respect to C2  
 NCD1 NCD2 NCD3 Relative score 
NCD1 1 1/5 1 0.1488 
NCD2 5 1 4 0.6908 
NCD3 1 1/4 1 0.1604 




NCDs are pairwise compared with respect to C3. 
With respect to C3  
 NCD1 NCD2 NCD3 Relative score 
NCD1 1 2 1/5 0.1865 
NCD2 1/2 1 1/4 0.1265 
NCD3 5 4 1 0.6870 
λmax = 3.0940; CI = 0.047; CR = 0.081 
The results from all tables are then synthesised to get a total score for each NCD. Criteria 
weights are multiplied by their relative scores. The weighted scores are summed up across all 
criteria to achieve a total score for each NCD, as shown below. 
NCD1 = (0.1365 × 0.7470) + (0.6250 × 0.1194) + (0.2385 × 0.1336) = 0.2085 
NCD2 = (0.1365 × 0.1488) + (0.6250 × 0.6908) + (0.2385 × 0.1604) = 0.4903 
NCD3 = (0.1365 × 0.1865) + (0.6250 × 0.1265) + (0.2385 × 0.6870) = 0.2684 












4.4 Introduction to PAPRIKA and 1000m 
1000m (available at https://www.1000minds.com), developed by Paul Hansen and Franz 
Ombler in 2002, is the only software that implements the PAPRIKA method, as stated earlier. 
PAPRIKA has been widely used in various countries and by international organisations. For 
example, as mentioned earlier, the WHO has recently used PAPRIKA to prioritise antibiotic-
resistant bacteria to guide research of new antibiotics (Tacconelli et al. 2018).63 1000m has 
been used in NZ for ranking patients (e.g. for hip and knee replacements, varicose veins 
surgery, plastic, heart valve and cataract surgeries) to receive elective health care services since 
2004 (Blackett et al. 2014; Gwynne-Jones et al. 2016; Hansen et al. 2012).  
As explained briefly in Chapter 3, PAPRIKA is considered a Discrete Choice Experiment 
(DCE)64 method (Nemeth et al. 2019). PAPRIKA addresses different levels of performance for 
each criterion and it involves pairwise ranking two hypothetical alternatives defined on two 
criteria at-a-time (Hansen & Ombler 2008). An example of a pairwise-ranking question appears 
in Figure 4.6. The number of pairwise questions in a DCE is based on the number of criteria, 
their levels, the order of questions65 and participants’ answers to preceding questions during a 
survey (Hansen & Ombler 2008; Tacconelli et al. 2018). PAPRIKA is considered a choice-
based decision-making method as it involves the natural process of decision-making most 
people experience in their everyday life (Drummond et al. 2015; Marsh et al. 2016; Thokala et 
al. 2016). PAPRIKA identifies and then eliminates all dominated pairs of alternatives. A 
dominated pair is identified with a higher level for at least one criterion and no lower level for 
the other criterion. For example, the combination of ‘death: high’ and ‘cost to patients: 
                                                 
63 Please visit https://www.1000minds.com/sectors to check other published papers that have used the PAPRIKA 
method in a variety of fields. 
64 DCE is an endorsed method to elicit participants’ preferences especially in health-related settings. It is based 
on comparing (hypothetical) scenario cases of alternatives. Some studies refer to DCE and Conjoint Analysis 
(CA) interchangeably (Salloum et al. 2017). Others differentiate among DCE and CA and suggest that these two 
methods are evolved based on different theories. Interested readers are referred to Louviere et al. (2010) and 
Nemeth et al. (2019) for in-depth information about DCE and CA. DCE is widely employed by economists, and 
the way paired comparisons are presented and analysed in 1000m differs from the methods more conventionally 
employed. For example, the number and order of comparisons does not depend on choices made in preceding 
comparisons, and the weights are estimated statistically. 
65 PAPRIKA reduces the potential order-effect bias by changing the order of the questions for different 




medium’ dominates the combination of ‘death: medium’ and ‘cost to patients: medium’. In 
contrast, an undominated pair is a pair of two alternatives where one is described by a higher-
ranked level for at least one criterion and a lower level for at least the other criterion. 
The number of potential trade-offs (questions) increases as the number of criteria and their 
levels increases.66 Examples of models with different numbers of criteria (and levels) appear 
in Table 4.4. It is noteworthy to mention that PAPRIKA substantially reduces the number of 
questions by identifying undominated pairs and enforcing logics such as transitivity and the 
joint-factor independence property (i.e. adding or cancelling the common variables from both 
sides of pairs), as will be explained with an example in the next section (Krantz 1972; Hansen 
& Ombler 2008). 
Each time a participant answers a question, the PAPRIKA method applies the logical property 
of transitivity to identify and eliminate all other pairs of hypothetical NCDs, as shown in Figure 
4.6, defined on two criteria at a time that are pairwise ranked, thereby minimizing the number 
                                                 
66 It should be noted that some of the pairwise-ranking combinations might be impossible and can be removed by 
decision analyst from the decision model before being distributed. For example, ‘cost to health system: low’ and 
‘loss of QoL: high’ is an example of an impossible combination (i.e. question) since according to several studies, 
NCDs with high rates of disability and pain cause high health care cost (Blakely et al. 2019). 




of questions asked. For example, if a participant ranks NCD A ahead of NCD B and B ahead 
of NCD C, then A is ranked ahead of C (and so would not be asked about). Also, each time a 
person answers a question, based on all preceding answers PAPRIKA adapts with respect to 
choosing the next question (always one whose answer is not implied by earlier answers).26 
This adaptivity and the transitivity-based elimination procedure ensures the number of 
questions a participant is asked is minimised while ensuring they end up having pairwise 
ranked all hypothetical NCDs defined on two criteria at a time, either explicitly or implicitly 
(by transitivity).  
The number of questions to be answered by participants, thereby reducing the elicitation 
burden, was also reduced by taking advantage of the software’s interpolation feature. For 
example, if a criterion has five levels – e.g. ‘low’, ‘low to moderate’, ‘moderate’, ‘moderate to 
high’ and ‘high’ – then only the first (‘low’), third (‘moderate’) and fifth (‘high’) levels are 
included in the pairwise-ranking questions. The weights for the second (‘low to moderate’) and 
fourth (‘moderate to high’) levels are interpolated using Bézier interpolation – i.e. in essence, 
by fitting a smoothed curve through the weights for the first, third and fifth levels, as explained 
in Chapter 3 (Burden & Faires 1993; Farin et al. 2002; Johnson et al. 1993; Kananenka et al. 
2016). Thus, the granularity arising from having the full set of levels available for rating the 
NCDs on the criteria is maintained while the number of questions that survey participants are 
asked to answer is limited. 
Table 4.4: Examples of decision models with the number of questions required when using PAPRIKA 




8 criteria, 4 levels each 48 = 65,536 2,147,450,880 402,100,560 ~95 
10 criteria, 4 levels 
each 
410 = 1,048,576 549,755,289,600 68,646,770,676 ~160 
12 criteria, 5 levels 
each 
512 = 244,140,625 29,802,322,265,625,000 3,674,775,327,316,600 ~ 900 
20 criteria, 4 levels 
each 





PAPRIKA can be administered as a full ordinal information method, where participants begin 
with ranking the 2nd-degree pairwise-ranking questions as they are considered least cognitively 
difficult. The number of criteria used in pairwise-ranking questions to describe the two 
alternatives shows the degree of the pairs. For example, with three criteria of x, y and z and 
two levels of performance on each (i.e. 1 and 2), a 2nd-degree pair is (y2z1) vs (y1z2), and a 3
rd-
degree pair is (x1y2z1) vs (x2y1z2). Participants can continue to answer pairwise questions 
defined on more than two criteria at-a-time, which involves consideration of the interaction 
effects across three criteria (or more) criteria, until all undominated pairs are identified and 
ranked (either explicitly or implicitly). However, Hansen and Ombler (2008) extensively 
simulated the PAPRIKA method to measure the accuracy of the rankings when a participant 
does not answer every undominated pair compared to a participant’s true overall ranking list, 
which results from ranking every possible alternative. The authors showed that the pairwise 
questions defined on only two criteria – i.e. the two-interaction effect –67 at-a-time would 
provide sufficient information to generate a ranking list that is highly correlated with the 
ranking results yielded from the pairwise comparisons of all possible alternatives, involving 
interactions on two criteria and more (Hansen & Ombler 2008). In addition, the comparisons 
on two criteria at-a-time are cognitively less difficult than full-profile comparisons – i.e. that 
include interaction effects across all criteria – which reduces the decision-making burden for 
participants. Therefore, PAPRIKA does not ask participants to rank all undominated pairwise 
questions and that it can be considered as an incomplete ordinal information method (Jaynes et 
al. 2017; Nicolet et al. 2018; Reed et al. 2013).  
As described earlier, the PAPRIKA method, in the present context, involves participants being 
asked to pairwise rank two hypothetical NCDs defined on two criteria at a time and involving 
a trade-off, in terms of which is more of a problem for society and thereby more eligible for 
research funding. An example of a pairwise-ranking question from 1000m appears in Figure 
4.6. Such pairwise-ranking questions are repeated with different pairs of hypothetical NCDs – 
always defined on two criteria at a time and involving a trade-off. From each participant’s 
                                                 




answers to the pair-wise-ranking questions, PAPRIKA uses linear programming methods to 
obtain criteria weights. The weights across all criteria are summed to achieve a total score for 
each alternative. Although multiple solutions can be considered for linear programming, the 
resulting values produce the same overall ranking of alternatives (Hansen & Ombler 2008). 
Interested readers are referred to Hansen and Ombler (2008) for more detailed technical 
information about PAPRIKA. 
4.5 A real-world example of how PAPRIKA works 
Assuming the same decision example for PAPRIKA, suppose that the policy-maker faces the 
problem of prioritising NCDS for health research funding for the next five years. Suppose, 
there are three NCDs: ‘NCD1’, ‘NCD2’ and ‘NCD3’ to be evaluated based on three criteria: 
‘C1’ (i.e. x), ‘C2’ (i.e. y) and ‘C3’ (i.e. z) with two levels of performance (i.e. 1 indicates low, 
and 2 indicates high) on each criterion.  
PAPRIKA initially identifies all possible alternatives formed based on the criteria and their 
levels in the decision model. Given three criteria (i.e. x, y and z) and two levels on each (i.e. x2 
> x1, y2 > y1, z2 > z1), in this example, there are eight possible NCDs that can be shown as 
ordered triples of the levels on three criteria: 222, 221, 212, 122, 211, 121, 112 and 111. 
Suppose NCD1 is rated high on first and second criteria and low on third criterion (i.e. x2y2z1 
or 221), NCD2 is rated high on the first and third criteria and low on the second criterion (i.e. 
x2y1z2 or 212) and NCD3 is rated high on the second and third criteria and low on the first 
criterion (i.e. x1y2z2 or 122).  
Although only three NCDs are considered in the example, PAPRIKA efficiently identifies all 
eight possible NCDs, as mentioned above. As seen in Table 4.5, with three criteria and two 
levels, there are eight possible combinations representing eights possible NCDs and nine 
undominated pairwise questions. The 221 vs 212 or (x2y2z1) and (x2y1z2), for instance, is an 
example of an undominated pairwise question. The shaded three pairs in the table represent the 
three duplicates (or replicas). After subtracting common variables from pairs (both sides), there 




Table 4.5: Undominated pairs for a decision model with three criteria (and two levels) in PAPRIKA (Hansen & Ombler 2008) 
NCDs 222 221 212 122 112 121 211 111 
222  ― ― ― ― ― ― ― 
221   
(y2z1) vs (y1z2) 
(i) 
(x2z1) vs (x1z2) 
(ii) 
(x2y2z1) vs (x1y1z2) 
(iv) 
― ― ― 
212    
(x2y1) vs (x1y2) 
(iii) 
― 
(x2y1z2) vs (x1y2z1) 
(v) 
― ― 
122     ― ― 
(x1y2z2) vs (x2y1z1) 
(vi) 
― 
112      (y1z2) vs (y2z1) (x1z2) vs (x2z1) ― 
121       (x1y2) vs (x2y1) ― 
211        ― 
111         




Due to the additive nature of how criteria weights are calculated in PAPRIKA, common 
variables can be removed or added to both sides of the pairs, which is called the ‘joint-factor’ 
independence property of additive models, as explained earlier (Krantz 1972; Hansen & 
Ombler 2008). For example, 212 (x2 + y1 + z2), representing NCD2, is low on the second 
criterion and high on the first and third criteria and 122 (x1 + y2 + z2), representing NCD3, is 
low on the first criterion and high on the second and third criterion. Both NCD2 and NCD3 are 
rated high on the third criterion (i.e. z2) so that z2 can be removed from both sides when 
comparing these two NCDs. Likewise, when 221 and 122 are compared, y2 can be removed 
from both sides. After subtracting the joint variables from both sides, the cancelled form of 
x2z1 and x1z2 (2_1 and 1_2) remain (‘_’ reflects the identified criterion with identical level). 
PAPRIKA presents all pairs in their cancelled forms to be ranked by participants. 
Suppose the participant begins with pair (i) _21 vs _12. She is asked which NCD is more of a 
problem for society, and therefore, should receive more health research funding (_21 vs _12, 
identical on criterion x) or is she indifferent between the two (see Figures 3.3 and 4.6)? 
Suppose, the participant ranks _21 over _12 that can be shown as _21 >_12. Starting with pair 
(i), the participant prefers _21 to _12 and given x2 > x1 (x2 represents the higher level of 
performance on criterion x, which is naturally greater than x1 that represents the lower level), 
then pair (iv) is ranked as 221 > 112 (x2 + y2 + z1 > x1+ y1 + z2). Continuing with pair (ii), if the 
participant ranks 1_2 over 2_1 (x1 + z2 > x2 + z1) and given y2 > y1, then pair (vi) is ranked as 
x1y2z2 > x2y1z1. The pairs of (i) y2z1 > y1z2 and (ii) x1z2 > x2z1 imply pair (iii) is ranked as x1y2 
> x2y1 (by adding the corresponding sides of the inequalities for pairs (i) x2y2z1 > x2y1z2 and 







If the participant ranks the last explicit pair (v) as x2 + y1 + z2 = x1 + y2 + z1 (i.e. 212 = 121), 
then all six undominated pairs can be ranked by answering only three pairwise comparison 
questions (i), (ii) and (v) by the participant. Given, the assumptions of x2 > x1, y2 > y1 and z2 > 
z1 and the following two inequalities and one equation mentioned below, the linear 
programming is used to find the solution.  
(i) y2 + z1 > y1 + z2 
(ii) x1 + z2 > x2 + z1 
(v) x2 + y1 + z2 = x1 + y2 + z1 
For example, one feasible solution is x1 = 0, x2 = 2, y1 = 0, y2 = 7 and z1 = 0, z2 = 5. The highest 
levels on the criteria show their weights, therefore, after normalising the weights for all three 
criteria: C1 (i.e. x) = 14.29%, C2 (i.e. y) = 50.00% and C3 (i.e. z) = 35.71%. The weights are 
summed across the criteria (and levels) to get a total score for each NCD, as presented in Table 
4.6. As supposed earlier, NCD1 is rated high on the first and second criteria and low on the 
third criterion (i.e. 221), NCD2 is rated high on the first and third criteria and low on the second 
criteria (i.e. 212) and NCD3 is rated high on the second and third criteria and low on the first 
criterion (i.e. 122). Therefore, the total scores of the selected NCD are NCD1 = 2 + 7 + 0 = 9 
(normalised score = 64.28%), NCD2 = 2 + 0 + 5 = 7 (50.00%) and NCD3 = 0 + 7 + 5 = 12 
(85.71%), as bolded in Table 4.6. 
Table 4.6: NCDs scores calculated in the example via PAPRIKA 
 All possible NCDs 
 222 122 221 212 121 112 211 111 
Total score 
2 + 7 + 5 𝟎 + 𝟕 + 𝟓 𝟐 + 𝟕 + 𝟎 𝟐 + 𝟎 + 𝟓 0 + 7 + 0 0 + 0 + 5 2 + 0 + 0 0 + 0 + 0 
14 12 9 7 7 5 2 0 
Normalised 
score (%) 






The relevant literature was reviewed in search of a set of MCDA selection criteria. PubMed 
and Google Scholar were the main search engines used to find the relevant articles and reports 
for the period 1990-2019. Articles and reports were restricted to the English language. Various 
combinations of these keywords were used: Multi-criteria decision analysis methods, MCDA, 
MCDM, multiple criteria technique and/or decision-making software package, decision 
support system and/or selection, evaluation and comparison criteria. In addition, the criteria 
used by ‘Informs ORMS (the Institute for Operation Research and the Management Science) 
Today’ in their software survey were also reviewed.68 Table 4.7 presents all the selection 
criteria used (or proposed) by different studies to select an appropriate method (and software).  
As explained earlier, selecting a suitable MCDA method is an integral part of the decision-
making process as it influences both the process and the results (Cinelli et al. 2014). Many 
studies failed to consider all available MCDA methods (and software) (Wątróbski et al. 2019). 
For example, Wątróbski et al. (2019) recently analysed a large number of available MCDA 
methods (and their combinations). However, the authors did not justify the reasoning for 
choosing these methods or why not including other methods such as DCE and PAPRIKA in 
their study. The authors also failed to include the associated decision-making support system 
in their framework. The authors created an online platform (available for public use at 
https://www.mcda.it) that could help choose the appropriate MCDA method(s) based on a set 
of selection criteria. The platform does not seem to consider the true characteristics of the 
included MCDA methods. For example, when choosing ‘has weights’ and ‘quantity for weight 
type’, AHP does not appear among the eligible methods (Wątróbski et al. 2019). 
                                                 
68 ORMS Today conducts biennial online surveys to introduce a variety of advanced decision-making software 
available by different vendors. Unlike EC, 1000m has appeared in the ORMS Today recent surveys for 





Table 4.7: Selection criteria used to evaluate the appropriate MCDA method(s) 
Authors (year) Scope of the study  Relevant selection criteria  Potential criteria for the present study 
Polatidis et al. (2006)  Renewable energy 
planning 
- Input data (quantitative or qualitative or mixed) 
- The interaction with the method  
- Practical considerations (e.g. ease of use, the ability to support a 
large number of participants, low requirement of time and money) 
- The input data type 
- Users’ perceived ease-of-use 
- The software (and its features) can be evaluated in 
terms of different selection criteria. 
Jadhav and Sonar 
(2009)  
A review of software 
selection studies 
- User interface and ease-of-use  
- Platform variety 
- Scalability 
- Training and user manual 
- Free-trial version 
- Technical support 
- Licence cost 
- Users’ perceived ease-of-use 
- Platform supported 
- Scalability 
- User manual 
- Demo and free trial 
- Technical support 
- Licence cost 
Roy and Słowiński 
(2013)  
A review of studies 
undertaken in different 
areas 
- Input data (qualitative or quantitative) 
- Weight calculation and aggregation method 
 
- Degree of compensation  
- Preference elucidation method 
- The input data type 
- Weight calculation and aggregation methods can 
be defined in terms of two separate criteria. 
- Degree of compensation 
- Preference elicitation mode 
Cinelli et al. (2014)  Sustainability assessment - Input data (qualitative or quantitative) 
- Weight calculation and aggregation method 
 
 
- Degree of compensation 
- Software support 
 
- Ease-of-use (participants’ feedback) 
- Possibility to update the framework when new information 
becomes available 
- The input data type 
- It can be defined in terms of two separate criteria 
(criteria and alternatives’ weight computation 
method and preference aggregation method) 
- Degree of compensation 
- The software (and its features) associated with the 
method can be evaluated in terms of different 
selection criteria. 
- Users’ perceived ease-of-use 





Authors (year) Scope of the study  Relevant selection criteria  Potential criteria for the present study 
Li and Thomas (2014)  Real estate - Input data (qualitative or quantitative) 
- Preference elucidation method 
- Weight calculation and aggregation method 
- The input data type 
- Preference elicitation mode 
- It can be defined in terms of two separate criteria 
(criteria and alternatives’ weight computation 
method and preference aggregation method) 
Saaty and Ergu (2015)  ― - Ease-of-use (participants’ feedback) 
- Comprehensive structure (e.g. considering sub-criteria in the 
decision 
- The scale of measurement (ordinal or cardinal) to rank 
alternatives 
- Preference aggregation function  
- Using pairwise-ranking to assess the relative importance of 
criteria and alternatives 
- Users’ perceived ease-of-use 
- It is one of the criteria included in the software 
evaluation process. 
- The input data type 
- Preference aggregation method 
- Preference elicitation mode 
Sabaei et al. (2015)  Maintenance management - Input data (qualitative or quantitative) 
- Preference elicitation mode and aggregation method 
- The input data type 
- It can be defined in terms of two separate criteria 
(preference elicitation mode and preference 
aggregation method) 
Hodgett (2016)  Equipment selection, 
product development 
- Input data (qualitative or quantitative) 
- Ease-of-use (participants’ feedback) 
- The scale of measurement to rank alternatives 
- The input data type 
- Users’ perceived ease-of-use 
- The input data type 
Marsh et al. (2016)  Health care - Scoring function 
- Level of compensation 
- Cognitive burden posed to participants 
- Theoretical foundation (such as choice-based, transitivity) 
- Preference aggregation function  
- Time and budget restriction 
 
- Level of skills need to use the method/software 
 
- Weight determination method 
- Degree of compensation 
- Users’ perceived ease-of-use 
- It can be defined in terms of several criteria. 
- Preference aggregation method 
- It can be defined in terms of two criteria: time and 





Authors (year) Scope of the study  Relevant selection criteria  Potential criteria for the present study 
- It can be defined in terms of two different criteria 
for MCDA practitioners and participants separately. 
Mustajoki and 
Marttunen (2017)  
Environmental planning - Ability to support a large number of stakeholders 
- Software support and facilities 
 
- Preference elicitation mode 
- One of the criteria used to evaluate the associated 
software. 
- The software (and its features) can be evaluated in 
terms of different selection criteria. 
- Preference elicitation mode 
Guarini et al. (2018)  Real estate and land 
management 
- Number of criteria, alternative and stakeholders could be included 
 
 
- Input data (qualitative, quantitative or mixed) 
- Technical support 
 
 
- It can be defined in terms of three separate 
software selection criteria (number of criteria 
supported, number of alternatives supported and 
number of participants supported by the software) 
- The input data type 
- The software (and its features) coming with the 
method can be evaluated in terms of different 
selection criteria. 
Ishizaka and Siraj 
(2018)  
Comparing five university 
coffee shops 
- Ease-of-use (participants’ feedback) - Users’ perceived ease-of-use 
Wątróbski et al. (2019)  Economics and 
management 
- Taking into account different weights of individual criteria in the 
decision problem 
- Input data (e.g. qualitative, quantitative or relative) 
- The type of ranking results (e.g. ranking, classification, selection) 
- Preference aggregation method 
 
- The input data type 




Despite a large body of literature dealing with the MCDA selection problem, little attention 
has been paid to the decision support system – i.e. associated software package – and the 
features that are associated with MCDA methods (Li & Thomas 2014). Franch and Carvallo 
(2003) and Jadhav et al. (2009) suggested a generic and long list of software selection criteria 
that are compliant with the ISO/IEC 9126 software quality evaluation framework. The authors, 
however, did not illustrate how their framework works. Weistroffer et al. (2005) and 
Weistroffer and Li (2016) provide information about the main MCDA decision software 
packages. Examples of widely-used MCDA software that support a large number of 
stakeholders are given in Table 4.10 in Appendix 4.10.2. As can be seen in Table 4.10, most 
of the available decision-making software packages implement the AHP method. Furthermore, 
many MCDA studies often fail to include the user’ (i.e. MCDA practitioners and participants69) 
perceived ease-of-use of the method (and software) in their framework, as mentioned earlier 
(Marsh et al. 2016). 
Informed by the relevant literature, a list of salient selection criteria was specified. This list was 
then classified into three groups of criteria related to method, user and software, as indicated 
in Table 4.8. The method-specific criteria are considered to examine the properties and 
methodologies used from eliciting to aggregating the stated preferences. The user-specific 
criteria are specified to assess participants’ perceived ease-of-use of the survey implemented 
in the MCDA software as well as evaluating other features relevant to MCDA practitioners, 
such as user manual, technical support, price and effort spent to establish the survey. The 
software-specific criteria are deployed to evaluate the features and inbuilt options offered by 
the decision-making software package to examine and support the MCDA results. 
 
                                                 
69 In many cases, participants may be lay people taking part in the surveys. The choice of a particular method can 
affect the understandability of the participants and the accuracy of their elicited stated preferences as well as the 





AHP and PAPRIKA (and their associated software EC and 1000m) were evaluated in terms of 
three groups of criteria related to method, user and software, as presented in Table 4.8. AHP 
and PAPRIKA use different methodologies for eliciting participants’ stated preferences as well 
as measuring the criteria weights and alternatives scores. AHP is a compositional method as it 
involves eliciting participants’ preferences over criteria and alternatives separately. AHP 
calculates the criteria weights before determining the levels of alternatives performance on 
each criterion. By contrast, PAPRIKA is known as a decompositional method as it involves 
eliciting the preferences over alternatives that are defined based on two criteria, from which 
the criteria weights and alternatives scores are obtained simultaneously (Marsh et al. 2016). 
The stated preferences in PAPRIKA are based on elicitation modes that take into account levels 
of performance of alternatives. PAPRIKA requires participants to trade-off changes in one 
criterion for changes in another criterion, rather than evaluating the importance of criteria (the 
process that occurs in AHP). 
In AHP, no levels of performance are considered for the criteria. AHP uses pairwise 
comparison questions in terms of direct explication modes to elicit participants’ preferences 
with respect to criteria and alternatives, separately. AHP then derives ratio scale measurements 
from paired comparisons to calculate the criteria weights and alternatives scores. PAPRIKA 
uses choice-based pairwise questions to compare the performance of two hypothetical 
alternatives described based on two criteria at-a-time. PAPRIKA derives ordinal scale 
measurements from paired comparisons. The two methods investigate participants’ preferences 
in a way that provides sufficient information to estimate the weight from each individual’s 
responses to the survey questions. However, the two methods take different approaches to keep 
the decision-making burden low enough to be practical while still collecting enough 





Table 4.8: Theoretical comparison of AHP (and EC) and PAPRIKA (and 1000m) based on different selection criteria 
Selection criteria Definitions (where applicable) AHP (and EC) PAPRIKA (and 1000m) 
Method-specific criteria 
Categories 
Compositional methods elicit participants’ preferences for criteria and 
alternatives separately, while decompositional methods consider both 
alternatives and criteria to elicit participants’ preferences (Marsh et al. 
2016). 
Compositional Decompositional 
Direct explication methods directly elicit participants’ preferences to 
measure the criteria and known alternatives’ relative importance, while 
indirect methods use indirect techniques to elicit participants’ preferences 
with regard to hypothetical alternatives and integrate the stated preferences 
with scientific data to measure the alternatives scores. The former method 
is also called a priori and latter, a posteriori (Angelis & Kanavas 2017; Kao 
2010). 
Direct explication Indirect explication 
Input data type Types of input data supported by the method. Quantitative, qualitative or mixed Quantitative, qualitative or mixed 
Preference elicitation 
mode(s)/scale 
Mode(s) used to elicit participants’ preferences with respect to criteria and 
alternatives as well as types of scales derived from the paired comparisons. 
Ratio scale-based pairwise 




Compensation degree In compensatory methods, the weights represent the trade-offs across the 
criteria. Compensation degree shows the extent to which the poor 
performance on one criterion can be compensated for by a good 
performance on others (Marsh et al. 2014). 
Complete Partial 
Transitivity property Based on the logic of transitivity, if A is preferred to B and B is preferred to 
C, then A is preferred to C. 
Nontransitive Transitive 
Rank reversal Rank reversal refers to changes in the order of alternatives due to removing 




The method used to calculate the criteria weights and alternative scores. Eigenvector (and eigenvalue) method Linear programming 
Preference aggregation 
method(s) 
The method used for aggregating participants’ stated preferences and 
combining both criteria and alternatives weights to rank and score the 
alternatives after completing the survey. 
Arithmetic mean (i.e. average) 
Additive value model 
Arithmetic mean (i.e. average) 




Selection criteria Definitions (where applicable) AHP (and EC) PAPRIKA (and 1000m) 
Output 
The variety of outputs from MCDA that can be used to support different 
types of decisions and perform further analysis. 
Cardinal scores and ordinal ranking Cardinal scores and ordinal ranking 




The effort spent and the number and the nature of the parameters that the 
MCDA practitioner has to assess to familiarise herself with the software and 
create the decision models. 
Moderate  Moderate 
User manual The availability of a user manual with valuable information such as video 
and examples for the MCDA practitioner to understand the concepts and 
how to use different features. 
Yes Yes 
Consultancy Availability of technical support and consultancy by the software support 
team. 
Yes Yes 
Training and education Offering online training, tutorial or classes for universities, institutes, 
individual users. 
Yes Yes 
Demo and free trial71 The availability of a free trial version. No Yes (for 21 days) 
Price policy  Pricing policy for the academic licence. US$ 900 for a PhD project US$ 395 for a PhD project 




Ease of answering (pairwise comparison) questions and survey 
format/structure.  
Participants’ perceived ease-of-use of AHP and PAPRIKA and their 
associated software are explored and reported in Chapter 5 based on two 
different real-world decision examples. 
Decision support system (i.e. software)-specific criteria 
Software licence The availability of the software licence for academic and/or commercial 
purposes. 
Academic and commercial  Academic and commercial 
Web-based application The accessibility to the specialised software over the network. Yes Yes 
Work with all the web 
browsers  
The capability of the software package to run on a wide variety of internet 
browsers such as Internet Explorer (IE), Google Chrome and Firefox. 
Only the decision analyst needs to 
use IE to access EC. No limitation for 
the participants. 
Yes 
                                                 
70 User includes both the decision analyst (or MCDA practitioner) and participants. 




Selection criteria Definitions (where applicable) AHP (and EC) PAPRIKA (and 1000m) 
Supporting all the 
operating systems 
Supporting all the operating systems and computer platforms such as 
Windows, Mac OS and Linux. 
Yes Yes 
Mobile compatibility Compatibility of the software with smartphone devices. No Yes 
 
Scalability 
The ability to support a large number of participants/stakeholders. Yes Yes 
The ability to handle an increasing number of MCDA practitioners, criteria 
and alternatives and a higher load of transaction. 
Yes (the price is likely to change with 
a larger number of participants and 
projects) 
Yes 
Invitation email to the 
survey 
The ability to send (general or personalised) email (directly from the 




The possibility to embed other surveys into the main survey (at the 
beginning or the end of the main survey). 
Yes (however, EC is not able to pass 





The availability of participants’ comment entry. Yes Yes 
The possibility to 
change the stated 
preferences 
The availability of back and forth buttons in the surveys for participants to 
allow changes to their stated preferences during the survey. 
Yes Yes 
In-built checks The availability of inbuilt checks offered by the software to measure the 
robustness of results such as sensitivity analysis, consistency check Kendall’ 
W, interpolated levels and inconsistency ratio.72 
To some extent (only sensitivity 




offered by the software 
The availability of additional features such as export and import data, Value 
for Money, a variety of charts, graphs and interactive graphics. 
Yes Yes 
Publications  Whether the methods (and the associated software) used in publications (e.g. 
Journals, books). 
Yes Yes 
                                                 




Each time a participant answers a question, the PAPRIKA method applies the logical property 
of transitivity to identify and eliminate all other pairs of hypothetical alternatives that can be 
pairwise ranked implicitly, thereby minimising the number of questions asked. Each time a 
person answers a question, based on all preceding answers PAPRIKA adapts with respect to 
choosing the next question (always one whose answer is not implied by earlier answers). This 
adaptivity and the transitivity-based elimination procedure ensures the number of questions a 
participant is asked is minimised while ensuring they end up having pairwise ranked all 
hypothetical alternatives defined on two criteria at a time, either explicitly or implicitly (by 
transitivity). The important benefits of enforcing transitivity are a shorter survey and transitive 
choices – i.e. answers. However, the participant might have made inaccurate choices along the 
way, which then could affect the estimates of the utility weights. 
Unlike PAPRIKA, AHP does not enforce the logic of transitivity, resulting in a longer survey 
and non-transitive choices. However, with intransitive choices, there is perhaps a lower risk of 
inaccuracy in utility weights when the participant makes an inaccurate choice, and the 
researcher is alerted to the intransitivity. In addition, the scale of 1 to 9 that is used in AHP 
could create high levels of inconsistency since the participants are limited to using only values 
within this ratio scale. For example, if A is four times greater than B and B three times greater 
than C, then A is 12 times greater than C. However, the AHP scale does not include 12 as it 
limits the lower and upper bounds (i.e. values) to 1 and 9.73 As a result, stated preferences by 
AHP are likely to be highly inconsistent. AHP is also criticised for the so-called ‘rank reversal’ 
phenomenon, which refers to changes in the ranking order of pre-existing alternatives with the 
removal or addition of an alternative. PAPRIKA is immune to rank reversal as it enforces 
transitivity. 
The two methods support both qualitative and quantitative criteria, but they apply different 
methods to measure the criteria weights. AHP is a complete compensatory method. In contrast, 
                                                 
73 The participants may frequently use values greater than three or four for the first two comparison questions, 
which requires them to choose any value greater than 12, which is not in the relative scale of 1 to 9, for the third 
question. At its extreme example, if A is preferred 9 times greater than B and B, 9 times greater than C. Then A 





PAPRIKA is known as a partially compensatory method as it does not consider the magnitude 
of the differences when two alternatives are compared (Cinelli et al. 2014; Mendoza & Martins 
2006). AHP uses the eigenvector method, whereas PAPRIKA uses linear programming to 
determine the criteria weights. AHP and PAPRIKA produce both individual and aggregate 
preference values for the participants. The aggregate preferences show the collective decisions 
made by all participants and indicate a preference ranking for the selected alternatives. 
EC did not offer any free trials while the author was undertaking this PhD thesis. 1000m offered 
a 21-day free trial as well as free licences available for academic purposes (particularly for 
students without funding). EC and 1000m provide MCDA practitioners with a user manual, 
information, examples and technical support. Establishing the decision model in the PAPRIKA 
method may require more effort as the MCDA practitioner needs to define different levels of 
performance (to be ranked from highest to lowest level) on each criterion. Nevertheless, 
according to several studies, creating a decision model in EC and 1000m requires MCDA 
practitioners to spend relatively the same amount of time and effort to familiarise themselves 
with the software (Nemeth et al. 2019).  
EC had some limits on the flexibility of changing and editing the user interface to promote its 
usability for participants, while undertaking this thesis. It had several redundant options for 
presenting the information required for designing the surveys in this thesis and it was not 
possible to remove some of them. Similarly, the MCDA practitioner was only able to access 
the software through Internet Explorer to create and edit the decision models. Both software 
work well with all computer platforms. EC was not mobile-compatible while undertaking this 
PhD thesis. Participants’ perception of ease-of-use of the software was measured based on two 
real-world examples about NCDs and smartphones, as will be explained in Chapter 5. 
Participants had fairly similar experiences of the surveys implemented through EC and 1000m. 





Both software are considered for group decision-making, and they both can support a large 
number of criteria, alternatives and participants. EC and 1000m provide MCDA practitioners 
with a variety of decision aids, tables and graphs. Both software have a feature to automatically 
construct a written report that explains the main results to MCDA practitioners as well as 
participants. 1000m offers a variety of in-built options such as a consistency check, interpolated 
levels and Kendall’ W, as explained in chapter 3, which helps MCDA practitioners improve 
and support the decision process. 
4.8 Discussion  
As mentioned earlier, the availability of a large number of MCDA methods (and software) 
makes it difficult for MCDA practitioners to choose the most appropriate method. Many 
MCDA practitioners choose a method (and software) based on their knowledge and familiarity 
with a very small set of MCDA methods used in a field or for a given decision situation (Guarini 
et al. 2018; Velasquez & Hester 2013). Informed by the literature, a list of MCDA selection 
criteria was specified. The list was then classified into three groups of criteria related to method, 
user and software. The established criteria were exemplified by two prominent examples of 
MCDA – i.e. PAPRIKA and AHP – and their associated software packages – i.e. 1000m and 
EC. The rest of this section discusses the main findings. 
The preference elicitation modes used in the decision-making process can have a significant 
effect on the decision results. The arbitrary ratio scale used to elicit preferences in AHP has no 
mathematical basis (Binnekamp 2010). Interpreting the degree of importance in terms of the 
AHP scale is likely to be less precise and more cognitively biased. Moreover, the intensity 
scale of importance used by participants to compare the pairwise-ranking questions is not 
pragmatic since this is not a natural task individuals experience when making choices in their 
everyday life (Moshkevich et al. 2012). As AHP does not require the stated preferences be 
transitive, Saaty suggests using a consistency ratio to measure the consistency of the results. 
Nevertheless, as explained earlier, the intensity scale of importance (scale of 1 to 9) used in 




use any values more than three or four when pairwise comparing the criteria (A vs B and B vs 
C) that imply using values greater than 12, which do not exist in the ratio scale, for the third 
pairwise comparison questions (A vs C).  
The additive model used in both AHP and PAPRIKA is the most extensively employed 
preference aggregation technique used in both compositional and decompositional methods 
(Dodgson et al. 2009).74 Belton and Stewart (2002) [p. 103] indicate that additive utility models 
“are easier to understand and construct and the errors introduced by using additive model have 
been generally extremely small for realistic ranges of problem settings”. Kaarni et al. (1990) 
demonstrate that the arithmetic mean (average), used by AHP and PAPRIKA to aggregate 
participants’ stated preferences, assumes that participants are of equal importance and provides 
a better correlation than the geometric mean weights 
The ultimate goal of MCDA is to help improve the decision-making process by reducing the 
potential errors and biases that participants may develop when making decisions individually 
and subjectively. Priority-setting at the macro-level, particularly in the health system, may 
involve a large number of questions that can be complicated in nature. MCDA methods can 
help eliminate the number of questions, thereby the decision burden for the participants by 
enforcing properties such as transitivity. 
Unlike AHP, PAPRIKA uses choice-based pairwise comparison questions that have an 
advantage over ratio scale-based questions since it is a natural task individuals experience in 
everyday life (Hung et al. 2016). Moreover, “choosing, unlike scaling, is observable and 
verifiable” [p. 135] (Drummond et al. 2015) and individuals seem to be more confident when 
choosing one pair over another rather than expressing the extent to which one pair is preferred 
over another. In addition, indirect scoring methods such as PAPRIKA use simulated or real-
life decision behaviours to measure weights (Jacquet-Lagreze & Siskos 1982; March 1979) 
and ensure the consistent scoring of alternatives. Indirect explication methods “reduce 
                                                 
74 “Multiplicative model, however, is less frequently used in practice since determining the functional form of a 
multiplicative model and estimating the parameters required to populate them are considered more complex than 




motivational biases75 that may exist because of peoples’ emotions, desires and motives, which 
could cause bias relating to the emotional predisposition for or against a specific outcome” [p. 
151] (Angelis & Kanavas 2017). Given AHP and PAPRIKA use different preference elicitation 
modes, the empirical question is which method performs better based on real-world decision 
case studies – the subject of Chapter 5. For example, do participants in practice tend to be more 
consistent when choosing rather than scaling? 
 The ISPOR that established the MCDA Emerging Good Practices Task Force in 2014 
endorsed the implementation of decompositional methods (Keeney 2002; Marsh et al. 2017; 
Thokala et al. 2016). Marsh et al. (2016) state that “weights are more likely to be scaling 
constants when they are based on elicitation tasks that take account of the range of performance 
of alternatives and that require participants to trade-off changes in one criterion for changes in 
another, rather than assessment of the importance of criteria. These conditions are best met by 
decompositional approaches” [p. 131]. In contrast, AHP elicits criteria weights without 
evaluating the alternatives on the criteria performance levels. Assigning the criteria weights 
without taking into account its range of performance is considered a common mistake in 
making trade-offs as it can produce a flatter weight distribution that could result in 
underestimating the criteria weights (estimating the importance rather than the ratio) as well as 
being insensitive to criteria levels of performance applied on the alternatives (Angelis & 
Kanavas 2017). 
The number of questions in PAPRIKA increases with the number of criteria (and levels). 
Similarly, more pairwise-ranking questions need to be made in AHP as the number of criteria 
(and alternatives) increases. PAPRIKA, however, can decrease the number of pairwise 
questions to a great extent by enforcing logics such as transitivity (Hansen & Ombler 2008). 
Consequently, relatively fewer pairwise-ranking questions need to be answered in PAPRIKA 
                                                 
75 Montibeller and von Winterfeldt (2015) and Angelis and Kanavas (2017) provide a good description of a 
number of biases including motivational biases that may exist. Angelis and Kanavas (2017) [p. 151] indicate that 
“all of these biases could be addressed by engaging multiple experts with alternative points of view, collecting 
views from a range of different experts as stakeholders or participants to provide different value perspectives and 




compared to AHP (as the number of criteria and alternatives increases in AHP) as shown in 
Table 4.9. 
Table 4.9: Examples of decision models with the number of pairwise comparisons required when using 
AHP and PAPRIKA 
Method 
Number of criteria (levels)* Number of alternatives Number of pairwise 
questions** 
PAPRIKA 
3 (3) Unlimited ~10 
4 (3 and 2) Unlimited ~11 
4 (4, 3 and 2) Unlimited ~14 
5 (4, 3 and 2)  Unlimited ~20 
5 (3)  Unlimited ~25 
AHP 
3 5 28 
4  5 36 
5 5 45 
5 6 55 
5 7 66 
*AHP does not consider the levels of performance on the criteria; ** This is the average number of questions in 
PAPRIKA. The number of questions may slightly differ across participants in PAPRIKA. 
As explained earlier, no levels of performance are specified for the criteria in AHP. Paired 
comparisons in AHP are presented between two criteria at-a-time, assuming all else equal. No 
interaction effects are then considered in the pairwise comparison questions in AHP. The 
participants’ preferences on criteria (and thus the criteria weights) are elicited (calculated) 
without evaluating the performance of the alternatives on the criteria. In PAPRIKA, the 
alternatives are pairwise compared based on two criteria at-a-time, assuming all else equal. The 
paired comparisons in PAPRIKA are made based on the so-called two-factor interactions – i.e. 
the interaction between two criteria (Hansen & Ombler 2008; Jaynes et al. 2017).  
As discussed earlier, in PAPRIKA, participants can keep on answering two pairwise questions 
described on more than two criteria – i.e. three-way and higher-order interactions – until all 
undominated pairs (both explicit and implicit) are identified and ranked. Including all 
interactions may provide more (accurate) information, particularly when they are dependent on 
the remaining attribute – i.e. criteria – effects. Estimating all interactions (two-way, three-way 
and higher-order interactions); however, requires participants to answer a larger number of 
comparison questions. It also requires sufficiently large sample sizes and, in many cases, it is 




are cognitively less difficult than full-profile comparisons – i.e. interaction effects of all criteria 
– that reduces the decision-making burden for participants (Jaynes et al. 2017; Nicolet et al. 
2018; Reed et al. 2013). 
Similarly, Hansen and Ombler (2008) extensively simulated the PAPRIKA method to measure 
the accuracy of the rankings when a participant does not answer every undominated pair 
compared to a participant’s true overall ranking list. The authors showed that the comparison 
questions described on only two criteria – i.e. the two-way interaction effect – at-a-time would 
provide sufficient information to generate a ranking list that is highly correlated with the 
ranking results yielded from comparisons of all possible alternatives, involving two-way, three-
way or higher-order interactions (Hansen & Ombler 2008).  
There are several criticisms that have been levelled against using AHP (Belton & Stewart 2002; 
Dyer 1990). Belton and Stewart (2002) argue that these major shortcomings in AHP 
differentiate this method from the rest of the methods in the utility theory family. Marsh et al. 
(2017) [p. 54] point out that “the lack of theoretical foundation and the lack of stability of the 
results are central points of criticism that should be considered before the application of AHP 
for preference measurement. The limited feasibility of interpretation of the scale used in AHP 
as well as the not very realistic way of the pairwise comparisons of single elements should be 
taken into consideration before the application of AHP”.  
Belton and Gear (1983) first argued that AHP might reverse the ranking of alternatives when 
an alternative is added or removed from the model that is known as the rank reversal 
phenomenon, as explained earlier. Dyer (1990) [p. 252] makes an argument that “the real issue, 
however, is not the phenomenon of rank reversal per se. Rather, rank reversal is a symptom of 
a much more profound problem with AHP: the rankings provided by the methodology are 
arbitrary”. Furthermore, in AHP, the ranking of the alternatives is affected by the alternatives 
considered for evaluation. The participants are required to re-assign the relative importance of 
the alternatives with any change in the number of criteria or alternatives (Jadhav & Sonar 




entirely by the inaccuracy of the measurement scale and the inconsistent judgements of 
participants. 
Rank reversal does not occur in Multi-Attribute Utility Theory (MAUT)76 (Belton & Stewart 
2002; Cinelli et al. 2014). Buede & Maxwell (1995), as stated by Aires and Ferreira (2018), 
examined various MCDA methods to measure the frequency and magnitude of rank reversal 
using MAUT as the reference. “MAUT has a key difference from AHP being that it requires 
that preferences be transitive” [p. 131] (Marsh et al. 2016). As PAPRIKA enforces the 
transitivity property, and the participants are indirectly asked to make the trade-offs of the 
hypothetical alternatives described on criteria, PAPRIKA is immune to rank reversal. 
In terms of perceived ease-of-use, participants had similar experiences of the decision surveys 
implemented through AHP and PAPRIKA, indicating that the ease of answering of the pairwise 
questions, used in EC and 1000m, were perceived reasonably similar by participants (detailed 
information about participants’ experience of the NCD and smartphone surveys is available in 
Chapter 5). In terms of the MCDA practitioners’ experience and software interface, it seems 
that PAPRIKA (and 1000m) needs a relatively larger amount of effort as the MCDA 
practitioner needs to define different levels of performance on each criterion (and order them 
from the highest level to lowest). This issue can be challenging for some criteria, where the 
levels do not have a defined order (for example, ‘gender’ and ‘region’) or there might be ethical 
and social issues regarding a particular order for the criteria levels (for example, the criterion 
‘age’ and different age groups).  
Mustajoki and Marttunen (2017) have rated both EC and 1000m similarly and suggest that both 
software are suitable for MCDA practitioners with prior education and experience of MCDA, 
but still need support for facilitation of the process (Mustajoki & Marttunen 2017).77 In another 
recent study, PAPRIKA was classified as a relatively complicated method that generates lower 
                                                 
76 MAUT is explained briefly in Appendix 4.10.1. 
77 The three groups of MCDA practitioners in Mustajoki and Marttunen (2017) are: (1) those who like to apply 
MCDA, but do not have prior education and experience of MCDA; (2) those who are MCDA practitioners, but 
need support for facilitation of the process; and (3) those MCDA practitioners who want to carry out sophisticated 




bias and AHP with moderate complexity, but generating high bias (Nemeth et al. 2019). 
Maruthur et al. (2015) [p. 9] state that “EC has some limitations in flexibility of editing the 
user interface to promote usability for those unfamiliar with the process” that is consistent with 
the author’s experience of designing and editing the surveys and removing the redundant and 
unnecessary options from the survey page in EC. 
4.9 Conclusion 
There exists ample evidence on the practicality of MCDA methods to deal with complex and 
multi-dimensional decision problems. However, as discussed earlier, the diversity of MCDA 
methods (and software) has made it challenging for MCDA practitioners to choose the best 
method. In addition, MCDA practitioners do not usually justify their choice of a particular 
method, which is one of the primary purposes of ‘step 7’ of the MCDA process. Ideally, the 
theoretical framework developed in this chapter could help MCDA practitioners properly 
evaluate various MCDA options and choose a method (and software) that is grounded on sound 
theoretical foundations.  
This chapter made a comparison of two prominent examples of MCDA – i.e. AHP and 
PAPRIKA – and their associated software – i.e. EC and 1000m – using a set of MCDA 
selection criteria. As discussed earlier, AHP and PAPRIKA were developed using different 
assumptions and methodologies. For example, the two methods use different types of pairwise 
comparison questions to elicit participants’ preferences. They also use different methodologies 
to calculate the criteria weights and alternative scores. Keeping these differences in mind and 
given the main purpose of MCDA to help MCDA practitioners make sound and legitimate 
decisions, the question is how well do AHP (and EC) and PAPRIKA (and 1000m) perform in 
practice? Which method can produce robust results based on real-world decision problems? In 
addition, there is a lack of empirical research on understanding participants’ experiences (i.e. 
perceived ease-of-use) of the surveys implemented through different decision-making 
software. Therefore, the other question is how do the participants find the surveys implemented 




Chapter 5, where the successful applications and robustness of AHP (and EC) and PAPRIKA 
(and 1000m) are investigated based on two real-world decision problems.  
4.10 Appendix 
4.10.1 Brief review of main MCDA families 
Main MCDA families are explained briefly in this section. Interested readers are also referred 
to Belton and Stewart (2002), Velasquez and Hester (2013), IJzerman et al. (2014), Marsh et 
al. (2014), Viergever et al. (2017) and Hansen and Devlin (2019), for a good review of main 
MCDA methods. The ISPOR Task Force classifies MCDA methods into the following groups: 
(1) utility (value) theory methods, (2) outranking methods and (3) set of decision rules 
(reference-level) methods (Thokala & Duenas 2012). 
Value function methods (e.g. MAUT, MAVT and PAPRIKA) 
Some of main utility (value) theory methods includes MAUT and Multi-Attribute Value 
Theory (MAVT)and PAPRIKA (Aires & Ferreira 2018; Belton & Stewart 2002; Costa & 
Vansnick 2008; Franek & Kresta 2014; Golan & Hansen 2012; Hansen et al. 2012; Hansen & 
Ombler 2008; Keeney & Raiffa 1976; Laszlo 2017; Maleki & Zahir 2013; Marsh et al. 2016; 
Saaty 2003; Sullivan & Hansen 2017). Utility theory methods use different mathematical 
methodologies to measure utility functions of participants on (quantitative and qualitative) 
criteria (Jacquet-Lagreze & Siskos 1982; Manski 1977). Utility theory methods are based on 
two properties: (1) transitivity, as explained earlier and (2) comparability that allows the 
participant to compare the options and indicate whether she prefers option X to option Y, or 
prefers Y to X or is indifferent between the two options (Belton 1999). These methods are 
known as compensatory techniques, as explained in Table 4.8 (Belton & Stewart 2002). These 
methods mainly apply additive models (Thokala & Duenas 2012).  
MAUT and MAVT are grounded on axioms of rational choice and transitivity. MAUT was 
first introduced by Keeny and Raiffa. MAUT takes uncertainty into account when making a 




a person needs to choose between two choices. Choice A is a lottery with 50% chance to win 
two oranges and two pears and choice B is to win two oranges for sure. The participant needs 
to decide between [(2, 2):(0.5,0.5)] and [(2, 0):(1,0)]. MAVT is a simple form of MAUT. 
Unlike MAUT, MAVT does not consider the participant’s risk preference (uncertainty), and 
uses simpler elicitation procedures that are more extensively accepted by many MCDA 
practitioners, as it is not easy to answer the following question: ‘what probability of winning 
two units of value is equivalent to one value?’  
In MAUT and MAVT, new alternatives can be added at any stage of the MCDA process and 
no rank reversal occurs (Langhans & Lienert 2016). MAVT and AHP differ primarily in terms 
of the underlying assumptions about preference measurement, the methods used to elicit 
participants’ preferences and transforming the stated preferences into quantitative scores 
(Belton & Stewart 2002). AHP is grounded in mathematics and psychology and has a different 
basis from the rest of the methods in this family (Aires & Ferreira 2018; Belton & Stewart 
2002; Marsh et al. 2017). Interested readers are referred to Belton (1999) for in-depth technical 
information about MAUT and MAVT. 
DCE is a choice-based method widely used in health care (Louviere et al. 2010). DCE asks 
participants to choose between choice sets of (hypothetical) alternatives described based on all 
decision criteria considered in the MCDA process (Nemeth et al. 2019). PAPRIKA is 
considered a DCE method, as explained earlier. The DCE questions in PAPRIKA are partial 
profile based since questions are just defined based on two criteria at-a-time, unlike the full 
profile techniques such as DCE that involve comparing all criteria together at once. Partial 
profile grounded questions make the process of decision-making less cognitively difficult for 
participants as only two criteria are compared each time (Hansen & Ombler 2008). 
Outranking methods (e.g. ELECTRE, PROMETHEE, GAIA) 
In outranking methods, alternatives are pairwise compared on each criterion to establish the 
preference ranking of each alternative on each specific criterion. The stated preferences are 




are aggregated into a concordance index, which is the sum of the criteria weights, where the 
alternative is performed better divided by the total sum of the weights. An example is shown 




and treatment B has a concordance index of 
10+2
20
= 0.6. If the pre-defined threshold is less than 
0.6, treatment B is chosen. Defining this threshold is very arbitrary and up to the judgment of 
the MCDA practitioners (Edwards & McIntosh 2019). 
Outranking methods are less widely used than utility theory methods (Thokala et al. 2016). 
These methods can only generate the ordinal/partial preference ranking (and not cardinal 
scores) of the alternatives (El Amine et al. 2014; Kangas et al. 2001). The outranking methods 
do not enforce the transitivity property and could be subject to inconsistent (and intransitive) 
results. These methods have been criticised for possible rank reversal (Aires & Ferreira 2018; 
Cinelli et al. 2014; Maleki & Zahir 2013). Outranking methods include the ELimination and 
Choice Expressing Reality (ELECTRE) family of methods (Figueira & Roy 2002; Wang & 
Triantaphyllou 2006), Preference Ranking Organization METHod for Enrichment 
of Evaluations (PROMETHEE) (Behzadian et al. 2010) and Geometrical Analysis for 
Interactive Aid (GAIA) (Belton & Stewart 2002). 
Set of decision rules methods or reference-level modelling (e.g. TOPSIS) 
Set of decision rules methods (also called goal programming), the less widely-used MCDA 
methods, involve defining a goal for each criterion and choosing the alternative that is closest 
to the ideal goal (Guarini et al. 2018; Marsh et al. 2017). The Technique for Order Preference 
by Similarity to Ideal Solution (TOPSIS) is one of the main methods in this family. In TOPSIS, 
the participants are required to score each alternative based on each criterion using a rating 




scale of 1-10 or 1-100. The scores are normalised in a decision matrix, and the weighted 
normalised scores are calculated. The scores are ordered and the best alternative is the one with 
the shortest distance from the positive ideal solution (that is the best value that could be yielded 
from each criterion) and longest distance from the negative ideal solution (that is the worst 
value that could be gained from each criterion) (Krohling & Pacheco 2015; Siregar & Rahim 
2017). Interested readers are referred to Behzadian et al. (2012) for more information about 
TOPSIS. 
4.10.2 Examples of web-based MCDA software 
Table 4.10: Examples of web-based MCDA software for surveying large number of participants (in 
alphabetical order) 
Name Website MCDA method(s) used 
1000minds https://www.1000minds.com PAPRIKA 
DecideIT https://www.preference.nu MAUT 
DecisionLab https://www.thedecisionlab.com PROMETHEE 
Decision Lens https://www.decisionlens.com AHP 
Definitive Pro https://www.definitiveinc.com/definitive-pro MAUT/MAVT and AHP 
D-Sight https://www.d-sight.com PROMETHEE 
Expert Choice https://www.expertchoice.com AHP 
HIPRE 3+ https://www.hipre.aalto.fi SMART and AHP 
Intelligent Decision System https://www.intelligentdecisionsystems.com MAUT/MAVT and AHP 
Logical Decision https://www.logicaldecisions.com AHP and SMART 
Super Decision https://www.superdecisions.com AHP and ANP 
TransparentChoice https://www.transparentchoice.com AHP 
Source: Amoyal (2018), Weistroffer & Li (2016), Weistroffer & Narula (1997) and Weistroffer et al. (2005). 
SMART: Simple Multi-Attribute Rating Technique. SMART uses direct rating techniques to calculate criteria 
weights. In SMART, criteria are listed from most to least important and then are assigned a value from 100 
(showing the most important criterion) to 10 (showing the least important criterion) (Hansen & Devlin 2019; 
Marsh et al. 2016). The criteria are then normalised to sum to unity to obtain the final weights. ANP: Analytic 
Network Process. ANP is a generalisation of the AHP method. Similar to AHP, ANP uses pairwise comparison 
questions to elicit participants’ preferences using the same ratio scale measurements (that applied in AHP). Unlike 



















The issue of choosing the best method becomes even more crucial since various MCDA 
methods may potentially lead to conflicting results for a given decision situation. Given the 
diversity of MCDA methods, the question is how well selected MCDA method(s) can perform 
based on real-world decision case studies? In this chapter, an empirical framework was 
developed to examine the performance of PAPRIKA and AHP based on two real-world 
decision examples. Potentially, the framework employed in this chapter could guide MCDA 
practitioners to integrate a series of checks into their priority-setting process to ensure the 
successful application of selected MCDA method and the legitimacy and robustness of the 
decisions made. 
5.1 Introduction  
The literature dealing with selecting an appropriate MCDA method(s), mainly recommends 
choosing the methods that best suit the MCDA practitioners’ particular preferences as well as 
their decision-making situations (Guitouni & Martel 1998; Sabaei et al. 2015), as discussed in 
more depth in Chapter 4. Multiple MCDA methods may suit a given decision problem, but 
they may potentially lead to divergent decision results and recommendations for the same 
decision problem (Wątróbski et al. 2019).  
The literature is inconclusive and presents contradictory reports on the degree of 
(dis)concordance between the results obtained by various MCDA methods (Mysiak 2006). The 
differences between the results given by different methods can be due to varied preference 
elucidation modes and algorithms used by various MCDA methods (Guitouni & Martel 1998; 
Wątróbski et al. 2019). Several studies point out that the inconsistencies in the results yielded 
by different MCDA methods are somehow inevitable and should be accepted as an expression 
of different methodologies and preference elucidation modes used by different MCDA methods 
and their associated software (Hobbs and Horn 1997; Hyde 2006; Lienert et al. 2016; Olson et 




Testing the logical soundness and robustness of results given by the selected MCDA methods 
is becoming more critical to find a method that generates robust, trustworthy and legitimate 
results (Aires & Ferreira 2018; Guba 1981; Guitouni & Martel 1998). Saaty and Ergu (2015) 
[p. 12] indicate that “the trustworthiness78 of the chosen MCDA method has been defined as 
the quality of a method and its findings that make it noteworthy to decision-makers”. Despite 
its importance, many earlier studies have failed to check (and compare) the robustness of results 
produced by the selected MCDA method(s) (Lienert et al. 2016). 
The aim of this chapter is twofold. First, it attempts to develop a set of robustness checks to 
examine the robustness of the selected MCDA methods, which is the primary purpose of ‘step 
7’ in the MCDA process, i.e. to support the robustness of MCDA results and justify their choice 
of method(s). Second, the robustness checks are illustrated by examining the overall robustness 
and the successful applications of two prominent examples of MCDA methods – i.e. AHP and 
PAPRIKA. 
5.2 Method 
This section is structured in two parts. The first part is concerned with establishing and 
proposing an empirical framework to examine (and compare) the robustness of the results given 
by the selected MCDA method(s). The second part attempts to use the proposed framework to 
evaluate the successful utilisation and overall robustness of AHP and PAPRIKA methods (and 
their associated software) in terms of two real-world decision situations. These parts are 
explained more fully in the next subsections. 
The robustness of AHP (and EC) and PAPRIKA (and 1000m) was compared primarily in the 
context of ranking NCDs to support health research funding (the main subject of this PhD 
thesis) among first-year students at the University of Otago. As the students might have less 
information or experience to be familiar with NCDs – as most of NCDs occur among the older 
population – or be particularly less interested in the NCD survey, a second decision survey was 
                                                 




designed to investigate university students’ preferences with respect to smartphones in parallel 
with the NCDs79 research funding priority-setting survey conducted through both EC and 
1000m.  
As smartphones are likely to be of greater interest than NCDs to young people, the second 
survey is intended to overcome the sampling issue with the NCD survey among the university 
students, as mentioned above (bearing in mind, as noted earlier that ranking of NCDs is the 
main subject of this thesis). In addition, the NCD and smartphone surveys reflect two real-
world decision examples from two different fields with different degrees of difficulty and 
involvement (e.g. policy-making or personal decisions) to examine the successful applications 
of AHP and PAPRIKA. More detailed information about designing analogous surveys through 
both EC and 1000m is given in the next subsections.  
5.2.1 Developing a set of evaluation criteria to measure the performance of MCDA 
As discussed in Chapter 4, many earlier studies mainly compared the MCDA methodologies 
based on their theoretical foundations and the extent to which a method suits a specific 
decision-making problem or MCDA practitioner. Very few studies have considered the ability 
of the MCDA methods to produce robust results (Nolberto 2016; Saaty & Ergu 2015). The 
relevant literature was reviewed to specify a set of checks – i.e. evaluation criteria – to measure 
the performance and the robustness of MCDA methods. PubMed and Google Scholar were the 
main search engines used to find the relevant articles, reports and grey literature for the period 
1990 to 2019. Articles and reports were restricted to the English language. Various 
combinations of these keywords were used: robustness checks, evaluation criteria, reliability, 
validity, sensitivity analysis and/or participant’s actual choices, participant’s preferences 
and/or multi-criteria decision analysis, MCDA, MCDM.  
This subsection provides a review of earlier studies checking (and comparing) the robustness 
of selected MCDA(s). Aissi and Roy (2010) [p. 116] state that “in MCDA, robustness is of 
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practical and theoretical importance”. Robustness can involve both a priori concerns (that could 
be performed when eliciting the preferences, e.g. consistency checks) and a posteriori concerns 
(that could be performed after yielding the decision results, e.g. sensitivity analysis) (Aissi & 
Roy 2010).  
Among those few studies that used robustness checks, many did not provide detailed 
information about how they performed these tests. For example, very few studies compared 
participants’ actual choice with their MCDA results to investigate the validity of a chosen 
MCDA method. Further, these studies did not adequately describe how they elicited 
participants’ actual choices80 or whether they considered the individual-level or aggregated 
data to test the validity of the selected method (El Amine et al. 2014; Ishizaka & Siraj 2018; 
Janssen et al. 2017). Table 5.1 presents examples of the robustness tests used to measure (and 
compare) trustworthiness of selected MCDA method(s).  
Uncertainty81 can be seen at any stage of the decision-making process. One primary source of 
uncertainty can arise from participants’ judgments. MCDA methods are prone to subjectivity 
in eliciting the judgements (Cinelli et al. 2014). The uncertainty in criteria weights lies in the 
judgements of the participants to specify the relative importance of the criteria (Esmail & 
Geneletti 2018). A robustness test can be examining the consistency of participants’ stated 
preferences. Consistency could be used and measured in a variety of ways.  
First, a consistency check82 can be performed during the survey to ask participants to re-answer 
a few questions for a second time to check the consistency of their answers (Hansen & Ombler 
2008; Marsh et al. 2016). Second, many studies indicate that a proper MCDA method should 
enforce the logic of transitivity (Aires & Ferreira 2018; Dede et al. 2015). Otherwise, as 
indicated by Saaty, a consistency ratio (CR) needs to be measured to determine the degree of 
                                                 
80 Simple decision-making tools such as a holdout task can be used to elicit participants’ actual choices, treated as 
their true preferences, when there is no real-world data about participants’ actual choice (Johnson & Orme 1996; 
Orme 2015). 
81 Uncertainty can affect the MCDA process at different stages. Interested readers are referred to Broekhuizen 
(2015) and Briggs et al. (2012), for a review of sources of uncertainty as well as the classification of approaches 
for dealing with uncertainty in MCDA.  




logical inconsistency – i.e. transitivity – of participants’ stated preferences. As explained in 
Chapter 4, the CR is obtained from comparing the consistency of the elicited preferences versus 
the average consistency of completely random judgments. According to Saaty (1980), if the 
CR is higher than 0.10 then the stated preferences are untrustworthy as they are close to 
randomness. 
Validity83 is another way to evaluate the robustness of MCDA results. It is measured by 
checking the extent to which an MCDA method can predict participants’ actual choices – i.e. 
unaided decisions made independently of MCDA methods – treated as participants’ actual 
choices (Rockers et al. 2012). As mentioned earlier, very few studies endeavoured to compare 
participants’ actual choices with their MCDA results. Most of these studies asked participants 
to prepare a priority list of all or some of the alternatives according to their own understanding 
and personal preferences (Ishizaka & Siraj 2018). Another common way to elicit participants’ 
actual choices, which is often used in conjoint analysis (CA) studies, but rarely used for other 
MCDA methods, is the holdout choice task analysis (Johnson 1976; Reed et al. 2013). A 
holdout task is a choice-based decision-making tool that resembles real-world decision-
making. After the main survey, the participants can be asked to answer a holdout choice task 
that includes a set of two or more alternatives described on all decision criteria – that are also 
considered in the priority-setting framework. The criteria level combinations are fixed across 
participants in the task (Janssen et al. 2017; Mühlbacher & Johnson 2016). The holdout task is 
the proximal indication of real-world decision-making in the absence of real-world data about 
participants’ actual choices, and it best represents how a product or service is viewed and 
evaluated in the real world.  
The holdout choice task is preferred to asking participants to provide a priority list of 
alternatives, as the participants might not have enough or accurate information about the 
alternatives. In the holdout task, alternatives are described on the main characteristics, which 
are also considered in the priority-setting framework. The holdout task provides participants 
                                                 
83 Some studies used the term ‘consistency’ (El Amine et al. 2014; Saaty & Ergu 2015). Some others used the 




with accurate information about alternatives, and enables them to make informed choices. 
Moreover, in the holdout task alternatives can be compared based on their characteristics 
without considering their names to reduce the motivational biases that may exist and affect 
participants’ choices (Armstrong 2001; Cunningham et al. 2017). 
Table 5.1: Potential checks to evaluate the performance of MCDA methods 
Authors (year) Scope of the study Relevant evaluation criterion 
Potential check for 
the present study 
Tony et al. (2011)  Health care system Reliability Test-retest reliability 
Rockers et al. (2012)  Health care system Validity Holdout task  




Saaty and Ergu (2015)  ̶ Sensitivity analysis 
Validity 
Sensitivity analysis 
Holdout task  
Mühlbacher and 
Johnson (2016)  
Health care system Test-retest stability 





Janssen et al. (2017)  A review of studies 
evaluated the 
validity and 





Sullivan and Hansen 
(2017)  
Health care system Reliability  Test-retest reliability 
 
Esmail and Geneletti 
(2018)  
A review of papers 







The advantage of a choice-based preference elicitation method, like the holdout task, is that 
“choosing, unlike scaling, is a natural human task at which we all have considerable experience 
and furthermore, it is observable and verifiable” [p. 145] (Drummond et al. 2015). The idea is 
to measure the ability of selected MCDA to predict the holdout task results as best as possible. 
The proportion of true predictions (hit rates) reflects the validity of the method, which is the 
number of times when the predictions (MCDA results) match the observed choices (responses 
to holdout task choices) for each individual. One or more holdout choice tasks can be asked 




Another source of uncertainty in a decision-making process can be due to variability in input 
parameters – e.g. criteria weights. Sensitivity analysis84 is used to identify the uncertainties and 
disagreements among participants (Thokala et al. 2016). Sensitivity analysis quantifies 
uncertainty and variation in a decision-making process and measures how changes in inputs 
affect the results (Hyde 2006; Janssen 2001). It is recommended to at least use a simple 
deterministic sensitivity analysis (Briggs et al. 2012), as explained in Chapter 3, to check the 
overall robustness of MCDA results (Marsh et al. 2016). Broekhuizen et al. (2015) [p. 445] 
suggest that “the deterministic approach is most likely sufficient for most decision-making 
frameworks because of its low complexity and straightforward implementation”.  












7.1 Consistency ratio (CR) of 
each participant’s stated 
preferences 
If the method does not enforce the 
transitivity property, CR is measured, as 
explained in Chapter 4. 
7.2 Test-retest stability or 
consistency check  
Uncertainty in criteria weights as 
specified by the same participant. 
7.3 Validity test The ability of the method to predict 
participants’ actual choices. 
7.4 Reliability test The results of the survey can be held 
when repeating the survey for a second 
time with the same participants. 
7.5 Sensitivity analysis Uncertainty in estimating criteria 
weights (or performance scores) affect 
rankings of alternatives. 
 
Reliability is another good practice to measure the robustness of MCDA results. Reliability is 
defined as “how consistently the method measures the outcome of interest” [p. 532] (Janssen 
et al. 2017). It demonstrates whether a decision-making process “measures something other 
than random noise” [p. 748] (Lienert et al. 2016). The literature reveals that even if individuals’ 
preferences change over time, it does not affect aggregated results of the population (Lienert 
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parameters. A comparison of different approaches to sensitivity analysis is provided by Broekhuizen et al. (2015). 
Some studies used the term what-if analysis when users ask what if questions about sensitivities. For example, 




et al. 2016; Marsh et al. 2014). Many studies neglect to check the replicability of selected 
MCDA and the reliability of their results over time (Drake et al. 2017; Tony et al. 2011a).  
Informed by the literature, a set of robustness checks was specified to measure the robustness 
of participants’ stated preferences and the results obtained by the chosen MCDA(s). Table 5.2 
shows more information about these robustness checks, along with their brief description. The 
following subsections first describe the various steps of designing analogous surveys about 
NCDs and smartphones through EC and 1000m, as shown in Table 5.3. Next, the robustness 
checks, as indicated in Table 5.2, are performed to test the robustness of AHP and PAPRIKA 





Table 5.3: Steps for designing and implementing analogous NCD and smartphone surveys via EC and 1000m 
Step Title 
Description 
NCD survey Smartphone survey 
1 Specifying the decision problem Which NCD is more of a problem for the society, 
and should, therefore, receive more research 
funding? 
Which smartphone would you prefer to purchase? 
2 Defining the prioritisation criteria Informed by the earlier literature, the potential criteria were initially specified and then validated based on 
experts opinions.  
3 Measuring and rating the 
alternatives’ performance 
Alternatives (i.e. NCDs, smartphones) were assessed and rated based on the criteria using the available data 
in the NZ context. Expert opinion was also sought in this step. 
4 & 5 
Weighting the prioritisation criteria 
& scoring the decision alternatives  
 
In AHP, NCDs were rated based on scientific 
evidence using direct rating scale measurement 
with respect to each criterion. In PAPRIKA, NCDs 
were also rated based on evidence using the 
corresponding criteria level of performance. Expert 
opinions were sought in this step for both NCD 
surveys implemented through EC and 1000m. 
 
In AHP, students answered 10 pairwise 
comparison questions to evaluate the criteria. Then 
five direct ranking questions were used to rate 
NCDs. In PAPRIKA, students answered 
approximately 20 pairwise comparison questions 
to evaluate two hypothetical NCDs described 
based on two prioritisation criteria at-a-time. 
In AHP, smartphones were rated based on their actual 
specifications using direct rating scale measurement 
with respect to each criterion. In PAPRIKA, 
smartphones were also rated based on evidence using 
the corresponding criteria level of performance. 
Smartphone salespersons opinions were sought in this 
step for both smartphone surveys implemented through 
EC and 1000m. 
In AHP, students answered 10 pairwise comparison 
questions to evaluate the criteria. Then five direct 
ranking questions were used to rate smartphones. In 
PAPRIKA, students answered approximately 25 
pairwise comparison questions to evaluate two 
hypothetical smartphones described based on two 
prioritisation criteria at-a-time. 
6 Ranking the alternatives based on 
steps 3 and 4 & 5 
Alternatives were ranked by applying the ratings from step 3 and the mean weight/scoring alternatives from 




5.2.2 Steps 1-3: Specifying the decision problem, criteria and rating the alternatives85 
Six smartphones to be prioritised were selected from the most commonly sold smartphones in 
NZ in 2017. They were ‘Apple iPhone X’, ‘Huawei P10 Plus’, ‘Nokia 8’, ‘Oppo R11’, 
‘Samsung Galaxy S9 Plus’ and ‘Sony Xperia XZ Premium’. The relevant literature was 
reviewed to create a list of prioritisation criteria. PubMed and Google Scholar were the main 
search engines used to find the relevant articles, reports and grey literature from 1990 to 2019. 
Articles and reports were restricted to the English language. Various combinations of these 
keywords were used: smartphone, cell phone, mobile phone and/or selecting, purchasing, 
buying and/or decision, intention, criteria. In addition, some of the main websites specialising 
in smartphones were reviewed to find essential characteristics (i.e. specifications) of 
smartphones commonly considered by specialists and customers. These characteristics were 
reviewed to identify and elicit potential prioritisation criteria for the present study.  
Next, the criteria (and levels) were validated through pilot-testing as well as seeking 
smartphone salespersons’ opinions from different smartphone businesses/companies (e.g. JB 
Hi-Fi, Spark and Vodafone) in NZ. The prioritisation criteria were ‘camera quality’, ‘battery 
life’, ‘operating system and performance’, ‘screen quality and design features’ and ‘weight’ as 
presented in Table 5.4. In rational choice theory, individuals are assumed to behave rationally 
by maximising their personal interest and reducing their costs (Eshaghi & Askari 2018). 
Keeping this in mind and given that ‘brand’ is mainly influenced by the specifications of a 
smartphone, ‘brand’ was not included as a separate criterion in the survey. It could, however, 
be considered later as an additional factor. In addition, as indicated by the ISPOR task force 
fifth report, ‘cost or price’ (a criterion with adverse effects) should be considered separately 
when the priority-setting survey only measures ‘benefits or values’ (criteria with positive 
effects) (Phelps et al. 2018). The ‘price’ as a criterion in the decision survey may also cause 
complexity and uncertainty in the trade-off questions. Therefore, it can be considered later 
when evaluating Value for Money (VfM),86 which is not the subject of this study (Marsh et al. 
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2018). As the number of pairwise comparison questions increases with the number of criteria 
(and their levels), some of the criteria can still be considered as additional factors in the priority-
setting process. Once these additional factors are considered, the overall ranking of the 
smartphones might change. 
 Table 5.4: The criteria (and levels of performance) used in the smartphone survey 
Prioritisation criteria Levels of performance 
Operating speed and Performance – e.g. 
RAM + storage, CPU and graphics, etc. 
Ok – i.e. suitable for routine use 
Good – i.e. suitable for multi-tasking 
Very good – i.e. suitable for faster web browsing, gaming and 
more powerful apps 
Camera quality 
Ok – e.g. suitable for normal shots 
Good – e.g. high-quality shots during daylight 






Screen quality and design features – e.g. 
headphone jack 
Ok – e.g. fine resolution on smaller screens 
Good – e.g. great resolution on most screen sizes 
Very good – e.g. stylish, suited to all screen sizes and virtual 
reality headsets 
Weight 
Heavy – i.e. 180 g and more 
Medium – i.e. between 161-179 g 
Light – i.e. 160 g and less 
 
Smartphones were evaluated and rated by the author based on their specifications – i.e. 
prioritisation criteria – using available information about smartphone websites well known in 
NZ as well as the smartphone salespersons’ opinions. Detailed information about rated 
smartphones is available in Appendix 5.8.1. With 19 NCDs in the survey, a large number of 
pairwise comparisons was required to be answered in EC. Therefore, direct rating questions 






5.2.3 Steps 4 and 5: Weighting the criteria and scoring alternatives 
The surveys implemented through both software were extensively pre-tested (consisting of 
face-to-face interviews as well as conducting online pre-test surveys) on several sub-samples 
drawn from the author’s personal and professional networks. The pre-tests led to several 
changes in the survey questions, the understandability and accuracy of the criteria (and levels) 
and the survey instructions in both software. The ethical approval of the study was obtained 
from the University of Otago Human Ethics Committee (Reference: D18/239). 
Students were recruited for this study as it was easy and low-cost to recruit from this 
population. First-year students were recruited from the University of Otago Business School to 
reduce participants’ background variability. Students ID numbers were randomised using the 
RAND function in the Microsoft Excel. The students were then randomly split into four groups 
– of 200 students – for four online surveys, as shown in Table 5.5. Each student received an 
email including a link to complete a survey – i.e. the NCD or smartphone survey implemented 
through 1000m or EC – as well as information about the survey. Examples of the emails sent 
to students and the surveys’ instructions in EC and 1000m are available in Appendices 5.8.2 
and 5.8.3, respectively. The participants were initially given two weeks to complete the survey, 
with a reminder email sent out after about 10 days. 
Table 5.5: Random assignment of each group of students to one survey – i.e. NCD or smartphone – 
implemented through EC or 1000m 
Software/survey NCD Smartphone 
EC √ √ 




Figure 5.2: Example of a pairwise-ranking question, smartphone survey, from 1000m 




Using 1000m, participants, on average, answered approximately 20 pairwise comparison 
questions in the NCD survey and 25 pairwise comparison questions in the smartphone survey. 
Using EC, both NCD and smartphone surveys included 10 pairwise comparison questions 
assessing the criteria and five direct rating questions evaluating the alternatives. Examples of 
pairwise comparison questions from the smartphone surveys conducted through both software 
appear in Figure 5.1 and Figure 5.2. 
In addition, Qualtrics surveys were embedded into both EC and 1000m surveys to ask students 
more questions about their background information such as ethnicity, gender and their 
experience of the surveys as well as a holdout choice task, as will be explained shortly. 
Participants were also asked two questions about the easiness of ‘pairwise comparison 
questions’ and ‘survey structure’ in both software. The answers were given on a Likert scale 
of five levels ranging from ‘very easy’ to ‘very difficult’ as provided in Appendix 5.8.4. 
5.2.4 Step 6: Ranking alternatives based on steps 3, 4 and 587 
From each participant’s answers, the EC applies the eigenvalue method, as discussed in 
Chapter 4, to determine the weights on the criteria, representing their relative importance, as 
well as the alternatives scores. Then for each alternative, criteria weights were multiplied by 
the relative scores. The weighted scores were then summed up across all criteria to achieve a 
total score for each alternative. Finally, the alternatives were ranked based on their total scores 
in the EC surveys. 
From each participant’s answers, 1000m applies linear programming method to determine the 
scores or weights on the criteria (and the levels within each criterion), representing their relative 
importance. The scores were then summed across the criteria to get a total score for each 
alternative, via which all alternatives were finally ranked in the surveys implemented through 
1000m. Bézier spline (smoothed or non-linear) interpolation, as explained more fully in 
Chapter 3, was used to construct (or interpolate) additional levels between each successive pair 
                                                 




of levels on the quantitative criteria to more accurately rate the smartphones based on criteria 
levels and improve the sensitivity (interpolated levels are shown in Appendix 5.8.5). 
5.2.5 Step 7: Measuring the robustness of AHP and PAPRIKA 
The robustness of AHP and PAPRIKA were investigated based on the following steps (as 
presented in Table 5.2): (1) Consistency ratio for AHP (and EC); (2) Consistency check for 
PAPRIKA (and 1000M); (3) Validity; (4) Reliability and (5) Sensitivity analysis. These steps 
are described more fully in the following subsections. 
5.2.6 Step 7.1: Consistency ratio for AHP (and EC) 
As explained in Chapter 4, Saaty (1977) indicates a CR is calculated since AHP does not 
enforce the transitivity property. A CR is automatically calculated by EC for each individual. 
A CR higher than 0.10 indicates that the stated preferences are untrustworthy and erroneous to 
a certain degree as they are close to randomness (Saaty 1977). The CR is not applicable for 
PAPRIKA as this method enforces transitivity. 
5.2.7 Step 7.2: Consistency check for PAPRIKA (and 1000m) 
Three questions were repeated during the 1000m surveys to evaluate each participant’s 
consistency with their preceding answers, as explained in Chapter 3, to check the consistency 
of participants in 1000m. This option is not available in EC, therefore it was not possible to 
repeat a few questions for a second time and check the consistency of responses in EC.  
5.2.8 Step 7.3: Validity analysis 
A holdout choice task was employed to elicit each participants’ actual choices treated as their 
true preferences. The holdout task used in this study included full-profile case scenarios of two 
alternatives – i.e. NCDs and smartphones – described on prioritisation criteria based on the NZ 




5.3.88 The holdout task employed for two NCDs is provided in Appendix 5.8.6. The 
alternatives’ names were not listed to avoid motivational biases that would direct participants 
to choose an alternative without considering (and comparing) their attributes – i.e. the 
prioritisation criteria. The two alternatives were not equal based on all criteria levels, and no 
alternative would dominate with respect to the prioritisation of all criteria.89 The holdout choice 
task for smartphones was revised due to an error in describing the smartphones’ levels. Only 
the holdout task for smartphones was redistributed again among the students – who completed 
the main smartphone surveys implemented through EC and 1000m in the first time – after a 
time delay about six months. 
Kemeny distance (DKem) measurement90 is a well-founded distance measurement used to 
compare preference rankings to indicate similarities or differences between the ranking results 
                                                 
88 No option was considered for preference indifferences (i.e. ties) in the holdout task since there were concerns 
about participants clicking on only ‘they are equal’ option without thoroughly reading the characteristics of the 
two alternatives. 
89 Participants should not be asked to choose among alternatives where one dominates in the sense that most 
people agree which is best. Similarly, it is recommended to “avoid presenting alternatives that are equally 
attractive, since equal shares of preference could be predicted by a completely random simulator” [p. 3] (Orme 
2015). 














(Can & Storcken 2018; Heiser & D’Ambrosio 2013). DKem was used to measure the 
proportion of matches (hit rates) by each MCDA method. A DKem of 0 indicates the number 
of matches, where the ranking result obtained by MCDA and holdout task match for each 
participant, suggesting that MCDA method can truly predict individual participants’ actual 
choices. The DKem analysis was programmed and conducted in MATLAB version R2018a.  
5.2.9 Step 7.4: Test-retest reliability  
Four convenience samples of 25 people were asked to complete one survey twice, two weeks 
apart, in order to check the test-retest reliability and robustness of four surveys implemented 
through the EC and 1000m. Both parametric (i.e. paired sample t-test) and non-parametric (i.e. 
Wilcoxon signed-rank test) tests were performed to check for statistically significant 
differences of the criteria mean weights from the surveys. The Wilcoxon signed-rank test (the 
non-parametric version of paired sample t-test) was used to assess whether the relative rankings 
(or the order) of the criteria are different between the original and retest surveys. More detailed 
information about the test-retest reliability was provided in Chapter 3. 
5.2.10 Step 7.5: Sensitivity analysis 
A one-way sensitivity analysis was performed to find out whether the overall rankings of the 
alternatives – NCDs or smartphones – can be influenced by changes in the criteria (levels or 
weights). A graphical visualisation for one-way sensitivity analysis is a tornado chart, as 
explained in Chapter 3, where the changing variable – i.e. criteria – are presented on the x-axis 
and the output – i.e. NCDs or smartphones – is observable on the y-axis (Borgonovo 2017). 
The variables are plotted in a descending order where the wider bars appear on the top and 
drive the most substantial impact on uncertainty in ranking results. The decision analysts need 
to focus on the top variables with bigger bars (Benke et al. 2011; Wang et al. 2017). 
                                                 
Where Rs and Rt show two ranking distributions, m is the number of alternatives and x(s)ij is defined as equal to 1 
if alternative i is preferred to alternative j in ranking s, equal to −1 if the reverse is true and equal to 0 if the two 




5.3 Findings  
The findings of this study are presented as follows. (1) An overview of participants’ 
characteristics and the overall results (criteria weights and alternatives ranking) of the NCD 
and smartphone surveys are reported; (2) The results of the robustness checks are reported for 
both AHP and PAPRIKA surveys; (3) The overall robustness of AHP and PAPRIKA methods 
are compared and summarised based on two decision case studies about NCDs and 
smartphones. 
5.3.1 General findings 
In general, students found the smartphone surveys much easier than the NCD surveys with 
respect to the easiness of ‘answering pairwise comparison questions’ and ‘survey structure’. 
Students found the surveys (i.e. NCD or smartphone) relatively similar regardless of the 
software. In EC, the completion and response rates for the smartphone surveys were 69% and 
21% respectively.91 In 1000m, the completion and response rates for smartphone surveys were 
90% and 34% respectively. More students completed smartphone and NCD surveys through 
1000m. Table 5.6 provides more information about participants.  
                                                 
91 Students who did not complete the EC surveys, were contacted and asked why they dropped out of the survey. 




Table 5.6: Participants’ characteristics and other general information about the surveys 
Characteristics 
Smartphone surveys NCD surveys 
AHP n (%) PAPRIKA n (%) AHP n (%) PAPRIKA n (%) 
Gender  Male 20 (47.6) 30 (44.1) 11 (40.7) 22 (46.8) 
 
Female 22 (52.4) 38 (55.9) 16 (59.3) 25 (53.2) 
Gender diverse 0 (0) 0 (0) 0 (0) 0 (0) 
Ethnicity1 Domestic NZ European 26 (62.0) 49 (72.1) 20 (71.9) 31 (66.0) 
Māori 3 (7.1) 2 (2.9) 1 (3.1) 2 (4.3) 
Chinese 5 (11.9) 8 (11.8) 2 (15.6) 5 (10.6) 
 Other 3 (7.1) 5 (7.4) 2 (6.3) 4 (8.5) 
International  5 (11.9) 4 (5.8) 2 (15.6) 5 (10.6) 
Academic department F&A* 13 (30.9) 16 (23.5) 6 (22.3) 13 (27.7) 
Economics 9 (21.4) 16 (23.5) 11 (40.7) 14 (29.8) 
Management 6 (14.3) 12 (17.6) 3 (11.1) 4 (8.5) 
Marketing 7 (16.7) 14 (20.6) 3 (11.1) 6 (12.8) 
Tourism 1 (2.4) 4 (5.9) 1 (3.7) 3 (6.4) 
Other 6 (14.3) 6 (8.9) 3 (11.1) 7 (14.8) 
Easiness of answering pairwise 
comparison questions 
Very easy 10 (23.8) 17 (25.0) 1 (3.7) 2 (4.3) 
Easy 18 (42.8) 29 (42.6) 4 (14.8) 3 (6.4) 
Medium 11 (26.2) 18 (26.5) 8 (29.6) 13 (27.6) 
Hard 2 (4.8) 4 (5.9) 10 (37.1) 22 (46.8) 
Very hard 1 (2.4) 0 (0) 4 (14.8) 7 (14.9) 
Easiness of survey structure and 
format  
Very easy 12 (28.6) 30 (44.1) 0 (0) 5 (10.6) 
Easy 19 (45.2) 16 (23.5) 13 (48.1) 11 (23.4) 
Medium 8 (19.1) 18 (26.5) 7 (25.9) 9 (19.1) 
Hard 3 (7.1) 4 (5.9) 6 (22.3) 17 (3.2) 
Very hard 0 (0) 0 (0) 1 (3.7) 5 (10.6) 
No of participants started the survey  61 76 44 63 
No of participants completed the survey  
(and included in the analysis)  
42 68 27 47 
Survey completion rate92  (68.8) (89.5) (61.4) (74.6) 
Survey response rate93  (21.0) (34.0) (13.5) (23.5) 
No of the pairwise question (approx.)94 10 25 10 20 
No of direct rating question  5 - 5 - 
Mean second per decision95  - 13 - 22 
Median second per decision  - 10 - 11 
*F&A: Finance and Accountancy; 1Percentages do not sum to unity, as some people identify with multiple ethnic groups.
                                                 
92 Survey completion rate is the number of participants who fully completed the survey divided by the total number 
of participants who started the survey.  
93 Survey response rate is the number of participants who fully completed the survey divided by the number of 
surveys sent out (i.e. the sample size is 200 in each survey). 
94PAPRIKA starts by asking each participant to answer a question, which has been randomly selected and could 
be different for different participants. The number (and the order) of the questions to be answered varies across 
participants, depending on their answers to the preceding questions. 




5.3.2 Criteria weights and priority lists of alternatives 
The criteria mean weights and the relative rankings of smartphones are reported in Tables 5.7 
and 5.8 for both EC and 1000m surveys. All smartphone surveys, main and repeated surveys, 
implemented through 1000m presented the same ranking orders and relatively similar mean 
weights, for the criteria and smartphones. ‘Battery’ was found as the most important (criteria 
weight=27.7%), ‘camera’ the second most important (24.3%) and ‘weight’ the least important 
criterion (11.8%). ‘Huawei’ was found as the first, ‘Samsung’ the second and ‘Sony’ as the last 
smartphone on the priority lists. The EC smartphone surveys revealed inconsistently ranked 
lists of criteria, with ‘operating’ as the most important criteria (mean weight=30.4%), ‘battery’ 
the second most important (27.8%) and ‘weight’ the least important criterion (5.2%), as well 
as different relative rankings for the top three smartphones, across main and repeated surveys.96 
The criteria weights and rankings generated based on the smartphone surveys in 1000m differs 
from the results given by the EC surveys. The relative rankings of the top three smartphones 
differ across EC and 1000m main surveys.  
Table 5.7: Criteria mean weights (%), smartphone main surveys, AHP (n=42) and PAPRIKA (n=68) 
 AHP (and EC) PAPRIKA (and 1000m) 
Criteria Weight Weight 
Operating speed and performance 30.4 18.1 
Battery life 27.8 27.7 
Screen quality and design features 20.1 18.0 
Camera quality 16.5 24.3 
Weight 5.2 11.8 
 
Table 5.8: Smartphones mean scores (%) 
Smartphone 








Original Retest Original Retest 
Huawei P10 Plus 79.8 81.3 76.6 82.0 80.9 83.6 
Samsung Galaxy S9 Plus 75.7 77.3 79.6 75.5 73.9 73.6 
Apple iPhone X 76.5 76.0 68.3 72.5 71.2 73.5 
Nokia 8 67.8 70.0 66.0 70.2 68.8 72.0 
Oppo R11 59.8 60.3 62.3 62.2 63.0 61.2 
Sony Xperia XZ Premium 41.1 41.5 17.2 38.8 37.7 38.2 
                                                 
96 For example, in the main survey implemented through EC, Huawei was ranked first, followed by Apple and 




The criteria weights and the relative rankings of NCDs are reported in Tables 5.9 and 5.10 for 
all NCD surveys, main and repeated surveys, implemented through EC and 1000m. 1000m 
surveys presented very similar ranking orders, with relatively close mean weights; for 
prioritisation criteria and NCDs. ‘Deaths’ was identified as the most important criteria (mean 
weight=26.9%), followed by ‘loss of QoL’ as the second most important (23.2%) and 
‘vulnerable groups’ the least important criterion (11.8%). In EC, the relative rankings of criteria 
generated by the main NCD surveys are similar to the rankings produced by 1000m survey.97 
However, this list is not consistent with EC surveys repeated over time. Similar to the main 
1000m survey, ‘CHD’, ‘back and neck pain’, ‘diabetes mellitus’, ‘dementia and Alzheimer’s 
disease’ and ‘stroke’98 are the top five NCDs and ‘headaches’, ‘NMSC’ and ‘addictive 
disorders’ appear at the bottom of the ranking lists in the main NCD survey at EC. Most NCDs 
were assigned to the same tier of priority in both EC and 1000m surveys.99 
Overall, the ranking results in the NCD surveys were relatively similar for both EC and 1000m 
but there were differences in the ranking results of the smartphones generated by EC and 
1000m. As the surveys were distributed among university students, who might have more 
information about smartphones or be more interested in this subject, compared to the NCD 
subject, the results of the smartphone surveys appear to be more reliable and trustworthy for 
subsequent conclusions on the performance of AHP (and EC) and PAPRIKA (and 1000m).
                                                 
97 According to the results given by EC, ‘vulnerable groups’ is considered more important than ‘cost to health 
system’. In contrast, in 1000m, ‘cost to health system’ was ranked over ‘vulnerable groups’ by participants.  
98 Similarly, in EC, CHD, back and neck pain, diabetes, dementia and Alzheimer’s disease and stroke are the top 
five NCDs. But the ranking orders are different for some other NCDs. For example. COPD was ranked higher 
than depressive disorders and colon cancer. 
99 As explained in Chapter 3, consistent with the presentational style and terminology used by the WHO for its 
priority list of antibiotic-resistant bacteria (Tacconelli et al. 2018) and to simplify the presentation of the final 
priority lists of NCDs and to better communicate with policy-makers, the rankings were categorised into four tiers 
of priority: ‘very critical’, ‘critical’, ‘high’ and ‘medium’ that could be used to set short, mid and long-term 
policies and guide health research spending across NCDs. The tiers were simply established based on NCDs with 




Table 5.9: Criteria weights (%), NCD main surveys, AHP (n=27) and PAPRIKA (n=47) 
Criteria AHP (and EC) PAPRIKA (and 1000m) 
Deaths across the population 29.6 26. 9 
Loss of QoL across the population 27.5 23.2 
Cost of the disease to patients and families 19.5 20.6 
Cost of the disease to the health system 11.0 17.5 
Disproportionately affecting vulnerable groups 12.4 11.8 
 
Table 5.10: NCDs total scores (%) and tiers of priority 
NCD 
AHP (and EC)  PAPRIKA (and 1000m) 




Repeated surveys (n=25)  Main 
(n=476) 
G 
Repeated surveys (n=40) Main 
(n=47) 
G 
Repeated surveys (n=25) 
Original G Retest G  Original G Retest G Original G Retest G 
CHD 74.1 1 74.8 1 76.5 1  76.9 1 77.9 1 77.6 1 76.7 1 76.8 1 77.8 1 
Back and neck pain 69.6 1 71.6 1 73.1 1  72.3  1 70.2 1 73.0 1 73.2 1 68.9 1 71.5 1 
Diabetes mellitus 64.2 1 66.1 1 68.0 2  68.0  1 66.6  1 77.6 1 68.2 1 65.0 1 67.5 1 
Dementia and Alzheimer’s 55.9 2 56.0 2 58.8 2  58.8  2 59.0  2 57.4 2 60.7 2 57.1 2 57.4 2 
Stroke 53.8 2 54.4 2 54.1 2  54.3  2 54.7  2 55.5 2 53.4 2 54.8 2 55.5 2 
Colon and rectum cancer 42.4 3 43.4 3 43.8 3  44.0 3 44.4 3 45.5 3 43.2 3 44.0 3 45.3 3 
Depressive disorders 41.4 3 43.0 3 43.2 3  43.1  3 41.7  3 44.3 3 42.5 3 41.3 3 43.3 3 
COPD 43.0 3 43.6 3 42.7 3  41.0  3 43.1  3 44.3 3 41.6 3 43.6 3 44.3 3 
Breast cancer 34.5 3 36.1 3 36.9 3  38.1 3 36.7 3 38.5 3 36.2 3 35.9 3 38.0 3 
CKD 34.5 3 36.1 3 36.8 3  38.1 3 36.6 3 38.4 3 36.2 3 35.9 3 37.9 3 
Prostate cancer 34.5 3 36.1 3 36.9 3  38.1 3 36.7 3 38.5 3 36.2 3 35.9 3 38.0 3 
Arthritis 35.2 3 37.0 3 37.6 3  37.3 3 36.4  3 38.9 3 36.9 3 35.8 3 38.0 3 
Lung cancer 36.3 3 37.0 3 36.6 3  35.1  3 37.4  3 37.2 3 35.5 3 37.6 3 38.5 4 
Asthma 27.5 4 28.9 4 28.5 4  28.4  4 27.7 4 30.1 4 27.4 4 27.7 4 27.6 4 
Hearing loss 29.1 4 30.1 4 28.7 4  25.3  4 27.7 4 30.2 4 27.2 4 28.5 4 29.6 4 
MSC 22.3 4 23.3 4 22.4 4  20.3 4 22.6 4 24.4 4 20.9 4 23.1 4 24.3 4 
Addictive disorders 23.0 4 24.1 4 23.1 4  19.4 4 22.4 4 24.9 4 21.6 4 22.9 4 24.4 4 
NMSC 16.2 4 17.6 4 17.0 4  13.4  4 16.7 4 19.0 4 15.6 4 16.9 4 18.6 4 
Headaches 15.9 4 23.2 4 15.3 3  11.9  4 21.5 4 14.7 4 15.4 4 14.7 4 14.4 4 
G: Group/tier of priority. Four tiers of priority: ‘very critical’ indicated with ‘1’; ‘critical’ ‘2’; ‘high’ ‘3’ and ‘medium’ ‘4’. 





5.3.3 Results of consistency ratio for AHP (and EC) 
Approximately 70% of EC participants had a concerningly high level of inconsistency (CR > 
0.1), suggesting that participants’ stated preferences in EC are close to random. No participants 
were removed from the EC surveys due to the small number of participants who participated 
in the EC surveys.  
5.3.4 Results of consistency check for PAPRIKA (and 1000m) 
The consistency check in 1000m revealed that almost 85% of the participants in the smartphone 
survey consistently answered at least two of the three repeated questions, and 49% consistently 
answered all three repeated questions. The consistency check for the 1000m NCD survey 
showed that almost 60% of the participants consistently answered at least two of the three 
repeated questions, and 31% consistently answered all three repeated questions. In the 
smartphone survey, only four participants were identified with zero consistent answers and no 
participants answered ‘they are equal’ for all questions. In the NCD survey, only two 
participants were found with zero consistent answers and no participants answered ‘they are 
equal’ for all questions in 1000m. Although a few participants in 1000m had zero consistent 
answers in order to be consistent with the EC surveys, no participants were removed from the 
1000m surveys.  
5.3.5 Results of validity analysis 
A total of 47 participants in 1000m and 24 in EC answered the holdout task after completing 
the NCD surveys, and a total of 25 in 1000m and 16 in EC answered the redistributed holdout 
task for smartphones in the second time. Table 5.11 depicts the results of the holdout task and 
the internal validity of the AHP and PAPRIKA methods in all surveys. DKem was used to 
compare the MCDA ranking results with responses to the holdout tasks for each participant. A 
DKem value of 0 represents consistent ranking results given by the MCDA method and the 




participants’ actual choices. As presented in Table 5.11, higher preference match rates were 
obtained by PAPRIKA for both smartphone and NCD surveys. 
Table 5.11: Validity of AHP and PAPRIKA measured using holdout task and DKem100  
 
Smartphone surveys NCD surveys 
AHP PAPRIKA AHP PAPRIKA 
No of participants 16 25 24 47 
No of matches (DKem=0)* 9 21 14 30 
Match rate (hit rate) 56% 84% 58% 64% 
* DKem: Kemeny distance measurement; Number of matches shows the number of true predictions (reflecting 
the validity of the method) calculated by comparing the responses to the holdout task and stated preferences given 
by MCDA method for each participant. 
 
5.3.6 Results of test-retest reliability 
Table 5.12 presents the criteria weights for the original and retest smartphone surveys for both 
software. The paired sample t-test was performed to find out whether there are statistically 
significant differences between the criteria means generated by the original and retest surveys 
repeated over time.  
Table 5.12: Criteria mean weights (%), smartphone original and retest surveys, n=25101 
Smartphone 
AHP (and EC) PAPRIKA (and 1000m) 
Original survey  Retest survey Original survey Retest survey 
Operating speed 34.1 24.4 18.8 20.1 
Weight 5.9 7.5 13.0 12.7 
Camera quality 19.1 19.3 23.7 24.4 
Screen quality  12.9 11.5 17.7 16.4 
Battery life 28.0 37.3 26.7 26.4 
 
Before conducting the t-tests, the Shapiro-Wilk test was used to test whether the observations 
– i.e. stated preferences – are distributed (approximately) normally in both original and retest 
surveys. The results of the Shapiro-Wilk test (p-value> 0.05)102 presented in Table 5.13 suggest 
                                                 
100 Detailed information about matches and mismatches for all participants is given in Appendix 5.8.7 using 
DKem. 
101 The results of test-retest reliability for NCD surveys are provided in Appendix 5.8.8. Detailed tables (criteria 
weights and levels of performance) for smartphone and NCD surveys implemented through 1000m are provided 
in Appendix 5.8.9. 




that not all observations are distributed normally (which can be due to small sample sizes).103 
Therefore, a non-parametric test – i.e. the Wilcoxon signed-rank test – was implemented along 
with the parametric test – i.e. paired sample t-test – for both smartphone surveys to determine 
the significance of differences in mean weights and ranking of the criteria obtained from 
original and retest surveys. 
The paired (dependent) sample t-test compares the criteria means yielded by repeated surveys 
and determines whether the mean differences are significantly different from zero. As can be 
seen in Table 5.14, the results of the paired sample t-test show no statistically significant 
difference between the mean criteria weights of original and retest smartphone surveys at 
1000m as all p-values are higher than 0.05. In contrast, ‘battery’ and ‘operating’ criteria 
weights are significantly different across the original and retest smartphone surveys at EC. 
Given there are statistically significant differences in mean weights for two criteria, the EC 
smartphone survey provides a less reliable priority list of criteria over time.  
In addition, the results of the Wilcoxon signed-rank test demonstrate that there is no significant 
difference (p-value > 0.05 as shown in Table 5.15) between the rankings (or the order) of the 
criteria weights across the original and retest smartphone surveys at 1000m. However, there 
are significant differences between ‘battery’ and ‘operating’ relative rankings across EC 
smartphone surveys as indicated by the Wilcoxon signed-rank test and the paired sample t-test. 
                                                 
103 If the observations are normally distributed, a parametric test – i.e. paired sample t-test – can be used, otherwise 





Table 5.13: Results of Shapiro-Wilk test, smartphone original and retest surveys, n=25 
 AHP (and EC)  PAPRIKA (and 1000m) 




p-value Statistic Df p-value 
 
Statistic df p-value Statistic df p-value 
Operating  0.965 25 0.530 0.960 25 0.415  0.958 25 0.369 0.970 25 0.647 
Weight 0.683 25 0.000 0.560 25 0.000  0.903 25 0.022 0.870 25 0.004 
Camera 0.835 25 0.001 0.948 25 0.230  0.930 25 0.086 0.953 25 0.288 
Screen 0.840 25 0.001 0.843 25 0.001  0.918 25 0.046 0.975 25 0.772 





Table 5.14: Results of paired (dependent) sample t-test, smartphone surveys, n=25 
 
AHP (and EC)     PAPRIKA (and 1000m) 
Mean (SE) 
95% CI 
T Df P-value 
 
Mean (SE) 
95% CI  
t df P-value 
Lower Upper  Lower Upper 
Pair 1 Operating1 - Operating2 0.10 (0.02) -0.02 0.20 2.98 24 0.00  -0.01 (0.01) -0.05 0.03 -0.42 24 0.67 
Pair 2 Weight1 - Weight2 -0.02 (0.23) -0.07 0.05 -0.93 24 0.36  0.00 (0.01) -0.02 0.02 0.07 24 0.94 
Pair 3 Camera1 - Camera2 -0.00 (0.29) -0.03 0.02 -0.73 24 0.47  -0.01 (0.01) -0.03 0.03 -0.23 24 0.81 
Pair 4 Screen1 - Screen2 0.01 (0.21) -0.03 0.05 0.54 24 0.59  0.01 (0.01) -0.03 0.05 0.44 24 0.66 
Pair 5 Battery1 - Battery2 -0.10 (0.22) -0.13 -0.05 -3.80 24 0.00  0.00 (0.17) -0.04 0.04 0.37 24 0.70 

















AHP (and EC) 
Z -2.489 -1.329 -0.605 -0.183 -3.186 
p-value 0.013 0.184 0.545 0.855 0.001 
PAPRIKA (and 1000m) 
Z -0.443 -0.148 -0.013 -0.484 -0.350 
p-value 0.658 0.882 0.989 0.628 0.726 
 
The results of the paired sample t-test and the Wilcoxon signed-rank test show no statistically 
significant differences in criteria mean weights and rankings for both NCD and smartphone 
surveys implemented through PAPRIKA, indicating that PAPRIKA produced reliable results 
over time. In contrast, there are significant differences in some of the criteria mean weights 
calculated by AHP, suggesting that none of the EC surveys generated reliable results over time. 
Detailed information about the test-retest reliability of the NCD surveys is available in 
Appendix 5.8.9. 
5.3.7 Results of sensitivity analysis 
Overall, the ranking results were sensitive to any small changes in criteria levels in all surveys 
conducted in both software. The results of the sensitivity analysis for the smartphone survey 
implemented through 1000m are described in this subsection as an example. Figure 5.4 shows 
an example of the sensitivity analysis using tornado charts for all selected smartphones in the 
1000m survey. This figure displays the most important criteria that could be a source of 
uncertainty and the degree to which they could result in possible changes in the final ranking 
of the smartphones. As can be seen in Figure 5.4, ‘battery life’ is placed on the top, followed 
by ‘camera quality’, ‘screen quality’, ‘operating speed and performance’ and ‘weight’ 
respectively for most smartphones. These criteria have the potential to change the decision.  
Smartphones are compared based on the total utilities disaggregated across the five criteria as 
shown in Figure 5.4. The tornado charts provide information on how a particular smartphone 
– for instance, Nokia – would increase its market share and become the market leader by 




would happen if, for instance, Nokia’s attributes – i.e. criteria – were changed? (As explained 
before, bear in mind that this is an example and there are additional factors, e.g. price, to be 
considered to identify the smartphone market leaders). For example, relative to Samsung, 
Nokia is deficient with battery life and camera quality (on the other hand, Nokia is superior 
with respect to operating speed). This suggests it would be sufficient for Nokia to improve its 
battery life and camera quality to overtake Samsung. This can be seen from the tornado charts, 
as shown in Figure 5.4. 
Overall, the results of changing the criteria levels on smartphones suggest that smartphones are 
sensitive to changing the criteria levels. For example, if Apple iPhone X operating speed were 
reduced from ‘very good’ to ‘good – very good’. Apple iPhone X would receive a score of 




Screen quality and design features – e.g. headphone jack 
Operating speed and performance – e.g. RAM+storage, CPU and graphics, etc. 




5.3.8 Overall performance of AHP and PAPRIKA 
The overall robustness of AHP and PAPRIKA are compared in Table 5.16 using the robustness 
checks based on both NCD and smartphone decision examples. Overall, the participants had 
similar experiences of the surveys implemented through both software. However, the 
completion and response rates of the PAPRIKA surveys were higher than their counterpart 
surveys administered through AHP. Conceptually, the consistency tests – i.e. the CR for AHP 
(and EC) and consistency check for PAPRIKA (and 1000m) – differs across the two MCDA 
methods (and software), which limits the direct comparison of the results of these two 
consistency tests. For AHP (and EC), the CR is used to measure logical inconsistency – i.e. 
intransitivity – in each participant’s stated preferences, which is not applicable for PAPRIKA 
(and 1000m). Whereas, for PAPRIKA (and 1000m), the inconsistencies in answering the 
repeated questions are measured. As explained earlier, this option is not available in EC. 
The PAPRIKA method could better predict participants’ true responses (elicited through the 
holdout task) and generate reliable results over time based on two real-world decision 
situations. As a result, PAPRIKA is more likely to generate robust results, and therefore, 
outperform AHP based on two real-world decision case studies about NCDs and smartphones.  
Table 5.16: The overall performance of AHP (and EC) and PAPRIKA (and 1000m) 
Evaluation criteria 
Smartphone surveys NCD surveys 
AHP (and EC) PAPRIKA (and 1000m) AHP (and EC) PAPRIKA (and 1000m) 
Response rate (%) 21 34 14 24 
Completion rate (%) 69 90 61 75 
Validity (%) 56 84 58 64 
Test-retest reliability Less reliable More reliable Less reliable More reliable 
Choice of the method 
(and software) 





5.4 Discussion  
As explained, very few studies attempt to measure the ability of MCDAs to generate robust 
results – the primary purpose of ‘step 7’. A subset of MCDA methods might each suit a 
particular decision problem, but they may potentially produce conflicting results (Guitouni & 
Martel 1998; Mysiak 2006; Wątróbski et al. 2019). Investigation (and comparison) of the 
selected method(s) should be much broader than only using sensitivity analysis. Similarly, “a 
strict focus on only tests of validity or reliability will not guarantee a high-quality preference 
study” [p. 538] (Janssen et al. 2017). Moreover, many studies fail to provide detailed 
information about how they performed the robustness checks (Ishizaka & Siraj 2018; 
Wątróbski et al. 2019). 
This chapter developed and proposed a set of salient robustness checks to support the 
robustness of MCDA results. The present study contributes to a better understanding of and 
dealing with issues regarding ‘step 7’ of the MCDA process – i.e. justifying the choice of 
method and supporting the robustness of results. Next, the proposed framework was applied to 
examine the successful application and practical usefulness of the AHP and PAPRIKA 
methods based on NCD and smartphone decision case studies. A summary of the main findings 
is discussed in this section.  
The smartphone surveys had a higher response and completion rates compared to the NCD 
surveys. In addition, students found the smartphone survey much easier than NCD surveys, 
given that they might have a better understanding of and higher semantic knowledge about 
smartphones (Economides & Grousopoulou 2009). The students found both smartphone 
surveys relatively easy and NCD survey reasonably difficult. The response and completion 
rates of both 1000m surveys were higher than EC surveys, showing 1000m is more user-
friendly. This may also indicate the advantage of the choice-based preference elicitation mode, 
as discussed earlier, used in 1000m (Drummond et al. 2015). In general, lower response and 
completion rates might occur due to survey duration (i.e. taking longer than expected), 




structure and participants’ interest (Saleh & Bista 2017). A follow-up email was sent to those 
students who stopped completing the EC surveys to inquire into likely reasons they did not 
finish the survey. Only one student mentioned that EC is not compatible with smartphone 
devices.  
There exists a large body of literature endorsing transitive preferences as an essential 
requirement in rational decision-making as well as transitivity as a key property that provides 
a grounding for MCDA methods (Muller-Trede & Sher 2015: Thokala et al., 2016). Enforcing 
properties such as transitivity is more likely to reduce inconsistencies in the results (Guitouni 
& Martel 1998). Although, some studies argue that human judgment is subject to intransitivity 
and inconsistency (Saaty 1977), this issue indicates the superiority of using explicit and 
transparent methods such as MCDA to overcome the deficiencies and problems that face the 
decision-makers (Dyer 1990; Muller-Trede & Sher 2015). 
AHP is criticised for its inherent pitfalls104 such as not conforming to the transitivity property 
and using an arbitrary scale105 to elicit preferences, as described in Chapter 4, which produces 
a high level of inconsistency and arbitrary results (Belton & Gear 1983; Belton & Stewart 2002; 
Dyer 1990). Similarly, 70% of the participants in both AHP surveys had an inconsistency ratio 
of higher than 0.10, indicating that the stated preferences are close to randomness and that are 
erroneous to a certain degree. Saaty suggests revising or repeating the survey, but this is a 
profound limitation of the AHP method since many MCDA practitioners are not able to re-
conduct their study due to their tight schedule and budget limitations and that AHP may lead 
to inconsistent results again mainly due to the ratio scale measurements used in AHP to elicit 
participants’ preferences (Aires & Ferreira 2018). The empirical results of this study indicate 
that the trade-offs 1000m impose that make the survey tractable – e.g. enforcing transitivity – 
have lower costs than those imposed by EC. 
                                                 
104 The shortcomings of AHP were discussed more fully in Chapter 4. 
105 Unlike an absolute scale, an arbitrary scale can progress in both directions and can provide arbitrary ranking 




The holdout task for the smartphones (for both AHP and PAPRIKA methods) was revised due 
to an error in defining the smartphone levels and redistributed among the same participants 
who completed the main smartphone surveys in the first time. The students were only asked to 
answer the revised holdout tasks about smartphones. A total of 64 in 1000m and 41 in EC 
answered the holdout task for smartphones in the first time, whereas only 25 in 1000m and 16 
in EC answered the redistributed holdout task in the second time. Fewer students answered the 
revised holdout task for smartphones after a time delay of about six months. 
The error was describing the two smartphones based on their prices in the holdout task 
distributed for the first time (while the price was not considered as one of the prioritisation 
criteria in the study). There might be uncertainty in the responses to the repeated holdout task 
as students might have remembered the prices of smartphones and that it could have affected 
their responses. Lienert et al. (2016) [p. 748] point out that “the existing knowledge or past 
experience of the participants may affect preference stability and may lead to response variation 
in repeated experiments, but this hypothesis was not confirmed in real-world experiments”. 
Very few studies have been carried out on preference stability over time. As such, Brouwer 
(2006) and San Miguel et al. (2002) reported that the previous experiences and the level of 
knowledge did not affect the preference stability of the participants when the survey was 
repeated after two months. Therefore, it can be assumed that six months have been long enough 
for the students and their past experiences of answering the first holdout task might not have 
affected their choices when answering the repeated holdout task for the second time. 
 Findings of the holdout task revealed that PAPRIKA yielded higher validity than AHP based 
on two decision case studies. PAPRIKA could predict 84% and 64% of participants stated 
preferences respectively in both smartphone and NCD surveys. However, AHP showed a lower 
level of validity with the hit rates of 56% and 58% in smartphone and NCD surveys, 
respectively. To the best of the author’s knowledge, this is the first study that has measured the 
validity of PAPRIKA using the holdout choice. The holdout choice task is an endorsed method 
commonly used to evaluate the validity of CA studies, however, it has been rarely used to 




discussed earlier, the holdout task is preferred to asking participants to provide a priority list 
of alternatives as the participants might not have enough or accurate information about the 
alternatives. In the holdout task, alternatives are described on the main characteristics, which 
are also considered in the priority-setting framework. The holdout task provides participants 
with accurate information about alternatives, and enables them to make informed choices. 
Moreover, in the holdout task, the alternatives can be compared based on their characteristics 
without considering their names to reduce the motivational biases that may exist and affect 
participants’ choices (Armstrong 2001; Cunningham et al. 2017). 
Lienert et al. (2016) [p. 748] point out that “one characterisation of a good elicitation mode and 
a desirable MCDA method could be that they produce stable weights over time”. According to 
the literature on preference stability, although individuals’ preferences change over time, it 
does not affect the aggregated level results of the population (Liebe et al. 2012; Lienert et al. 
2016; Schaafsma et al. 2014). The results of test-retest reliability revealed that both NCD and 
smartphone surveys implemented through PAPRIKA are reliable. Therefore, PAPRIKA is 
more likely to produce results that are replicable over time. This finding is consistent with the 
findings of the NCD survey conducted among the adults in Chapter 3. The findings of the 
paired sample t-test showed that none of the surveys implemented through AHP produced 
reliable results. To the best of the author’s knowledge, there is no other study that has attempted 
to measure the test-retest reliability of the AHP method. 
Sensitivity analysis is often overlooked by many MCDA studies (Wang et al. 2017). It allows 
the decision analyst to gain insight into which criteria affect the existing rankings of the 
alternatives (Borgonovo 2017; Wang et al. 2017). It is recommended to at least use a simple 
deterministic sensitivity analysis to check the overall robustness of results to alternatives 
(Marsh et al. 2016). Broekhuizen et al. (2015) [p. 445] indicate that “the deterministic approach 
is most likely sufficient for most health care policy decisions because of its low complexity 
and straightforward implementation”. Overall, based on the sensitivity analyses, it can be 





5.5 Strengths of the study 
The study has three main strengths. One, the proposed set of robustness checks was illustrated 
with two prominent MCDA methods (AHP and PAPRIKA) based on different real-world 
decision problems about NCDs and smartphones. Two, a holdout choice task, which is 
endorsed by several studies, was employed to elicit participants’ actual choices and measure 
the predictive validity of MCDA methods (Drummond et al. 2015; Orme 2015). Although the 
holdout task is commonly used to measure the validity of the CA studies, it is a novel approach 
among other MCDA methods. Three, the predictive validity of MCDA methods (based on the 
holdout task) was measured based on ‘individual-level’ preferences.  
5.6 Limitations of the study 
Two potential limitations should be acknowledged in this study. One, as explained earlier, the 
number of comparison questions and thus the respondent burden for the participants increases 
with an increase in the number of criteria. Therefore, the most important criteria can be 
included in the main survey and other criteria can be considered as additional factors. In 
addition, as new information becomes available, further criteria can be defined as additional 
factors in the priority-setting framework to evaluate the performance of alternatives and update 
the priority list with respect to new information. For example, Huawei was criticised due to 
issues regarding data security and privacy in 2019. As the smartphone surveys in Chapter 5 
were distributed in mid-2018, ‘data security and privacy’ was not considered in the framework. 
However, this criterion (and any other new information that becomes available) can be included 
as an additional factor in the prioritisation process. Once these additional factors are considered 
in the framework, the overall ranking of the smartphones might change. 
Two, the holdout task for the smartphone survey was repeated due to an error in defining the 
smartphone levels. Fewer participants took part in the repeated holdout task for both AHP and 
PAPRIKA. Although participants’ preferences may change over a long period of time, it was 
assumed that the choices were not affected by the holdout task distributed in the first time and 




Overall, it may not be a profound limitation since the error in designing the holdout task for 
smartphones occurred for both methods. 
5.7 Conclusion 
The advantage of using explicit priority-setting methods such as MCDA is that such methods 
can overcome human bias and selectivity. In addition, it is possible to systematically identify, 
resolve errors and support the robustness of results at various stages of the MCDA process. 
With a variety of MCDA methods available, MCDA practitioners need to support the 
robustness of selected MCDA results to improve the legitimacy of the decisions made and 
consequently, justify their choice of MCDA, through ‘step 7’ of the MCDA process, which is 
usually overlooked by many studies. 
In an attempt to stress the importance of ‘step 7’ in the MCDA process, a comparative analysis 
of two widely-used MCDA methods – i.e. AHP and PAPRIKA – was undertaken to measure 
their robustness using two different decision case studies. Although participants’ perceived 
ease-of-use of the surveys was reasonably similar, PAPRIKA is more likely to support the 
robustness of results and legitimacy of decisions by producing reliable results over time. In 
addition, PAPRIKA showed higher validity to predict participants’ true preferences. Therefore, 
PAPRIKA is more likely to outperform AHP based on two real-world decision surveys about 
NCDs and smartphones 
Ideally, the framework and the methodology employed in this chapter could guide MCDA 
practitioners to incorporate checks to ensure the robustness of the MCDA process as well as 





5.8.1 Rated smartphone based on their specifications (i.e. criteria) 
 




5.8.2 Example of the invitation email sent to students 
  




5.8.3 Survey instructions for EC and 1000m 
 

















5.8.5 Interpolated levels on criteria for smartphone survey 
 
 




5.8.6 The holdout task employed for two NCDs 
 
5.8.7 Match rates between ranking results given by selected methods and holdout task 
Table 5.17: Match rate for each participant calculated using DKem, for all surveys 
Participant 
NCDs surveys Smartphone surveys 
AHP PAPRIKA AHP PAPRIKA 
n=24 n=47 n=16 n=25 
1 2 0 0 0 
2 2 0 2 0 
3 2 0 2 0 
4 2 0 0 0 
5 0 0 2 0 
6 0 0 0 0 
7 0 0 0 0 
8 0 0 0 0 
9 0 0 2 2 
10 0 0 0 0 
11 0 2 2 2 
12 0 2 0 0 
13 2 2 2 0 
14 2 0 0 0 
15 0 0 0 0 
16 2 2 2 0 
17 2 0  0 
18 0 2  0 
19 0 0  0 
20 2 2  0 
21 2 0  0 
22 0 2  2 
23 0 2  0 
24 0 0  2 
25  2  0 
26  0   
27  0   
28  2   
Participant 
NCDs surveys Smartphone surveys 
AHP PAPRIKA AHP PAPRIKA 
n=24 n=47 n=16 n=25 
29  0   
30  2   
31  0   
32  2   
33  0   
34  2   
35  0   
36  0   
37  0   
38  0   
39  0   
40  2   
41  0   
42  0   
43  0   
44  2   
45  0   
46  2   
47  2   




5.8.8 Test-retest reliability of NCD surveys implemented through EC and 1000m 
Table 5.18: Criteria mean weights (%), NCD original and retest surveys, n=25 
Criterion 
AHP (and EC) PAPRIKA (and 1000m) 
Original survey Retest survey Original survey Retest survey 
Deaths 25.4 22.9 30.8 28.3 
Loss of QoL 29.1 26.3 20.5 22.5 
Cost to patients 22.1 20.5 18.5 19.8 
Cost to health system 10.3 17.1 17.1 15.1 
Vulnerable groups 13.1 13.2 13.1 14.3 
 
 
Table 5.19: Results of Shapiro-Wilk test, NCD original and retest surveys, n=25 
Criterion 
AHP (and EC) PAPRIKA (and 1000m) 
Original survey Retest survey Original survey Retest survey 
Statistic df p-value Statistic Df p-value Statistic df p-value Statistic df p-value 
Deaths 0.81 25 0.00 0.78 25 0.00 0.97 25 0.63 0.96 25 0.47 
Loss of QoL 0.95 25 0.35 0.90 25 0.01 0.94 25 0.18 0.96 25 0.59 
Cost to Patients 0.91 25 0.04 0.96 25 0.45 0.97 25 0.79 0.95 25 0.34 
Cost to Health system 0.66 25 0.00 0.87 25 0.00 0.89 25 0.01 0.90 25 0.02 






Table 5.20: Results of paired (dependent) sample t-tests, NCD original and retest surveys, n=25 
 
AHP (and EC)    PAPRIKA (and 1000m) 
Mean (SE) 
95% CI of the Difference 
t Df P-value Mean (SE) 
95% CI of the Difference 
t df P-value 
Lower Upper Lower Upper 
Pair 1 Vulnerable1 - Vulnerable2 -0.00 (0.02) -0.03 0.01 -0.99 24 0.3 -0.01 (0.01) -0.05 0.07 -1.04 24 0.30 
Pair 2 Costtopatients1 - Costtopatients2 0.02 (0.03) -0.03 0.07 0.66 24 0.51 -0.01 (0.01) -0.07 0.05 -2.07 24 0.17 
Pair 3 Costtohealth1 - Costtohealth2 -0.07 (0.01) -0.18 0. 08 -3.87 24 0.01 0.02 (0.01) -0.02 0.06 1.22 24 0.23 
Pair 4 LossofQoL1 - LossofQoL2 0.03 (0.04) -0.03 0.04 0.50 24 0.61 -0.02 (0.01) -0.06 0.02 -0.56 24 0.57 
Pair 5 Deaths1 - Deaths2 0.03 (0.09) -0.05 0.01 1.53 24 0.13 0.03 (0.01) -0.01 0.05 1.46 24 0.15 
 













AHP (and EC) 
Z -0.28 -0.02 -3.11 -0.92 -0.74 
p-value 0.77 0.97 0.03 0.35 0.45 
PAPRIKA (and 1000m) 
Z -0.39 -1.92 -1.25 -0.48 -1.06 




5.8.9 Detailed information for original and retest surveys, PAPRIKA 
Table 5.22: Criteria (and levels) mean weights (%), smartphone original and retest surveys, n=25 
Criteria Original Retest  
Operating speed and performance   
Ok  0 0 
Good  10.0 10.9 
Very good  18.8 20.1 
Weight   
Heavy 0 0 
Medium 7.5 6.8 
Light 13.0 12.7 
Camera quality   
Ok  0 0 
Good  13.2 13.9 
Very good  23.7 24.4 
Screen quality and design features   
Ok  0 0 
Good  10.0 8.6 
Very good  17.7 16.4 
Battery life 
Short  0 0 
Medium 13.8 16.7 
Long 26.7 26.4 
 
Table 5.23: Criteria (and levels) mean weights (%), NCD original and retest surveys, n=25 
Criteria Original Retest 
Deaths   
None (or low)  0 0 
Moderate 15.2 14.1 
High 22.9 21.9 
Very high  30.8 28.3 
Loss of QoL   
Low 0 0 
Moderate 10.9 11.7 
High 20.5 22.5 
Cost to patients   
Low 0 0 
Moderate 8.5 10.2 
High 18.5 19.8 
Cost to the health system   
Low 0 0 
Moderate 10.1 9.3 
High 17.1 15.1 
Vulnerable groups 
No 0 0 












6.1 Thesis overview 
As discussed earlier, NCDs are growing substantially due to population ageing and unhealthy 
lifestyles. NCDs are the leading cause of high rates of premature death, disability and health 
care expenditure worldwide (Benziger et al. 2016). NZ, like other countries, is grappling with 
allocating scarce health research funding across NCDs. As explained in Chapter 2, several 
methodologies have been developed – e.g. ENHR, CHNR, CAM and JLA,– to support health 
research funding priorities (COHRED 1997). These methods are very helpful for exploring and 
compiling all available information, considering a multi-criteria based approach and involving 
main stakeholders, but the methods themselves do not explicitly generate the priorities (Rudan 
et al. 2010; Yoshida 2016). By contrast, MCDA is concerned with explicitly forming and 
solving the multi-dimensional aspects of the decision problems, weighting the criteria and 
scoring the alternatives (Hansen & Devlin 2019). Adopting priority-setting methods based on 
MCDA have attracted a great deal of interest among researchers and policy-makers. MCDA 
helps direct limited health research resources into areas of greatest need (when there is a dearth 
of information about benefits) and strengthen the health research priority-setting system 
(Viergever 2010). 
This thesis primarily aimed to use MCDA to support health research funding decision-making 
across NCDs. The thesis contains three main chapters – i.e. Chapters 3, 4 and 5. In Chapter 3, 
a widely-used MCDA method – i.e. PAPRIKA that was recently used by the WHO to guide 
health research and development into new antibiotics – was applied to develop a priority-setting 
framework at the macro-level of the NZ health research funding. A set of criteria was specified 
to elicit the preferences of a wide range of key stakeholders – i.e. patient or the general public, 
health workforce, policy-maker or health researcher – with respect to NCDs priorities for health 
research funding in NZ. Participants’ stated preferences were integrated with scientific 
evidence to create a priority list of NCDs to support health research funding decision-making. 
As discussed earlier, the term ‘support research funding decision-making’ is used in this thesis 




are also important (and not included in this framework) when research projects are being 
assessed and funds are allocated in pursuit of value for money. 
Real-world decision-making is often multi-dimensional in nature. MCDA helps structure this 
multi-faceted nature of decision problems and improve the transparency of the decision-making 
process (Hout et al. 2016; Ishizaka & Siraj 2018). Nevertheless, with a multitude of MCDA 
methods (and software) available, it is challenging to choose the best method. Moreover, many 
MCDA practitioners fail to justify their choice of a method over another that is the ultimate 
purpose of step 7 in the MCDA process, as explained earlier. Chapter 4 attempted to stress the 
importance of step 7 and deal with the issue of choosing an appropriate MCDA method (and 
software). This chapter specified three groups of criteria related to method, user and software 
to compare PAPRIKA with the most widely-used MCDA method – i.e. AHP – from a 
theoretical perspective. The AHP method is considered a benchmark among MCDA methods 
by many MCDA practitioners.  
Both AHP and PAPRIKA are two prominent examples of MCDA methods since both methods 
have been used in many different fields and appeared in many publications (Belton & Stewart 
2002; Marsh et al. 2017; Marsh et al. 2014; Thokala et al. 2016). It is worthwhile to evaluate 
the two methods further based on the methodologies they use at different stages of the decision-
making process from eliciting participants’ preferences to generating the decision results. As 
explained in Chapter 4, 1000m is the only software package that administers the PAPRIKA 
method. EC is one of the several software packages that implements AHP, and it has been cited 
in numerous publications. Along with the two methods, their associated decision-making 
software – i.e. EC and 1000m – were also considered in the evaluation process.  
Since the selected MCDA methods – i.e. PAPRIKA and AHP – have been developed based on 
different theoretical foundations, they may potentially lead to conflicting results for a given 
decision situation (Drake et al. 2017; Thokala et al. 2016). As explained in Chapter 5, the 
literature indicates that the differences in the results yielded by different MCDA methods are 




and preference elucidation modes used by different MCDA methods. Logistically, when there 
exists no gold standard, an appropriate MCDA method needs to produce robust results. Chapter 
5 developed an empirical framework to evaluate the successful applications of AHP and 
PAPRIKA based on two real-world decision examples about NCDs and smartphones among 
university students.  
6.2 Main findings and research contributions 
The main findings of the thesis are summarised as follows. 
The NCDs prioritisation framework to guide health research funding 
The MCDA-based framework developed in Chapter 3 shows that the most important criterion 
with respect to prioritising NCDs in terms of their overall burden to society (and hence their 
importance for health research funding) is ‘deaths across the population’ (mean weight = 
27.7%), followed by ‘loss of QoL across the population’ (23.0%), then ‘cost to patients, 
families and community’ (18.6%), ‘cost to the health system’ (17.2%) and the least-important 
criterion, ‘disproportionately affects vulnerable groups’ (13.4%). The weights were summed 
across the criteria to get a total score for each NCD. Each NCD’s total score was presented 
based on a 0-100% scale, where 100% indicated an NCD with the highest levels on all criteria, 
and 0%, an NCD with the lowest levels on all criteria.  
Consistent with the presentational style and terminology used by the WHO for its priority list 
of antibiotic-resistant bacteria (Tacconelli et al. 2018) and to simplify the presentation of the 
final priority list of NCDs to better communicate with policy-makers, the NCDs ranking was 
categorised into four tiers: Priority 1 (very critical): coronary heart disease, back and neck pain, 
diabetes mellitus; Priority 2 (critical): dementia and Alzheimer’s, stroke; Priority 3 (high): 
colon and rectum cancer, depressive disorders, chronic obstructive pulmonary disease, chronic 
kidney disease, breast cancer, prostate cancer, arthritis, lung cancer; Priority 4 (medium): 





The results of this priority-setting exercise were supported by further analyses such as test-
retest reliability and cluster analysis. The results of the test-retest reliability of the NCD survey 
revealed that the survey could produce reliable results over time. The results of the cluster 
analysis showed that participants’ stated preferences are associated more with their 
idiosyncratic personal preferences than their demographic characteristics. To the best of 
author’s knowledge, this is the first study to have used an MCDA method – i.e. PAPRIKA – 
to develop a priority list of NCDs to support health research funding decision-making. 
Choosing the best MCDA: A comparative study of AHP (and EC) and PAPRIKA (and 
1000m) 
The findings of the theoretical comparison of AHP (and EC) and PAPRIKA (and 1000m) 
revealed that the two methods are developed based on different theoretical foundations and 
they use different methodologies to calculate the criteria weights and alternatives scores. As 
such, AHP uses ratio scale-based pairwise comparison questions to elicit participants’ 
preferences. AHP is considered a compositional scoring method as it generates separate 
estimates of criteria weights and alternatives scores. AHP uses the eigenvalue (and eigenvector) 
method to calculate the criteria weights and alternatives scores and the stated preferences in 
AHP are not required to be transitive. In contrast, PAPRIKA uses choice-based pairwise 
comparison questions to elicit preferences and is considered a decompositional scoring method. 
PAPRIKA indirectly elicit participants’ preferences and enforces the transitivity property. 
1000m offers affordable prices for academic purposes (with free licence available for students). 
Participants’ perceived ease-of-use of the surveys implemented through both software was 
reasonably similar. Participants found both smartphone surveys relatively easy and NCD 
surveys relatively hard. The response and completion rates of both 1000m surveys were higher 
than EC surveys, indicating that 1000m is more user-friendly. The results indicate that 
PAPRIKA is more likely to outperform AHP based on two real-world decision surveys about 
NCDs and smartphones. As such, PAPRIKA is more likely to support the robustness of results 




actual choices with higher validity. To the best of the author’s knowledge, this is the first study 
comparing the performance of AHP (and EC) and PAPRIKA (and 1000m) based on real-world 
decision-case studies. 
The other research contribution of this thesis is the holdout choice task used for eliciting 
participants’ actual choices and measuring the validity of selected MCDA methods in the 
absence of real-world data about participants’ actual choices. Although the holdout task is 
commonly used for investigating the validity of CA studies, it is rarely employed among other 
MCDA methods. In addition, the Kemeny distance measurement, which was used to compare 
and measure the differences in the ranking results given by MCDAs and the holdout task, is 
another method contribution of this thesis. Overall, the novelty of this thesis is the verification 
of the practicality of MCDA based on three essentials: (1) sound theoretical foundations (e.g. 
using a choice-based preference elicitation mode that resembles the real-life decision-making 
as well as properties such as transitivity to improve the decision-making process); (2) the 
associated decision support system (e.g. user-friendly, reasonable price and the variety of 
features and inbuilt options to improve the decision-making process); and (3) producing robust 
(e.g. reliable and valid) results. 
6.3 Limitations of the thesis 
This thesis has several limitations, as follows. One, all the 19 NCDs considered in Chapter 3 
are rather heterogeneous – e.g. stroke can range from being a mild and transient event to a 
major disabling event requiring nursing home care for the rest of life. However, it was not 
possible to consider the heterogeneous NCDs and further classify them in the framework due 
to the lack of detailed information on heterogeneous health conditions. Two, anxiety disorders 
associated with relatively major health burden and dental disorders associated with high health 
care costs (predominantly not funded by the NZ Government) were excluded from the priority-
setting framework developed in Chapter 3 due to a paucity of available data. Three, due to a 
lack of detailed data on NCDs’ health care costs, the proportion proposed by Blakely et al. 




Government, and the remaining 18% is incurred by households – was used in Chapter 3 to 
estimate the cost burden by patients (and family) and Government separately. Four, there was 
very little evidence on NCDs-related health care expenditures by the private sector and non-
governmental organisations (e.g. Cancer Society). However, given 82% of NZ’s total health 
care expenses are estimated to be publicly-funded, this may not be considered as a serious 
limitation. 
Five, the sample of participants took part in the NCD survey in Chapter 3 is not representative 
of the NZ population. To ensure a diverse range of key stakeholders (e.g. patients or members 
of the general public, health providers, policy-makers or researchers), participants were 
recruited using convenience and purposive sampling with snowballing. Because of these 
sampling methods, it was not possible to calculate a response rate; nonetheless, the number of 
participants (n=517, resulting in 476 usable responses) was larger than in other studies that 
conducted online surveys to set research priorities across health interventions. The priority-
setting framework could be repeated with a more representative sample. 
Six, as explained earlier, the number of comparison questions and thus the respondent burden 
for the participants increases potentially with an increase in the number of criteria. Therefore, 
the most important criteria can be included in the main survey and other criteria can be 
considered as additional factors. In addition, as new information becomes available, further 
criteria can be defined as additional factors in the priority-setting framework to evaluate the 
performance of alternatives and update the priority list with respect to new information. For 
example, Huawei was criticised due to issues regarding data security and privacy in 2019. As 
the smartphone surveys in Chapter 5 were distributed in mid-2018, ‘data security and privacy’ 
was not considered in the framework. However, this criterion (and any other new information 
that becomes available) can be included as an additional factor in the prioritisation process. 
Once these additional factors are considered in the framework, the overall ranking of the 




Seven, the holdout task employed for the smartphones in Chapter 5 was repeated due to an 
error in defining the smartphones levels. Fewer participants took part in the repeated holdout 
task for both AHP and PAPRIKA. Although participants’ preferences may change over a long 
period of time, it was assumed that the choices were not affected by the holdout task distributed 
in the first time and they remained reasonably stable over six months (Lienert et al. 2016; San 
Miguel et al. 2002). Overall, it may not be a profound limitation since the error in the holdout 
task for the smartphones occurred for both methods. 
6.4 General conclusions and policy implications 
This section provides general conclusions and the policy implications of the main three 
chapters. The MCDA-based framework developed in Chapter 3 could be used somewhere else 
to evaluate the multi-dimensional aspects of NCDs and create a priority list of them to guide 
health research funding. The results of this chapter reveal that mental, neurological and 
musculoskeletal disorders are placed in the first and second tiers of the NCDs priority list, 
indicating that NZ, like many other countries, is undergoing a disability transition. This 
suggests that the proportion of the world’s population that are experiencing nonfatal health loss 
(i.e. disability and pain) is growing substantially. This epidemiologic transition demonstrates a 
shift to morbidity (not only mortality), affecting the elderly, younger adults and children due 
to population ageing and unhealthy lifestyle.  
As stated by the GBD 2016 studies, YLD rates are increasing more rapidly than YLL rates so 
that nonfatal health losses as a proportion of DALYs are outgrowing (Benziger et al. 2016). 
Long-term conditions such as musculoskeletal, mental and neurological disorders are growing 
rapidly and affecting a larger population. In addition, as discussed in Chapter 3, the top-ranked 
NCDs are mainly associated with high health care costs showing a correlation between high 
health care costs and morbidity (i.e. disability) that has also been found in other recent studies. 
The priority-setting framework developed based on five criteria suggests that it is essential to 




health care costs to health providers and patients – of NCDs to determine their priority for 
health research funding. 
This thesis primarily aimed to establish a priority list of NCDs at the macro-level to support 
health research funding decision-making. In NZ, MOH, HRC and Ministry of Business, 
Innovation and Employment (MBIE) are closely engaged with setting health research priorities 
for health conditions, including NCDs. HRC, in conjunction with the Healthier Lives National 
Science Challenge (a national research collaboration) has currently embarked on establishing 
the health research priorities in the context of cancers, cardiovascular diseases, diabetes and 
obesity in NZ for the period from 2017 to 2027. According to the report provided by the HRC 
Policy and Strategy Team, the priority-setting framework developed for NZ is required to meet 
the goals of the NZ Health Research Strategy (NZHRS) that are providing transparency, taking 
a collaborative approach, supporting research excellence and partnership with Māori.106 
The report, however, has not clearly stated the reasons why the afore-mentioned NCDs have 
been selected over others. In addition, it has been mentioned in the report that MCDA is not 
appropriate to be operationalised at the national level (HRC 2018). By contrast, the WHO has 
recently used the PAPRIKA method – that is an MCDA-based method – to develop a priority-
setting framework to guide health research funding into new antibiotics at the international 
level. Likewise, many other studies used MCDA to establish priority-setting frameworks at the 
national level, indicating the practicality and benefits of MCDA to explicitly set and support 
health research priorities at both national and international levels (Marsh et al. 2017; Tacconelli 
et al. 2018; Thokala et al. 2016). 
Furthermore, the priority-setting framework developed in Chapter 3 can help the NZ 
Government, MOH and HRC achieve the goals of NZHRS and improves the transparency and 
research excellence in the priority-setting process by capturing the preferences of a wide range 
of key stakeholders, including Māori and other ethnic groups as well as using the scientific 
                                                 
106 Interested readers are referred to the report provided by the HRC Policy and Strategy Team available at 
https://www.hrc.govt.nz/sites/default/files/NZHRS%20Action%20One%20-%20Background%20Evidence.pdf 




evidence on NCDs. The NZ health system has been more successful at decreasing the rates of 
mortality in many fatal NCDs than disability (i.e. nonfatal aspects) attributed to many NCDs 
such as musculoskeletal, neurological and mental disorders (NZ MOH 2016b). According to 
the framework developed in Chapter 3, NCDs such as musculoskeletal and neurological 
disorders are also ranked in the first and second priority tiers due to high rates of disability and 
health care costs they cause. For example, some NCDs causing high rates of disability (living 
longer but suffering more ill-health and morbidity) are competing with fatal NCDs such as 
coronary heart disease since the former NCDs affect a larger population and contribute to high 
health care expenditure, which was also found in other studies (Blakely et al. 2019).  
The priority-setting exercises, particularly at the macro-level of health care, have always been 
controversial across various parties. Transparent and structured decision-making tools such as 
MCDA help policy-makers improve the priority-setting results by considering multiple criteria 
as well as the scientific evidence on alternatives to evaluate the multi-dimensional aspects of 
the decision problems. MCDA also helps reduce the motivational biases that may exist by 
engaging a broad range of key stakeholders, which is recommended by many studies as well 
as many key organisations in the NZ health sector. In addition, another advantage of using a 
transparent and structured priority-setting framework is that it is easy to revise and update it 
when new (or additional) information becomes available about the current list of NCDs (or 
other major NCDs not considered in the framework due to a lack of data). Therefore, the 
priority-setting framework developed in Chapter 3 could be used to help the NZ Government 
and policy-makers make more informed and legitimate funding decisions and more effectively 
allocate scarce health research funding across major NCDs. 
The advantage of using structured and systematic priority-setting approaches such as MCDA 
is that they can overcome human bias and selectivity. In addition, it is possible to systematically 
identify, resolve errors and support the robustness of results at various stages of the MCDA 
process. There exists ample evidence of the practicality of MCDA methods to deal with 
complex and multi-dimensional decision problems. Given the ultimate purpose of MCDA to 




are developed on sound theoretical foundations, simulate real-life decision-making and satisfy 
the principles of rational decision-making. As discussed in Chapter 5, PAPRIKA is more likely 
to produce robust results and outperform AHP based on two real-world decision surveys about 
NCDs and smartphones. PAPRIKA uses preference elicitation questions that resemble real-life 
decision-making. In addition, PAPRIKA enforces transitivity rule that helps make rational 
decisions and improve the decision-making process. 
Despite being extensively used in many different fields, AHP produces results that are highly 
inconsistent. The key reason is using a ratio scale of 1 to 9 to elicit participants’ preferences, 
as discussed in Chapter 4. Many studies used AHP failed to report the consistency ratio of their 
results. As reported in Chapter 5, the results revealed that almost 70% of the participants in 
both EC surveys had high levels of inconsistency (CR > 0.10), suggesting that the preferences 
are very close to random. Therefore, the results produced through AHP (and EC) are erroneous 
to a certain degree. Saaty suggests repeating the survey when the results are highly inconsistent. 
However, repeating the survey is not a practical solution as the ratio scale measurement used 
in AHP itself causes high levels of inconsistency in the results, as discussed in Chapter 4, and 
imposes a profound limitation on using the AHP method. 
Some studies recommend using a hybrid approach or multi-method MCDA application and 
draw a conclusion based on the results given by different methods. However, a hybrid model 
can be a costly and time-consuming process. In addition, different MCDA methods may 
potentially lead to conflicting results as the preference elicitation mode and the formulation of 
the decision problem can affect the results. Therefore, evaluating the chosen MCDA method(s) 
based on their theoretical foundations may not be sufficient. An appropriate MCDA method 
also needs to produce robust results. Ideally, the theoretical and empirical frameworks 
developed in Chapters 4 and 5 can help MCDA practitioners consider a holistic approach to 
justify the choice of MCDA – which is the primary purpose of step 7 in the MCDA process – 





6.5 Future research 
Although patients or the general public with higher education were recruited in the priority-
setting framework developed in Chapter 3, the framework could be piloted among a larger 
population, including patients (particularly those with NCDs) and families or the general public 
without tertiary education. It would be interesting to understand the preferences of the lower 
educated population with respect to NCDs priorities to receive health research funding. 
However, MCDA practitioners should ensure that the targeted samples of patients (and 
families) have a good understanding of the concepts and terms used in the future studies to 
ensure the meaningful contribution of this group of participants to study. 
The lack of information about health conditions, including NCDs (e.g. YLL, YLD, DALY, 
costs incurred by patients and health providers) highlights areas of future research. There is a 
need to improve the quality (and availability) of data on NCDs. Further efforts are needed to 
conduct cost of illness studies from both patients and health provider perspectives to generate 
data for economic evaluation studies and aid policy-makers to perceive where (and how much) 
the public funding is spent (and how much should be spent). Future research should focus on 
developing evidence-informed priority lists of potential areas of research (health interventions, 
e.g. prevention and/or treatment) by considering both the merits (e.g. scientific rigour and 
feasibility) and their value for money (Tuffaha et al. 2019), which are not well captured by 
many studies, to help address the exponential growth of NCDs (and their co-morbidities). 
The (theoretical and empirical) frameworks developed in Chapters 4 and 5 could be used to 
evaluate and compare other MCDA methods such as MAVT, TOPSIS and PROMETHEE. The 
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